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EDITORIAL 
THE TRIALS 
O f all the diagno es that a person can be labeled with, cancer has always been one of the mo t feared, and certainly the mo t varied in what it 
means to both the patient and hi health care provider . 
Some of the most aggre ive, lethal di ea e proce e fall 
under the heading of ' cancer'- diagno es that usually 
carry life expectancies of week or month . And yet, other 
neoplasm carry very little morbidity and mortality, and 
have cure rates of over 90%. One name, but thousands of 
di ea e , each with its own treatment, progno is, and 
high-risk population. In thi en e, at lea t, not much ha 
changed ince the times in which people died inexplicably 
of illne e vaguely referred to as ' consumption' or 
'wasting sickne '. 
De pite thi , the field of oncology it elf-the treatment 
of the one di ea e that is really many different one -has 
become one of the most dynamic and rapidly changing 
a reas of medical re earch today . Over the last three 
decade , we have gone from a time in which the Qnly 
treatment available wa urgery to a ituation in which a 
newly diagno ed patient and hi phy ician are often faced 
w ith a menu of options in treatment protocol .1 The 
arrival of radiotherapy, followed by the still ever-growing 
pharmacopoeia of chemotherapy, have been followed 
more recently by immunological, histological, and 
molecular genetic discoverie into the treatment of cell 
which have lo t the delicate and e sential control required 
to function normally.2 Each new step in each field ha 
repercu sion that usually extend throughout all of 
oncology, and not just the specific cancer for which it wa 
developed . 
The ocial and public health aspect of cancer are a 
dramatic a the recent technological advance . It i the 
econd most common killer in both men and women after 
heart disease in orth America. More alarmingly, the 
w orld burden of cancer seems to be increasing at a 
con siderable rate: in 1985, 7.6 million cancer were 
diagno ed world wide, and 5 million people died of their 
cancer . In 1990, the number of deaths rose to about 5.7 
million, and the predicted number of deaths for the year 
2000 is 7.1 million, and a projected 10.6 million new 
diagnose will be made.3 Much re earch and speculation 
has revolved around the e climbing numbers, and 
every thing from the depleted ozone layer to extended 
life pans have been irnplicated.3•4 
The social repercus ions of the demographics will 
hopefully be lessened by technological advances in 
oncology treatment. It i clear from the number of 
submissions for this volume of the University of Western 
TO BE FACED 
By Carla Garcia & Aaron M. Glickman, Editors-In-Chief 
Ontario Medical Journal that oncology is an area of active 
re earch and inve tigation in our medical community. It 
is, however, also clear from the number of submis ions for 
this volume that oncology impact ignificantly on most, if 
not all, branche of medicine. This makes it a problem 
that will require immense re ources into and likely 
beyond the next millennium. 
REFERE CES 
1. Sou/rami, Robert & Tobia , Jeffrey. Caucer & its Mauagemeut. Blackwell 
Scieuce Press, London. 1998. pp. 2-22. 
2. Bishop, James. Cancer Facts: A coucise oncology text. Harwood Academic 
Pub., Syduey. 1999. ppB-12. 
3. Audreoli, T., Carpenter, C., Bennet, f., & Plum, F. General Cousiderations 
in Oncology. I : Cecil Essentials of Medicine. W .B. Saunders Co., 
Philade/plria. 1997. pp. 425-437. 
4. Kitclreu , Kirk. Carcinogenicity: testing, predictiug, aud iuterpreting 
chemical effects. Marcel Denker luc. , ew York. 1999. pp. 1-11. 
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PROFILES 
EDITOR: HELE LEWANDOWSKI 
INTERVIEW WITH 
D r. Varagur M . Venkatesan i a R a diation 
Oncologis t at the London 
Re gi onal Cancer C ntr e 
(LRCC) who ha a pecial 
intere t in brachy thera py. 
Brachytherapy i a form of 
radiotherap y wherein the 
radioacti ve ub tance i 
placed near or in contact 
with the tumor. Treatment in 
thi way i called 
brachytherapy which means 
" hort di tance therapy" a 
oppo ed to teletherapy or long di tance therapy. Although 
brachytherapy ha b en available to cancer patient for a 
few decade , it i currently performed in only elected 
centre aero Canada. One of the e centr is the London 
Regional Cancer Centre. 
Dr. Venkate an received hi under-gradua te m dical 
education in India, following which he moved to England 
to pur ue training in Ear, o e and Throat Surgery. He 
completed an E T fellow hip in Edinburgh, and received 
po t-fe llow hip training at the Univer ity of Wale , 
Cardiff, U.K. He emigrated to Canada in 19 3 and trained 
in radiation oncology at the London Regional Cancer 
Centre. Six year later, he joined the London Regional 
Cancer Centre a a taff radiation oncologi t, a po ition he 
has held ince that time. In 1993, Dr. Venkate an had the 
opportunit to travel on abbatical to ancy, France 
where he received advanced training in head and neck 
brachytherap . He al o received training in pro tate 
brachytherapy in SeattJ , Wa hington. He i an A ciate 
Profe or in the Department of Oncology at the Uni er ity 
of We tern Ontario, and i involved in clinical re earch 
pertaining head and neck and pro tate cancer. He i 
married and ha a on who i at the Univ r ity of Windsor 
doing a bu ine degree. His favorite activitie include 
cricket, golf and traveling with hi family. 
Could you talk about head and neck brachytherapy? 
Head and neck brachytherapy is widely practiced in 
Europe, e pecially in France and Italy . Howe er in 
Canada it is till in it infancy. The radioactive source that 
is u ed in head and neck brachytherapy i iridium 192 
who e half-life is 74 days. It is a temporary implant (i.e. 
the radiation ource i left in the area of interest for a few 
day and then removed). In orne tumor of the head and 
DR. VENKATESAN 
By Helen Lewandowski, MEDS 2001 
neck, brachytherapy i u d as the primary modality of 
treatment, however in other it is u ed as the final pha e 
of treatment (boo t), that i , after an initial cour e of 
external beam radiation . The obviou advantage of 
brachy therapy in treating any malignancy i that the 
radioactive ource i plac d either in the tumor or very 
do e to the tumor and hence receive a relatively higher 
do e of radiation. However, a you move away from the 
ource, the radioactivity fall precipitously, and the 
urrounding normal ti ue receives a relatively le s 
amount of radiation. Henc , if brachytherapy procedure is 
carri d out properly, (i.e. the ources are placed in 
appropriate locations and at appropriate interval ) we are 
able to achieve very good tumor control with acceptable 
treatment complication . One of the major ide effect of 
e temal beam radiotherap in head and neck cancer i 
xero tomia (dry mouth) w hich occur a a re ult of 
irradiation of alivary gland . In brachytherapy, ince the 
major alivary gland do not receive ignificant amount of 
radiation, the incidence of xero tomia is minimal. Thi i a 
major advantage. Brachytherapy in general i not only a 
cience but al o an art. It i le forgiving compared to 
external beam radiotherapy, meaning that if the procedure 
i not carried out properly, and the implant i uboptimal, 
the outcome i bound to b poor. There i major empha is 
in the quality control a p ct of brachytherapy when you 
obtain training in brachytherapy. If the radioactive ource 
are too do e or too far apart, you may end up with not 
enough radiation, which means tumor control is poor, or 
too much radiation in which ca e the complication are 
bound to be severe and unacceptable. Adequate training is 
e enti a! before one contemplate carry ing out 
brachyth rapy. 
Since I have had formal training in ear, no e and 
throat urgery, I felt I could u e my experti e to trea t 
patient with head and neck cancer. My previous surgical 
training has certainly help d me in learning the technique 
of head and neck brachytherapy. I started the head and 
neck brachytherapy program at the Lo ndon Regional 
Cancer Centre a few year ago. Since then I have been able 
to do 19 lr implant in highly elected patient with tumor 
involving the tongue, floor of mouth and lip . 
You are also using brachytherapy to treat patients with 
prostate cancer. Can you describe the principles of this 
treatment? 
Dr. Glenn Bauman and I have started a pro tate 
brachytherapy program at the London Regional Cancer 
Centre . It i done in a multidi ciplinary etting in 
8 
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conj unction with the urology department and the 
radiology department. Dr. Joe Chin i the urologi t 
involved, and we are al o collaborating with Dr. Downey, 
a radiologi tat the niver ity Ho pita) and Dr. A. Fenster, 
a cienti t at the Robart Re earch In titute who ha a 
pedal intere tin 3D transrectal ultra ound. 
Pro tate brachythera y involves implantation of 
radioacti e iodine eed (1 1 ) into the pro tate and seminal 
ve icle under transrectal ultra ound guidance (TRUS) 
utilizing a template to guide the needle. Radioactive I125 
ed are permanently implanted in the pro tate and they 
relea e the radiation over a period of time. The large t 
e perience of tran rectal ultra ound guided pro tate 
brach therapy i from Seattle, Wa hington, where over 
1500 patient have been treated over the Ia t 10 to 12 year . 
In a elected group of prostate cancer patient , extremely 
good re ult have been reported by them. The e include 
patient with mall, low grade pro tate cancer with PSA 
<10. The grade of the tumor i determined b y th e 
pathologi t, who as ign a core to the tumor ba ed on the 
hi topathological feature and thi i referred to a the 
Glea on score. In the tudie reported to date, they have 
found that the patients with a Glea on core of 6 or le 
tend to do very well. Serum pro tate pecific antigen 
(PSA) level i a ve ry u eful prognostic indicator in 
pro tate cancer. PSA i a glycoprotei n that can be 
mea ured in the erum of patient . Higher value indicate 
wor e progno i . The number of radioactive iodine eed 
that are inserted under transrectal ultrasound guidance i 
determined b the ize and shape of the pro tate gland, 
which i again determined by the tran rectal ultra ound . 
The procedure i carried out by a team con i ting of the 
urologi t, radiation oncologi t, and the radiologi t. The 
procedure can be done either under general anae the ia or 
pinal anae the ia and take appro imately an hour or 
two. 
Currently, the modalitie of treatment which are 
con idered to be tandard for organ confined pro tate 
cancer are urgery and external beam radiotherapy . 
Pro tate brachytherapy i till con idered omewhat 
experimen tal. It has been around for appro imately 10 to 
15 years, and hence, long term re ult of thi treatment 
modality are not available. It i hoped that in 5 to 10 year , 
it will be con idered a one of the acceptable treatment 
option for organ confined pro tate cancer. Brachytherapy 
i now offered to a highly elected group of patient who 
have mall organ confined tumor with Glea on core 6 or 
le and a PSA le than 10. We feel that the e patient 
b nefit the mo t. We have already treated everal patient 
u ing this modality and the program i expanding to the 
point that in the near future, we will be doing at lea t one 
or two implant per week . We are in the proce of 
commencing a tran -Canada randomized trial w hi ch 
compare radical pro tatectomy with brachytherapy for 
early tage low grade organ confined pro tate cancer with 
PSA le than 10. 
How does brachytherapy compare to more conventional 
treatment modalities for prostate cancer? 
If the patient are elected properly for pro tate 
brachytherapy u ing the criteria outlined above, the 
outcome i thought to be comparable to urgery and 
Profiles 
e ternal beam radiotherapy. There are no prospective 
randomized trial which compare brachytherapy with 
other modalities. The re ult are mainly from retro pective 
serie . One of the main advantage of brachytherapy is the 
convenience to the patient. The patient i discharged home 
on the day of the procedure or the very next day and ince 
the po t-operative recovery is quick, he returns to hi life 
routine within a hart period of time after the I125 implant. 
Brachytherapy doe have ide effects, including urinary 
frequency, nocturia, dy uria and urgency. There i a mall 
ri k of perineal hematoma. A mall proportion of patients, 
le than 3%, develop comple te urinary retention for 
w hich an indwelling urinary catheter is required for a 
period of time. The incidence of impotence i thought to 
be relatively le s compared to urgery and external beam 
radiothera p y. Most of the ide effects from pro tate 
brachytherapy are u ually minimal and temporary . If 
properly selected, the incidence of incontinence with 
brachytherapy i ver y low compared to radi cal 
pro tatectomy. The duration of hospitalization a tated 
above is less compared to urgery. One of the major 
advantage of brachytherapy over external beam radiation 
therapy is the duration of treatment is short and hence it i 
very convenient to the patient. As stated before, pro tate 
brachytherapy is an art a well a a cience and there i a 
learning curve for the team which carries out the implant. 
It ha been recentl y reported that it takes the team 
approximately 4 to 5 year to perfect this technique. The 
re ult of pro tate implant i only a good as the geometry 
of the implant and there i le s room for error compared to 
external beam radiotherapy. It i less forgiving compared 
to external beam radiation. If the radioactive eed are not 
in erted in appropriate place , you may end up with the 
eed too far apart re ulting in under-dosage and hence 
poor tumor control or the eed may be crowding in one 
area re ulting in a hot pot a nd, hence, increa ed 
complication rate uch a urinary incontinence due to 
urethral damage. Thi i very much a technique oriented 
modality and the experti e of people concerned i very 
important in term of outcome. 
Is there a difference in survival between prostate cancer 
patients treated with b rachytherapy and those treated 
with surgery and external beam radiation? 
Currently we have -year re ults on the tumor control 
and complication rate for pro tate brachytherapy from 
the Seattle group. In patients who are carefully elected for 
brachytherapy there ult are very comparable to urgery 
and external beam radiation therapy. However, ince we 
do not have long term follow-up, (i.e. 10 to 15 year 
follow- up ) we cannot claim that the re ult of 
brachy therapy are a good a tho e of urgery and 
radio therapy. To orne ex tent, brachytherapy ha 
with toad the te t of time. The Seattle group ha ve 
demon trated that the biochemical progression free and 
clinical di ea e free survival curve have reached a plateau 
a t 8 years. 
In your opinion, w hat are important issues in prostate 
can cer research at the p resent time? 
i. Conf ormal Exte rn a l Bea m Ra dio t herapy using 
Computerized Tomography (CT) 
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A practical i ue in external beam radiotherapy i how 
be t to deli er the radiation do e, to the pro tate gland 
without giving excessive radiation to the urrounding 
normal ti ue . We are now u ing a new technique 
called "conformal external beam radiation therapy" 
which refer to treating the pro tate with a margin. 
Computerized tomography (CT) ha improved our 
ability to localize and recon truct the tumor and the 
anatomy of the urrounding tructures in order to 
accurately de ign the radiotherapy treatment field . 
Many tudies are currently underway to a e the 
efficacy and toxicity of conformal external beam 
radiation therapy in pro tate cancer. In imple term , 
the patient i immobilized, the location and ext nt of 
the pro tate gland i delineated using a CT can and 
then with ophi ticated computerized technology, the 
radiation do e is delivered to the prostate gland with a 
margin in an accura te manner. With thi unique 
technique, we have now proved that it is po ible to 
give a relatively higher dose of radiation to th e 
pro tate gland with acceptable ide effect . In patient 
with omewhat bulky pro tate cancers, we hop that 
by giving higher do e of radiation than before, we 
might be able to achieve better control of the tumor. 
We ultimately hope that thi will tran late to a better 
urvival. There are many cancer centre wherein 
re earch pertaining to thi area are being carried out 
including our . Since we are only treating the pro tate 
gland with a mall but acceptable margin and avoid 
exce ive irradiation to the urrounding normal tis ue, 
we are able to grad ually increa e the do e (do e 
e calation tudie ) and the re ult of this exciting 
re earch i awai ted. 
u. High Risk Localized Prostate Cancer 
Standard therapy for the e patient yield poor re ults. 
Re earch i under way to improve the re ul ts by 
combining hormone therapy given before, during 
and/ or after external beam radiotherapy. Multicentre 
trials are underway to look at the efficacy a well a 
the quality of life issue . 
u1. Metastatic Prostate Cancer 
The conventional treatment for meta tatic pro tate 
cancer i hormone therapy, i.e., ca tration, either by 
urgical or medical mean . Although Androgen 
ablation re ult in rapid and often dramatic 
improvement in mo t patient , the duration of 
re pon e i limited and ultimatel y mo t of them 
develop hormone refractory di ea e. Almost a ll of 
the e patient with hormone refractory di ea e die of 
their disea e within a year or two . Research i 
underwa y to tudy the mechanism of h ormone 
refractionne and examine the role of drug re i tance 
marker . Ultimately the goal of this re earch i to 
develop treatment which will be effective for the e 
patient , e.g., molecular directed therapy. Q 
Have you heard? 
With HP Stethos, HP 
has applied decades of 
technology advances 
to redefine a 
fundamental tool of 
medicine. HP Stethos greatly 
expands acoustic thresholds, 
amplifying sounds at the touch of a 
button, filtering out unwanted 
sounds, and eliminating sound loss. 
The HP Stethos (M4504A) is a 
product well worth hearing more 
about! For information, or to place 
an order, call l -800-291-6743, 
option 1. 
Information about HP Medical Pr oducts 
Group can be found on the World Wide 
Web a t h ttp://www.hp.com/go/medical. 
New product information: 
Click on ffitrasound Imaging and learn more 
about the ImagePoint Hx: HP's new 
multispecialty ultrasound y tern with 
Harmonic Imaging. 
Fl,;'tl HEWLETT ~~PACKARD 
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EDITOR: D AVID J. SATIN & NYAN NARINE 
GUT REACTIONS: AN ETHICAL ANALYSIS OF 
EMERGING BIOTECHNOLOGIES 
For thi i ue' ethic editorial, I have cho en to di cu everal broad ethical con iderations urrounding an article written b Glenna Cuccarolo 
entitled, "AT RISK FOR BREAST CANCER? Tlze Ups and 
Downs of Genetic Breast Can cer Tes ting. " 1 A it's title 
ugge t , her article pre ent potentially positive and 
negative a p ct of the biomedical application of per onal 
genetic information; namel y elective creening for 
mutations in brea t cancer u ceptibility gene (BRCAl 
and 2) and the medica] manag ment thereof. I will employ 
BRCA gene technology both a an e ample (albeit not an 
e emplar) of a ver po itive development and a a foil for 
potentially negative trend in the field of biotechnology. 
I am a firm believer in the wi dom of the G.I. tract. It' 
not that I di count more cerebral analy i , rather I 
con ider vi cera! ensation riou ly enough to merit 
inve tigation. When we hear the term ' uclear' and the 
name 'Ein tein' in the same ntence we typically picture 
an eccentric, kindly-looking old man, with white hair 
flailing atop a head of geniu . - Thi i our gut reaction. 
However, when we put the name 'Oppenheimer' together 
with " uclear", few among u imagine the my terie of 
the univer e unraveling in the ph ici t' cloud chamber. 
Rather, mo t of u picture a very different cloud over 
Hjro hjma or aga ab- Another gut reaction. I propo e 
that these gut reactions repre nt a valuable di tinction we 
can take to heart when con idering revolutionary 
di coverie and new technologie . T day, our gut reaction 
to the name 'Wat on and Crick' coupled with 'Genetic ' 
i mo t probably a pristine picture of the beautiful double 
helix - A po itive gut reaction. I hope we feel the arne in 
fifty year . 
My gut reaction i rruxed. Ju t a nuclear power can be 
a force of rna ive amount of energy a well a rna 
de truction, genetic biotechnology hold the potential to 
cure di ea e or devalue humanity. I do feel hopeful when 
con idering our current capacit to empower orne 
women with valuable knowledge of their own D A. I 
marvel at the pro pect of curing genetic di ea e. But I feel 
unea y when picturing the very rea] potentia] for trung to 
go terribly awry. These are not apocalyptic scribble on 
the picket ign of a street-corner fanatic. The e are the 
view voiced by our cienti t , phy ician , ethici t , 
economi t , and politician .u~ M concern here, i no 
more over the cientific di co ery of the gene than over 
the di covery of the atom, for tho cat have long b en 
out of the bag. Furthermore, I would hardly choo e to de-
di cover uch phenomena, for I could never turn away 
from their irnmen e po itive potential- but my family did 
By David J. Satin, MEDS 2001 
not live in ffiro hima, aga aki, Three Mile I land, or 
Chernobyl. A emotionally laden a the term ' uclear' i 
pre ently, I believe 'Genetic' may one day urpa it in 
heer magnitude. Whether the direction of the e emotion 
will be po itive or negative i the ubject at hand. 
I believe we have a collective duty to actively promote 
the positive technological developments and actively 
denounce the negatives - or at very lea t contribute to 
public debate. Di cerning the po itive from the negative 
i an integral part of what I believe ought to be the moral 
debate. The following i a fragment of the type of 
rea oning I believe hould b involved in di criminating 
among 'good' and 'bad' biotechnologie . I do not purport 
to b providing a complete account of the i ue at hand. 
Far from a doctrine, I offer food for the thought of 
phy icians. I wiU employ the current practice of elective 
BRCA (1 and 2) screening a repre entative of an overall 
'good' technology. I will contra t the approach taken with 
re pect to uch technology with the current approach of 
the Human Genome Project. 
Clas ically trained , I'm compelled to begin my 
analy is by con idering how a given technology fare with 
re pect to tandard etrucai theorie . The Utilitarian hold 
tock in mo t biotechnologie for, like mo t technologie , 
they are de igned to improve outcome thereby incr a ing 
the total happines of the u er. Selectively creening for 
BRCA gene mutations may certainly achieve uch a goal 
a early diagno is tend to improve overall outcome .1 The 
Human Genome Project aim to con truct a complete 
blueprint of the human genome. The Utilitarian ought to 
approve of tru project under the condition that its re ult 
ultimately increa e th total happine of the population. 
Practically, thi means that if information derived from the 
complete blueprint enabl phy ician to cure a given 
di ea e uch a mu cular dy trophy, then the Utilitarian 
would b wayed toward approval. 
Thu far, both our candidate are doing well. 
However, the moral tatu regarding the order (or lack 
thereof) in which the Human Genome Project currently 
uncover information ha recently been challenged.:uA The 
project ha no mandate tating that we ought to fir t 
uncover the natur of the genes responsible for 
humanity's mo t prevalent di ea es, or tho e di ea e 
a ociated with the highe t mortality or morbidity. 
Without uch a mandate, the mo t ought after gene 
patent effectively become tho e mo t economically 
beneficial to the re archer. 
ot only might we find fault in the project' lack of 
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prioritie , but we may question the w i darn of mapping 
the entire human genome. For e xample, there are 
current) Biotech Corporations earching among the 
Icelandic genome for the blond hair, blue eyed ca h-cow.2 
The not- a-futuristic image of eugenics, o r the 
bioengineering of ' perfect' people, ought to be di turbing. 
But the Utilitarian may be les faint of heart, for it i a 
contingent matter whether a homogeneou 'master-race' 
may indeed promote the greatest happine . This virtual 
reduc tio-ad-absu rdum demons trate why we cannot 
entertain a unidimensional, or purely Utilitarian analy i -
our gut reactions ought to be negative. 
Ju tice demand that no biotechnology marginalize a 
group of people or create greater unfaimes . Selective 
creening, uch a the aforementioned BRCA protocol, 
ultimate ly bridges fairnes gaps by empowering and 
indirectly promoting the phy ical health of tho e at high 
ri k of disea e. There is alwa y a concern however, 
regarding the question of who get creened and who 
doe not. Currently, tho e who fulfill the creening criteria 
(i.e. tho e at highe t ri k) are offered funded creen while 
tho e who are at a les er ri k may purcha e the creen. 
Thi rai e the specter of unequal health care, fo r the 
wealth woman can effectively purcha e empowerment in 
the form of more informed deci ion with respect to a 
wide variety of health care management trategie . While 
thi i an important i ue to be worked out, it is not a 
challenge particular to biotechnologie but rather to health 
care in general. 
The result of the Human Genome Project on the other 
hand, will probably not only hares thi problem in 
pade , but may allow parent of the future to purcha e 
' p rfect' de igner children. The que t for ' perfection' i the 
i ue here. The proce of attaining perfection force u to 
identify, tigrnatize, and devalue ' imperfection'. Thi may 
lead to the marginalization of tho e who fail to meet the 
tandard ; a haunting theme often revisited in novel 
formerly known as fictional. 
Finally, Kantian (or more broadly, Deontological) 
ethic demand respect for human dignity. Selective 
creening for oncogenic BRCA mutations promote 
human dignity by giving women greater control over their 
health, and enabling them to po sibly avoid a crippling 
di ea e . Uncovering all human genetic information may 
ultimately detract from the elf-re pect and dignity of the 
' imperfect'. Several que tion ought to be con idered, 
"Can the earch for non-di ea e-cau ing genes be halted? 
What count a a di ea e-cau ing gene? For example, i 
Tourette' ufficiently di abling to merit re earch with the 
goal of eradicating the di ea e from future generations? I 
rneiopia? How about hart, or even average stature?"3 We 
ought not promote the reduction of human valu , or 
dignity, to the urn of our attributes. 
The allure of biotechnologie re ide in our 
overw he lming, pervasive, and mo t ea ily acce ible 
Utilitarian leaning . 'Succe ' i ty pically judged by 
practical outcomes, accurately mea ured and preci ely 
calculated to the nth decimal place. Utili ty is conducive to 
science. Justice and human dignity are not. They cannot 
be quantified. Some therefore interpret them as bein g 
invaluable, others see them as having no value at all. It 
thus s tands to reason that we must see beyond science if 
w e a re to app reciate w hat is at s tak e in evaluating 
biotechnologies. We must embrace our roles as f hY icians 
qua persons, and physician qua political entities, le t our 
legacy be a gut feeling of the war t kind. 
Ein tein wa once quoted in conversation with 
colleague H .A. Lorentz aying, "One must divide one's 
time between politic and equations. But our equations are 
much more important to me."6 Einstein often spoke in a 
Kantian way by referring to duty. He recognized that 
there can be no uch thing as a complete, exclu ive, 
scientist qua scientist; for all cienti t are persons, and all 
per on are, by definition, moral beings. Due to the nature 
of their work, phy ici t of that time ought to have openly 
expre sed political commitments as well a scientific one . 
Phy icians today are in a very similar position. 
The purpo e of the opening to this editorial wa not to 
demonize Oppenheimer, for I hold him in high regard . 
Rather i t is to illustrate how exclusive scientists qua 
scientists, even great one , cannot fulfill their social 
obligations. While Oppenheimer may have had the be t of 
intention and the mo t noble of beliefs, he nevertheless 
went unheard. Einstein on the other hand, i known for 
his objection to the very project for which he constructed 
the theoretical groundwork. 
The type of warnings we currently hear regarding 
biotechnologie re ernble tho e voiced by Einstein. His 
insight and public a sertions helped separate his per ana 
from Oppenheimer' s . Let u ensure that when we look 
back upon Wat on and Crick, our gut reaction leave us 
with a pleasant atiety rather than a bellyache and a 
feeling of impending doom. Let u be more gourmet than 
gourmand. I'm dedicated to the belief that the outcome of 
medical biotechnology lie in the hand of the phy ician 
that employ it. Some believe that since they did not make 
the world the way it i , they cannot be held accountable 
for upholding the tatu quo. In truth, I believe we a ll 
make the world the way it i . 
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MEDICINE ON T HE INTERNET 
EDITORS: ANAND PANDYA & MUNSIF BHJMANI 
ONCOLOGY ON THE INTERNET 
Like any other medical field , oncology has an appreciable repre entation on the Internet. This i not surprising, a cancer is one of the leading cau e 
of mortality in developed nation like Canada 
(www.s tatcan.ca/Daily/Engli sh /980416/d980416.htm). 
Therefore it i important a medical practitioners, to rely 
on ource of information that are reliable and evidence-
ba ed . A may be expected, a short article cannot do 
ju tice to all the internet ite on oncology. However, the 
beauty of the Internet lie in the pre ence of 'hyperlinks' 
that connect ite to one another. Therefore, if one can 
begin an adventure of web surfing by looking up a few 
ite on a particular topic, then one i bound to be 
infinitely linked to a plethora of additional site , each 
containing va t amount of enlightening information. 
A a medical student, perhap the mo t important 
que tion in my mind i one of re ource allocation. The 
word 'cutbacks' ha become an anthem to mo t Canadians 
and e pecially to phy ician who bear the brunt of 
government cutback in health-care. When dealing with 
oncology, my first impul e would be to ask how acce sible 
is specialized cancer treatment for people in rural area . 
The internet hold the answer to thi dilemma by uniting 
information from around the world at your fingertip . 
Perhap the fir t web- ite to vi it for such 
information is the Cancer Care Ontario (CCO) page 
(www.cancercare.on.ca). ceo i an agency formed by the 
government of Ontario to provide leader hip to variou 
cancer-care ervices in Ontario. The web-page ha much 
information regarding government initiatives in oncology 
including uch recent news as the opening of new cancer 
centre in 0 hawa, Mi i auga and Kitchener-Waterloo 
a well a the long waiting li t for radiation therapy. It 
also contain hyperlink to the eight regional cancer 
centres in Ontario which are located in Hamilton, London, 
Toronto, Wind or, Kingston, Thunder-Bay ( orth-
We tern Ontario) and Sudbury ( orth-Eastern Ontario). 
Web- ite for each of the e regional cancer centre contain 
a wealth of information on the service available at each of 
the e localitie , the re earch being carried out there, and 
various medically relevant material. All eight cancer 
centres can be acces ed from the ceo web page and 
would be an excellent tarting point to apprai e the 
facilitie available in rural regional cancer centre . It 
would al o be a good way of getting in touch with health 
care profe ionals at different community based cancer 
centres. 
After thi , the next tep would be to find out more 
about the therapeutic and re earch aspect of oncology. 
Basically, surgical excisions of tumor , chemotherapeutic 
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intervention, radiation therapy or combinations are 
currently used to treat most malignancie . Physician 
pecializing in each of the e area (surgical oncologists, 
medical oncologi t and radiation oncologi t 
re pectively) carry out the different therapeutic strategie . 
The Oncolink web-site at the Univer ity of Penn ylvania 
ha a detailed ection devoted to each of the therapeutic 
mode (www.oncolink.upenn.edu/speciality) . The site 
al o keep track of frontier therapeutic re earch such a 
monoclonal tumor- pecific antibodie conjugated to toxins 
or anti-tumour cytokine . 
On the commercial side, Genentech, a biotechnology 
company experimenting with everal anti-cancer 
therapie , maintain a very informative oncology ite 
(www.biooncology.com). One area they adverti e i a 
novel therapeutic agent Herceptin®, a monoclonal 
antibody u ed to treat breast cancer. This site al o include 
information on upcoming meeting , an oncology glossary 
and link to other equally informative ite . Entremed, the 
company that hold patent for Angio tatin and 
Endo tatin, ha a web ite (www.entremed.com) with 
much information on new therapie including update on 
when human clinical trial are expected to begin. 
To enhance our knowledge of the ongoing advance in 
the world of oncology even further, we can urf over to 
the Oncology Therapeutic etwork web site 
(www.otnet.com) or vi it the immunotherapy and gene-
therapy weekly new relea e at www.newsfile.com. I 
al o ugge t visiting the medicine-online web site at 
www.meds.com where one can find an online cancer 
library and a databa of chemotherapeutic agents. Thi 
ite al o has an online calculator for calculating the 
do age of variou chemotherapeutic drug . 
Another idea for the net surfer would be to vi it the 
web ite of variou cancer centre in the United State . 
Some of them are definitely involved in novel therapie 
that may be of intere t to u in Canada. All the American 
cancer centres are li ted with the IH at 
www .nci.nih.gov/cancercenters/centersl.htm. 
Keeping up with clinical research i highly 
important for oncologists . The Oncolink ite has a 
de v oted a ection to ongoing clinical trial 
(www .oncolink.edu/clinical_ trials) . One could even 
ub cribe to an automated electronic mailing list giving 
update on recent novel anti-tumour therapie . Another 
li t of clinical trial in the United State can be accessed at 
www.centerwatch .co m . Furthermore, the American 
ational Cancer In titute ( CI) ite 
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(cancernet.nci.nih.gov/nci.htm) at IH ha inter ting 
ections in various branche of oncology for both a ba ic-
cience re earcher, and a clinician. 
In keeping wi th the need for phy icians to b well 
informed of their patient population, it is es entia! to be 
aware of th tati tic a sociated wi th cancer incidence 
and mortality . Such ta ti tic ar readily obtain d by 
doing a earch on the Stati ti c Canada web- ite 
(www.statcan.ca) for cancer, oncology or indeed an other 
health related item . After a few econd , the arch 
re pond wi th numerou document , chart , and table 
ummarizing a multitude of relevant Canadian tati tic . 
However, if one want e en ea ier acce s to uch figure 
pecilically for cancer, I ugge t con ulting the Statistic 
ection of the ational Cancer In titute of Canada 
(www.cancer.ca/stats) where updat d 1998 stati tic can 
b obtained. 
The internet ites mentioned o far are only a few 
e ample of what i available out there . For tho e 
intere ted in vi iting a many web- ite a po ib le, I 
ugge t consulting a ite maintain d by the Univer ity of 
ewca ti e in England which ha a compilation of 
cancer link from a round the worl d 
(http :// www .ncl.ac. u k / -nch ww w/gui de s/ 
clinksl.htm). The have done an excellent job of 
ca taloguing the ite into categorie ba ed on 
region and type of cane r. In addition, the 
have indicated the usefulne of the e ite for 
patient , familie , phy ician and re earcher . If 
you are intere ted in cancer and enjoy urfing the 
Internet, a vi it to thi web page may begin a long 
journey into the multi-dimen ional nature of 
oncology. 
La tly, I would like to point out a few site 
that are good reference for our patient . Mo t of 
the reputable ite I have indicated o far contain 
a pedal ction directed pecificall to patient 
and their familie . The e include the Oncolink 
ite at the Univer ity of Penn y lvania and the 
American CI ite at the IH. Among Canadian 
re ource , the eight regional cancer centre all 
ha ve orne ort of information for patient . 
However, I found that the London Regional 
Cancer Centre (LRCC, www.lrcc.on.ca) and the 
Toronto-Sunnybrook Regional Cancer Centre 
(TSRCC, www.tsrcc.on.ca) are excellent in thi 
regard, directing patient not on! to credible 
information re ource but a! o to community 
re ource that patients may want to acce . The 
TSRCC ha a earchable 'community cancer 
re ource guide' which cover uch i s ue a 
prevention, home-care, caregiver re lief, and 
women and cancer. A imilar cancer re ource 
directory exists at the LRCC. In addition, the 
Canadian Cancer Society (www.cancer.ca) and 
the American Cancer Society (www.cancer.org) 
ha e va t amount of general information on 
cancer. Finally, clinical centre often have links to 
ite created by uppor t group compri ed of cancer 
patient and their familie . A good e ample of the e 
upport group can b en at www.w illow.org (mainly 
for brea t cancer pati nt ) and at www.cancerkids.org (for 
familie of children uffering from cancer) . The e 
r ource would b u eful to cancer patient and thei r 
familie in providing informa tion, ad vice and mu ch 
n ded upport. Q 
Family Physicians needed lor 
Sioux Lookout Zone, NW Ontario 
For a challenging practice opportunity, consider the 28 Fir t 
arion communities in the ioux Lookout Zone. Practice 
5 day /month in fly-in aboriginal communitie , 3 weeks/month 
in the ioux Lookout Zone Ho pita!. 
salaried positions, from S 150,000 - S 185,000, no overhead 
10% early arrival bonus for first 12 doctors 
substantial benefits package; relocation allowance 
- minimum 4 weeks paid vacation; 3 weeks CME; generous 
education allowance 
Ontario Ministry of Health incentive grants available 
teaching opportunities through Northwestern Ontario 
Medical Program (NOMP) 
- Funded site visits for you & your partner 
join the McMa ter Univer ity/ ioux Lookout Zone medical team. 
For more information, contact 
Dr. Harriet Lennox or Lois Mombourquette 
Sioux Loo out Zone Hospi1al Health Sc1ences North 
Box 1500 Box 2063, Sioux Lookout, ON PST 1J7 
Sioux Lookout, ON PST 1C2 1·Bn·S11-1141 (toll-free) or (807) 737-7525 
(807} 737·3030 Fax: (807) 737-7S24 
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ALTERNATIVE 
AND THE 
CANCER THERAPIES 
714X STORY 
C ancer morbidity and mortality is the major problem facing orth American public health today . 1 Chemotherapy and radiation therapie 
have been successful in improving the quality of life for 
many patients, but a definitive cure remains elusive. 
Partly in search for a cure, and partly to improve the 
quality of life for patients non-re ponsive to conventional 
therapie , age and quack alike are touting alternative 
therapie . Alternative therapies, including herbs, 
nutrition, chemical and electromagnetic timulation, have 
rapidly ari en over the past 25 year .1 Only a few of the e 
treatment have been rigorously te ted, and even fewer 
have been validated .5 A a re ult, a great debate has 
emerged between skeptics who await firm evidence before 
using them and tho e who tre that there i no time to 
wa te waiting for cientific authorities to come around 
while cancer patients are uffering. 
The u e of non-conventional therapie has al o 
parked many legal battle again t the companies and 
per on that upply them. The ca e of Charle Pixley and 
the drug 714-X is a particularly alient example? 
714-X is trimethyl bicyclo nitro-amine heptane-cl, a 
nitrogenous camphor product developed by 
biochemist I microbiologi t Gaston ae ens. He rea oned 
that cancer cell u e " co-cancerogenic K factor" to 
uppress the immune sy tern and harne the body's 
nitrogen to replicate. By providing an exogenous source of 
nitrogen, cancer cell could till replicate, but would not 
release "co-cancerogenic K factor" becau e there would be 
no need to capture endogenous nitrogen. This would keep 
the immune sy tern strong and allow for immunity to 
effectively out-compete low cancer growth and defeat the 
cancer. 1 
Ga ton ae ens received his microbiology training in 
France. In the 1960' , he developed an ultraviolet and La er 
light microscopic technique capable of viewing live blood 
with high magnification and re olution.6 Around 1962, 
ae ens reported the discovery of a previously unknown 
rnicroorgani m using hi micro cope. Thi he termed 
" omatid". Hi de criptions of the findings correspond to 
Mycoplasma, di covered by American researchers in the 
arne yearl. Working out of Canada, aessens applied his 
knowledge of the " omatidian" life cycle, gathered with 
u e of his new micro cope, to cancer cells and patented 
714-X a an anti-cancer agent in Canada in Augu t 19 0.7 
He developed a protocol u ing homeopathic rea oning. 
714-X is not intended to attack cancer cells specifically. It 
provide nitrogenou compound to the cell and in so 
doing, suppre ses production of what aes en termed 
"co-cancerogenic K factor", an anti-immune toxin. The 
agent is made more dilute before admini tration ince 
By Mahmoud Shnraf, MEDS 2002 
homeopath rea on the dilution proce to potentiate the 
medicine. 1 
ae ens' protocol involves daily intralymphatic 
injection (1 I day) for 21 days, followed by 2 days re t. This 
is repeated on a cyclical ba is until adequate re ults are 
achieved . Vitamins E and B12 should not be taken 
concurrently.1 A tudy by Bigel on, MD ha shown that 
714-X, in combination with other alternative therapie , 
results in 60-80% effectivenes at rever ing cancer. 1 
In 1989, ae ens wa charged with 4 counts of illegal 
practice of medicine and one count of contributing to the 
death of a person (a patient taking 714-X). 7 He wa 
acquitted on all charge . The arne year, his drug was 
approved in the United State under the Emergenct; Drug 
Relief Act for u e among de perate terminally ill patients.1 
Since 1990, Charle Pixley's company Writers and 
Research Inc. has marketed 714-X in the United State , with 
pre criptions being filled by direct order from aessen ' 
private lab in Rock Fore t, Quebec. Advocate of 714-X 
claimed 75% effectivene in treating cancers u ing the 
ae ens protocol. 
In 1992, the happy state of affairs wa brought to it 
fir t cri i point. The Food and Drug Admini tration, in a 
move contradicting it own per onal import policy on 
non-conventional remedie , i ued an import alert on 714-X 
even as 5000 orders were to be filled. 7 Pixley countered in 
1993 by e tabli hing an In titutional Review Board, a 
vehicle mandated by Congre s to make unapproved drug 
available to the public in preliminary trials. Dietmar 
Schildwaechter, MD, PhD was placed a chief medical 
inve tigator. To satisfy the law on informed consent and to 
ensure proper under tanding, the IRB put out a protocol 
guide entitled Do o Hnrm.7 
The FDA wa not completely satisfied, however. 
Pixley complied by deleting all mention of the IRB from 
the protocol and eliminating the link with physicians 
established under the Emergenct; Drug Relief Act by filling 
order directly to individual customers from the lab in 
Canada. 1 
In 1994, Canada's Health Protection Board concluded 
that 714-X i unsafe and refused official drug status. 
Under the terms of the Canadian In ves tigational and 
Emergency Drug List, the agent was nevertheles accorded 
availability on compa sionate grounds in Canada.6 This to 
date has not been re cindedl. We note that in 1994, 714-X 
wa available, albeit under limited term , in both Canada 
and the United States. 
The Institutional Review Board did not escape the eye 
of the FDA for long. In 1996, charge were brought against 
the IRB in circuit court for impeding an FDA investigation 
into it operation and for illegal importation of a drug 
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into the United State . Pixley and hi a odate were tried, 
convicted and entenced and the IRB wa disbanded and 
it publication suppressed . Mo t recently, Pixley is 
actively fund-raising to mobilize an appeal before the 
Second Circuit Court of Appeal to be headed up by the 
famed lawyer Alan Dershowitz. 1 
The ongoing saga of 714-X i only urprising in that 
government action ha been relati ely wift and ded ive. 
An immen e body of alternative and natural agents 
geared toward cancer and many other illnes e exi t and 
i being u ed by patients, in potentially unsafe way . The 
claim of their producer vary from ba ele to fairly 
rea onable, a in this ca e. Given the tremendou amount 
of concern these ill patient expre , and their 
vulnerability to opportuni tic manufacturers or wi hful 
thinking, it i advisable that the onu for proving efficacy 
be put on the advocate of al ternative treatment before 
their product can b marketed as having any medicinal 
value. Criminal penalty hould be the consequen e for 
infringement. 
The e recommendation will admitted! prejudice 
mall- cale producer who cannot challenge th monopoly 
held by the big pharmaceutical companie . However, it i 
fea ible that mall- cale producer could cooperate with 
academia to validate their product cientifically in 
exchange for profit haring or government re arch 
funding given on a merit ba i to group with alternative 
therap propo al . It i crucial that ound cientific 
evidence about medicinal treatment be ought in a timely 
fa hion, and then tran lated into safe product with 
therapeutic potential. 
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THE CAUSE AND 
ILLNESS AND HEALING 
CURE: 
IN 
CULTURES 
THE 
TRADITIONAL 
I n traditional culture , health and healing have been unified with the concept of religion and morality. Historically, healing practice have been ritualistic and 
religiou . Similarly, ickne ha been linked to the 
violation of e tablished moral norm . In many culture , 
phy ical illne s has been a ociated wi th a disharmony 
between the individual and the univer e. The concepts of 
bad karma in Hinduism and the connection in Christianity 
of illne and in are example of how moral digre ion 
can be considered to manife t in phy ical di ea e. Thu , in 
traditional cultures, ickne s ha distinct cau ation . 
Tradition culture al o often have pecific type of healer 
that can cure illnes through rituali tic or religiou 
method . Thi article i a brief review of di ea e causation 
and disea e cure in traditional culture . 
DISEASE CAUSATION 
Theories of disea e cau ation in traditional culture 
u ually involve personalized agents that afflict the 
unlucky or morally tran gre sive individual. Many 
traditional culture hare the view that all natural object , 
even tho e that are inanimate, po e a oul. The soul i 
e pecially potent in living things, and even more o in 
human being . This belief i termed anirni m (from anima, 
oul). Tho e who believe in animism con ider the world to 
be alive, and all objects in the world to have a will and 
per onality. Bad thing , uch a ickne , occur becau e 
they are willed by another, often for per onal rea ons. By 
calling ickne the re ult of a di harmonious interaction 
with another, it is framed in a moral context. The ill per on 
ha in ulted or offended omeone, u ually a deity, an 
ance tor, or another human being. 
Deitie exi tin mo t traditional cultures. They are 
re pon ible for the creation of both human life and the 
rule that human life mu t abide. Violation of the e law 
invite puni hment from the god or god , in the form of 
mi fortune, ickne s and death. Both Judaic and I Iamie 
tradition , for example, have very detailed and rigid code 
of conduct that are maintained by a ystem of reward and 
con equence. In orne culture , p cific di ea e are even 
directly linked with a god. For e ample, offence of the 
Hindu godde Shitala is thought to lead to mallpox. 
Offen e can al o be given to the dead, who in many 
traditional cultures are believed to have the ability to exi t 
in a noncorporal form. In the e culture , the dead take 
great intere t in the living, particularly in the activitie of 
their de cendant . Tho e that die in an unhappy tate may 
be tran formed into gho t or demon , who in their 
fru trated tate, try to avenge them elves on the living. 
By Sherry Rohekar, MEDS 2001 
The e traditional culture believe that illne s is caused by 
not re pecting and revering deceased relatives, or through 
the maleficence of angry and Listie s gho t . 
Traditional culture al o often view sicknes and bad 
luck a the con equence of more mundane interaction . 
There often exists a belief that inconsiderate behaviour to 
other can cau e illne . Thi is epitomized by the concept 
of the mal ojo or evil eye. Sickne is directly correlated 
with the hatred, jealou y, envy or wrath of an offended 
human being. The offended party may cau e the 
individual to become ick them elves or they may con ult 
a rna ter of charms, uch a a witch or sorcerer. 
Whether an illne i triggered b an angry human, an 
offended pirit, or a cro ed deity, there are u ually 
repeating theme in traditional culture of how thi energy 
i pent to cau e actual di ea e. Soul loss, object intru ion, 
pirit intrusion and di ea e orcery are the mo t common 
theorie of how illne is immediately cau ed. 
Soul los involve a relationship between the 
weakening of the body and the weakening of the soul. If 
the oul is in poor health, the body reflects thi and cannot 
heal. Whereas common orth American belief place 
greater importance in the exi tence of a body (no body, no 
per on), traditional culture view the oul a the main 
requirement for exi tence. Somewhat hypocritically, 
though, mo t orth Americans will not find it unusual to 
blame a per on' illne on a "lo t will to live". 
Sickne s caused by object intrusion is due to a foreign 
ub tance that has been introduced into the body. Many 
traditional culture propo e that orne object ha been 
injected into the afflicted; indeed, orcery is ba ed on the 
ability to do so. If the obj ct i not removed, it make the 
per on ill and then kill th m. Spirit intrusion i a similar 
concept, involving the po e ion of the ill per on by a 
pirit or ancestral gho t. It i often con idered the 
mechanism of mental illnes . Even modern orth 
American culture colloquially refer to the concept of 
pirit intru ion: "He' not him elf today, something ha 
gotten into him." 
Di ease orcery i an e ample of a traditional belief in 
which the immediate and ultimate cau e of illne ar the 
arne. In this belief, a witch or sorcerer is able to channel 
p ychic power or the energy of their will through charms 
and ritual . Di ea e cau ation i viewed by traditional 
culture as the re ult of personal interactions. The 
conviction that all inhabitant of the earth po e a will 
and soul allows tran gre ion against that culture' 
ethical norm to be translated into disea e ju tification. 
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DISEASE CURE 
Diagno i and therapy of illne in traditional culture 
relie heavily on the cau ative agent. The healer mu t b 
able to connect religion, custom and interper onal kills to 
determine the cau e of the sickne and thereby effectively 
combat it. For example, if a per on ha developed an 
illne due to soul Joss, the healer mu t be erudite in the 
path that the Jo t soul ha taken. Alternatively, if the 
illne i largely piritual, the healer must be able to olve 
the moral and religiou problem the tricken individual 
ha . In traditional culture , there are everal ty pes of 
medical peciali ts that appear repeatedly. The e are the 
shaman, the pirit medium, the prie t, the holy per on and 
the pre criptioni t. 
The haman i con idered to be a rna ter of the oul. 
He or he ha the ability to travel to the pirit realm where 
the ouls of the ick have wandered. Through thi direct 
connection with the spirit world, the shaman ha the 
ability to ee the soul and a k the help of a piri t or 
healing ally. In mo t traditional culture , the shaman i a 
part of the divine as much a the world of healing. 
The motif of a pirit medium u d to cure the ick i 
al o one that commonly appears in traditional culture . 
The pirit medium can summon spirit and allow them to 
act through his or her body to affect the material world. 
Unlike the haman, however, the medium is imply a 
pa ive tool of the pirit, who in tigate the actual healing. 
The theme of consulting pirituaJ power is repeated 
in another type of traditional healer: the priest. If the 
illne ha been triggered by offense or insult to a dei ty or 
spirit, the prie t can help appea e the offended party. 
Only trained prie ts know the prayer and rituals that 
upplicate angry deitie and pirit . Holy people derive 
their healing power from a imilar bond with deitie , 
how ever, they have an innate acredne s and healing 
power due to their goodne sand piety. It may be believed 
that a god i working through the holy per on. 
A pre criptioni t, in traditional culture , pecializ in 
preparing medicines. In addition to being learned in the 
natural attribute of plant , they have a special connection 
to the spirit of plant . The medicine i almo t al ays 
compo ed with the practice of ritual , or the saying of 
prayer . The ill per on may al o be given tringent rules 
about taking the preparation, and prayer to recite. 
Di ea e cure ha certain repeating theme in 
traditional culture . The healer all pos ess pecial talent 
that allo w them to be in intimate contact with the 
piritual world. This allow the healer to u e hi or her 
know ledge about the culture' belief and traditions in an 
attempt to correct the di harmony that i cau ing ickne . 
The concept of religion and moral con equence being 
combined with sicknes and health i quite prevalent in 
traditional cultures. To what extent tho e idea are 
manife t in our orth American culture' s view of health 
and healing i a topic that warrant further consideration. 
Doe modem medicine al o imply a connection between 
human behaviour, cau e and cure? An under tanding of 
the cultural environment that urround medicine can 
surely erve to improve medical practice. 
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THE TESTICULAR SELF-EXAM: 
SHOULD A WIDESPREAD EDUCATION 
PROGRAM BE IMPLEMENTED? 
D e pite the fact that te ticular tumours account for approximately 1% of all neoplasms in men, they are the mo t common form of cancer in men between 
15-35 years old. As a result, in the la t 15 year , there ha 
been an empha is by various groups to en ure that 
phy icians are instructing young men on the testicular 
elf-exam (TSE), and to en ure that men are in fact 
performing this exam on themselves. It appear that many 
groups see a parallel between brea t cancer in women and 
te ticular cancer in men and thu , they also see a parallel 
between the brea t self-exam (BSE) and the TSE. 1 The 
question arises a to just how effective the BSE and TSE 
are when compared to one another and if it is in fact cost-
effective to implement widespread TSE education to 
young men and physicians. 
Te ticular cancer, as mentioned above, is a mainly a 
disease of tho e under 35, as 20% of cancer in thi age 
group originate in the te tide. Thu the di ease tend to 
affect individual in the prime productive years of their 
life. The incidence of te ticular cancer in Caucasians has 
doubled over the pa t 50 year and now is approximately 
5.0/100,000 (in contra t, the incidence for breast cancer is 
6 /100,00). The age adju ted mortality rate, however, has 
been steadily declining, mo tly due to the development of 
more effective treatment modalitie . The current 5-year 
survival rate for most early stage testicular tumours is 
about 95%, although morbidity from treatments tend to 
be high.2 
The mo t important risk factor for te ticular carcinoma 
i cryptorchidism, or undescended te te . Other ri k 
factor of le s importance include a family hi tory of 
testicular cancer, high socioeconomic statu , Cauca ian 
race, gonadal dysgenesis, a congenital inguinal hernia or 
hydrocele and being the child of a mother who had 
exposure to exogenous estrogen during pregnancy. 
Testicular cancer can be grouped into 2 main major 
pathological categories. Seminomas account for 40% of 
te ticular tumours and tend to be radio ensitive. on-
eminomas (embryonal carcinoma, choriocarcinoma, 
endodermal inu carcinoma and teratoma) make up 50% 
of all testicular tumours and are generally les 
radio en itive. 2 One al o often ee tumour of mixed 
histology. Between 50-60% of eminomas and 30% of non-
eminomas pre ent at an early tage of di ea e. Despite 
this, even patients with meta tatic di ea e have about a 
90% cure rate. 
Both types of te ticular tumour tend to pre ent with a 
painle rna within the ub tance of the te tide and it is 
with thi rea oning that the te ticular elf-exam wa 
By Asif Doja, MEDS 2000 
developed. The exam hould be done while the scrotum i 
warm, preferably after a bath or hower. Both hands are 
u ed to roll each testicle between the thumb and finger . 
The te tes, epididymis and spermatic cord hould all be 
palpated and lump , irregularities and any dragging 
sen ations should be noted. It is recommended that men 
aged 15-40 years perform the exam monthly.3 
The American Cancer Society recommends that BSE 
be performed by all women beginning at age 20 and thu 
should be taught to every teenager as a method of 
preventative medicine. The ational Cancer Institute 
recently found that 90% of women in the United State 
were aware of the BSE, although only 24% actually 
perform monthly elf-exams.4 Thi can be contrasted with 
a recent tudy in which a survey of male college student 
indicated that over 41% had been taught TSE, but only 8% 
actually practiced TSE once a month.5 
It i thus argued that more of an emphasis needs to be 
placed on teaching TSE to men in order to attempt to 
detect te ticular cancer a early as possible, in an attempt 
to achieve a near 100% cure rate . Should as much 
emphasis be placed on the TSE a the BSE? Goldenring 
and Purtell1 ugge t that with the cure rate for cancer of 
the teste being greater than that of brea t cancer, and with 
the TSE being a much impler examination technique, our 
current effort are nothing hort of inadequate. Their 
sentiments are underscored ~ many in many other works 
by public health advocate .u ·6 
There ha al o been hown to be a documented delay 
between the onset of ymptoms and the dia3nosis of 
te ticular cancer - u ually in the order of around month . 
Many point to this delay as support for more education 
with regard to TSE. Unfortunately, thi delay appear to 
have more to do with reluctance on the part of both the 
physician and the patient. Patient tend to be reluctant 
because they fear the diagno i , believe they are 
respon ible (i.e . through masturbation or exce sive 
phy ical activity), or fear that treatment will leave them 
impotent or terile. Doctors have been shown in 1 I 3 of 
ca e to be re pon ible for the delay, mostly due to the 
a umption of the mas being a more benign condition 
uch as a hydrocele or epididymitis, or because they are 
reluctant to diagno e a relatively rare cancer in a young 
man .7 As are ult it doe not appear as if encouraging TSE 
education alone would be sufficient to prevent a delay, a 
the actual finding of a rna does not appear to be the 
primary problem. 
Some argue against TSE by claiming that there would 
be a great amount of anxiety caused by the number of 
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false po itives generated as the re ult of young men 
mi takenl y assuming that benign condition w ere 
cancerous.6 Thi has been refuted by a tudy by Weist and 
Finney which showed that training in the TSE among 
college and high chool tudents was not a ociated wi th 
elevated anxiety tates. 
The bigge t evidence against putting more money into 
the amount of TSE training comes by examining how co t 
effective widespread education would be. A mentioned 
before, there is an increa ing incidence in te ticular 
carcinoma amongst young men, but i an increa ing 
incidence a good enough ju tification? The answer mu t 
be no, since creening will only affect mortality and not 
the actual incidence of the disease. Since mortali ty (a 
hown above) is already o low, the scope for screening to 
have an effect i very mall9. In other words, even if TSE 
were to reduce mortality by half, 500,000 men aged 15-34 
would have to perform monthly TSE' for one year in 
order to prevent one death.7 
The major problem with TSE is that no randomized 
control studies have been performed to determine it 
actual benefit. Moreover, it i unlikely that uch a trial will 
ever be performed, due to the rarity of the di ease, the low 
number of death from it, and the high co t of such a trial. 
There have aJ o been no studies that show that men who 
examine their te te are more likely to detect cancer earlier 
or have an improved outcome than men who do not. 
Additionally, very few studies exist which show that 
teaching TSE motivates men to perform it, yet alone to 
perform it correctly.9 
It eem clear that there is a need to educate young 
men about the early pre entation of te ticular cancer in 
order to reduce the delay in diagnosis, but there seems to 
be little hard evidence supporting widespread education 
regarding TSE. The que tion then ari e a to why there 
eems to be o much support for TSE? Is it becau e of the 
parallel being drawn with brea t cancer and BSE? If thi i 
the ca e, it eem imperative to stre to all health care 
advocate that a correlation cannot be drawn between 
the e two di ea e simply becau e they each affect only 
one ex. 
If wide pread TSE education is ineffective, then what 
hould be done? It seems that if any education is to be 
done, it hould be aimed at primary care physician . The 
focus of thi education hould not be on the TSE, but 
hould rather be to simply rai e awarene of te ticular 
neoplasm in general. If family phy icain maintain a high 
index of u picion for testicular carcinoma when dealing 
with any crotal mass, we would mo t likely ee an earlier 
diagno i of the e lesions. Additionally, family doctor 
hould be aware of the u e of other inve tigative tool , 
uch as scrotal ultrasound, when the clinical exam prove 
to be equivocal. 
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THINKING ON YouR FEET 
EDITORS: NIMESH DESAI & ALLAN VESCAN 
A CASE OF CEREBELLOPONTINE 
ANGLE TUMOR 
You are a econd year urgical re ident, rotating through your two month ervice in otolaryngology when presented with the following clinical scenario. 
On Feb 15 an othenvise normal clinic has been booked for 
the day. You are feeling particularly refreshed after a rare full 
six hours of sleep the night before. The first patient you see that 
day is a woman by the name of "Mrs. Smith." On history, Mrs. 
Smith reveals that she was referred to the local E.N. T. specialist 
for her recent difficulties with hearing in her right ear. 
1. Identify two cia e of hearing lo and li t a few of 
the common etiologies of each. 
Upon further discussion, Mrs. Smith describes that her 
hearing lo s has been getting progressively worse in the right 
ear for the past 3 years . She also mentions that it is 110w so 
evere, he is unable to use that ear when speaking on the phone. 
2. Di cuss other points you would want to explore 
during the hi tory that would be pertinent with re pect to 
hearing loss. 
Mr . Smith reveals that she has also been experiencing a 
"hum" in her right ear that has been pre ent for approximately 
the same length of time as the hearing loss. She also recalls 
feeling unsteady at times, but denies any vertiginous epi odes. 
The re t of the history reveals 110 other significant details. On 
examination, a Weber test lateralized to the left and a Rinne test 
was positive in both ears. Romberg's sign was positive with the 
patient falling to the right. Further physical exam reveals no 
other abnormalities. The audiogram below was performed today 
prior to clime. 
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Figure 1. Audiogram of Mr . Smith at time of presentation. 
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3. Discu the above finding with relevance to the 
ca e at hand, including analysis of the audiogram. 
4. Your clinical experience to date leads you to u pect 
a cerebellopontine angle tumor, indicate the "gold 
tandard" imaging modality in thi cenario and li t the 
common tumor of the cerebellopontine angle. 
You have now completed your history and physical exam of 
Mrs. Smith and proceed to present the case to the consultant at 
clinic. 
5. You are asked by the con ultant to give the mo t 
common pre enting ymptom of an acoustic neuroma 
and their relative frequencie . 
The con ultant and yourself have viewed the MR1 images 
and discussed the findings with radiology; you feel rather 
confident that the problem at hand is an acoustic neuroma 
affecting cranial nerve VIII. You discuss with Mrs. Smith your 
suspected diagnoses and proceed to inform her that you feel 
surgical removal of the tumor is the recommended treatment 
modality. 
6. Di cu the different surgical options available and 
common complication a ociated with each. 
ANSWERS 
1. The two cla e of hearing lo s de cribed in the 
literature are conductive and en orineural hearing lo . 
Conductive hearing loss re ults primarily from lesions 
involving the external and middle ear, including the 
tympanic membrane. It can be further cia ified a either 
congenital or acquired . Some example of congenital 
malformations of the ear include atresia of the external ear 
and ossicular abnormalitie . Acquired malformation 
include most commonly, cerumen impaction of the 
external canal, otiti media either uppurative or erou , 
chronic otiti media (cholesteatoma and ero ion of the 
o icular chain), oto clerosi and traumatic perforation of 
the drum with o sicular disruption. 
Sen orineural hearing lo i the result of a lesion to 
the cochlea or auditory divi ion of the VIII cranial nerve, 
or both . It can al o be divided into congenital and 
acquired, with genetic inheritance and maternal rubella 
being two example of congenital hearing loss. Some 
example of acquired hearing lo include, pre byacu i , 
noi e induced hearing lo , ototoxicity due to 
arninoglycoside or cytotoxic , inflammatory condition 
uch as meningiti , mea les, mump , syphili and chronic 
otitis. eoplasm uch a acoustic neuroma and 
idiopathic etiologie uch as Meniere's disea e have al o 
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been implicated.1 
2. Other features that would be important to elicit on 
hi tory include: a ociated otalgia or otorrhea, tinnitu , 
imbalance or en ation of vertigo, exce sive n o i e 
expo ure, pertinent drug hi tory (ototoxic agent ) and 
family hi tory of hearing lo .2 
3 . The result of the Weber and Rinne te t are 
indicative of a ensorineural hearing lo in the right ear. 
The po itive Romberg' ign can be due to a right- ided 
ve tibular di order. The combination of a progre ive 
a ymmetric hearing lo , tinnitu and ve tibular related 
dy function i highly ugge tive of an acou tic neuroma 
of the the right VIllth cranial nerve.3 Audiogram analy i 
further validates our uspicion of a evere right ided 
hearing lo . 
4. The gold standard for the diagno e of an acou tic 
neuroma i gadolinium-enhanced magnetic re onance 
imaging. The ensitivity of high re olution cr to pick up · 
acou tic neuroma of le than lSmm ha been hown to 
be only 4 %.~ It ha b en ugge ted that the increa e in 
u e of MRI ha enabled the mean tumor ize at the time of 
detection to decrease from 27.9mm in 1975 to 
16.5mm in 19 9.5 
The common tumor of the cerebellopontine 
angle include 78% acoustic neuromas, 6.3% 
meningioma , 6.3% cholesteatoma , 5.9% gliomas 
and remaining 3.5% ab ce e and mi cellaneous 
tumour .6 
5 . The mo t commonly encountered 
pre enting ymptom in patients with acoustic 
neuroma were hown by Gillman and Parnes.7 
Thi wa done with a retro pective tudy of 83 
patient , w ith 84 acou tic neuroma , over a 6 year 
period. Hearing lo wa the mo t common 
pre enting ym ptom at 91 %, tinnitus 51 %, 
imbalance 49%, headache 15%, trigeminal nerve 
dy function 13%, facial nerve dy function 7% and 
other 1%. 
6. There are e entially three urgical options 
available when con idering removal of an 
acou tic n uroma. They are the translabyrinthine 
approach (TL), middle fo a approach (MF) and 
uboccipital approach. Each procedure ha its 
own advantage and di advantage . The goal of 
acou tic tumor removal i pre ervation of facial 
nerve integrity, total removal of tumor to prevent 
recurrence and mortality and, when po sible, 
pre ervation of hearing. Preservation of hearing i 
only po ible with MF and SO approache a the 
TL approach must sacrifice hearing in the affected 
ear. The other two objectives can be achieved by 
all three of the surgical option . Other 
management options in certain situations include 
tereotactic radio urgery and observation3 
Further analy i of the urgical approache will 
not be done in this case report. 
Some of the more common po t-operati ve 
complications include CSF leak at 11.2%, evere headache 
at 11.2%, wound 6%, cranial nerve injury (except VII and 
VITI) at 4.2% and meningiti at 2.8%.7 
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HUMOUR 
EorroRS: RoMY SAIBIL & BENJAMIN BARANKIN 
CLASSROOM MUSINGS 
There i an adage that "a mediocre teacher teache , a good teacher explains, and a great teacher inspire ." Apparently, orne lecturer believe that a mediocre 
teacher preache , a good teacher bore , and a great teacher 
edate . It i rather amu ing to think of all the a orted 
cenarios that can and have played out in the classroom. 
Take for in tance the lecturer, who when que tioned, 
w ill reply with "someone el e in this course will be 
teaching you thi ." While thi certainly may be the ca e, 
often it i not. This leave me wondering whether th 
lecturer ju t doe n' t know the an wer, or whether it might 
omehow go against the alignmen t of the co mic 
con tellation to enlighten u with the answer. I didn' t 
realize that a lecturer could plead the fifth . 
It i al o rather comical to have a lecturer who ha 
gotten stuck with teaching a particular clas . Thi i 
unfortunate for both lecturer and cla alike. In orne case , 
the lecturer i unaware of what information to emphasize, 
nor are they always as capable and knowledgeable on the 
given topic. A the lecturer drone on, the ubconsciou ly 
flog them elve with a Singaporean cane for agreeing to 
cover their colleague' norkeling emergency. The cia 
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ob erve thi unfortunate acrificial lamb with contempt a 
they enjoy their third hand of poker. 
Then there i the lecturer who engros es the cla into 
a edated tupor remini cent of a good benzodiazepine. 
The e lecturer are famou for inspiring impromptu 
" nack-time " or regre ion to naptime of a childhood 
pa t. 
One of the greater challenge in li tening to lecture i 
tran lating and decoding the rhetoric. "Don't bother 
writing thi down" has come to mean "You better know 
thi s word-for-word," and "You are the doctor of 
tomorrow" i now under tood to mean "God help us all." 
Then there is the ea ily tran lated "Today, we have a 
very pedal gue t for you" which ha come to mean "thi 
wa the only per on we could find" and "thi material i 
not te table" ea ily tran lates into "you have my 
permi ion to go home and frolic among t your elve ." 
While my argument may eem critical of lecturer , I 
do hold them in high regard. In fact, if I could, I would 
ing their prai e right her , for page and page on end . 
But adly, I am no Pavarotti and thu will re trict my 
inging to the tormenting of my brother. 
"We believe our first 
responsibility is to the 
doctors, nurses and 
patients, to mothers and 
fathers and all others 
who use our products 
and services." 
- From the first tenet of the 
Johnson & Johnson Credo. 
MEDICAL PRODUCTS 
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hiStory ci M!r diSease. PaNe IMlr disease cr '-"""'J';Jr1 Vlr1ISanWlaSe elevaoons a-e anrardcaoons lllhe use ci 
l..I'ITOO; such a anilon strud deYelop clmg t!leripy. lhe B'u!l strud be !b::oolrued 
-WTIIa Cil11int912; 11¥il4119-5Cl2. 
~- de!i1ed as iTlJSde a:lwtg cr illlSde weakness 11 aq.J1CIDl wah raeases 11 aealrW'e ~ 
vaiJes ll IJeatBr 11m !1!1111lleS lhe t4lP9' Iilii ci noonal. strud be OOi1Sidered II 8lfl patet citfuse 
myalgta. illlSde ll!l1demess lr weakress. inW nmed elevaoon ci CPK. Pa· strud be a<Msed to lepcxt 
pi1li'i'¢l '-"""'J';Jr1 illlSde pall. leRiemess cr weakness ~~ by malaiSe cr leYer l..I'ITOO 
t!1eripy strud be !b::oolrued i mai1<idy elevated CPK levels ocru 1r l11)q)athy IS <iq1osed 1r suspectEd 
Til! rSt ci ~ <nl illalxbn)<llySi clmg treatmert tf.1G-OlA ilW:Iase rtixars IS I1CieaSed Willi 
an:trTl!ft aarnstratJon ci C)dospcm fitn aad denva!Nes, l!f)'!tmTi)Ql. """" (r«:oonc ~- alllle armrtgals lr 
nefa2llOOne N. !here os ro ~ ll date Wlllllhe use ci l..I'ITOO QMli1 CXJllJT8'IIy W1!h these m.gs. Wilh lhe 
eapoon ci a ~ita~•• a:xN lOiiC S110J W1!h llf'/!lmnjcll. lhe benetils <n1 ns1<s ci such CXJmbined tle1lPY strud be 
carehly amdered (see ~- Drug l'maclo1sl 
~has been I1!IXX1ld 11 Vf!IY mre cases W1!h lJ'ITCfld>!e ~Drug neratiOlsl. 
..., renal ~ seco:my ll myogkJbruta has also been rep<Jted W1lh tt.1G-OlA recLaase 
rtixars. 
l.JliTOO tle1lpy strud be ~ W!lltalcr d!m1n.Ed 11 Blfl patetW1!h .., aa.re S80.IS ardiXXl sugges~~~e ci 
a ~crhaw-g a r9t f3cD ~ l>lhe ~ci nrta1 failre seta'dryll ~ (su:llas 
sewJe atUe rl8:lxn ~,. suglliy. oa.ma 5ellllll meliDi:. eOOXme <nl eleclltt,le <imlers. <nl 
lRXIIit*d sem.resl 
PRECAIITIONS 
liu!JI 
The etlects ol atorYastatin-ind changes in lipopotein levels, Including I!GJCiior1 ol serum 
- oo cardiovasallar morbidity or 111011ali!y or to1a1 111011ali!y line not been-
BekJe t!1eripy LI'ITOO!atllnlaSia!ll catun). a1 atleftlllstrud be m;r;~e lliXII1Iilll elevated sen.m 
liJqmerllevels W1lh awqm~e Oet. emase. m weqc recimJn 11 CMliWe1!tl patJeniS. <ntto treat IIIler 
llldel1yrtg me<ical problems (see NlCATOOS IW <lNCAL USE). Patetls strud be a<Msed lll1form ~ 
~ ci l!1e !XU use ci l.JliTOOcr Blflllller lipd-tlwemg ageriS. 
Ellect on !be L.ons 
QrrerllllrQ-Iernt data frlJn ch:al tnals 00 i1Cl nicate .., adw!rse elfea ci - 00 lhe IUnallens 
~~~~~~~ 
Si!JWi3t decreases II c:mAaln,j ~ levels II pa treated aiDrVasla ;nl IIIler SlatllS haYe been 
o!lser¥ec1. Til! ch:al sq1IICn:e ci a ~ m;rtoon statrl-llCl£8j de!i:tlny ci ~ has ra been 
estaltislted l 'las been repm~ that a decrease 11 i11jOC<Wtial ~levels axil lead Ill~ t3liac 
fln:oon II patentS borOeoi1e ronges1M! tm1 faln (see SEl£CTID BIUlGfW'IM 
Ellect on~ (al 
h some pabenls, lhe beneficial elfea ci klwered mta1 ~ <n1 Ul. -C levels may be I81IY bU1Ied by a 
an:omitr1t irmase II 4>(a) lew!ls.lhli fLrther e>periera is obtained, l is suggested, where - · that meas-
Liel1leflts ci sel\.ll1 Lp(a) be folowed ~ II patients plaa!d 00 aDvaslalrl thenl!lY (see SElECTID BIBUlGIW'HY). 
"" ~ l1jJmensi:M!y syrOome has been repml IIIler tt.1G-OlA recLaase rtixars wto:l1 has rcUted 
1 cr nue ci lhe fcbw'g featiJes iWlallh)'laxiS. a1gOldema. ~ erylhematous-l<e syrOoine po!ymyaiQia 
i11eu1W:a. va!Wibs. pt1Jll13.ltrnrnliocyl>pe ~ tem1ytx; anemoa. posiliYe NV<. ESR raease. 
eosrqtolia, • malgla. tlliC<m. aslhenia pl1ollserisitr;. !eYer. c:i*. lkJslwY,j. malaise. d!s!Jtea,I>XX: 
ep<lermall1ilCIIItjsis, erylhema l1lililorme. rcldng Stelens-#nsoo syrOome. Alltr:l.9t ., date l1jJmensi:M!y 
syr0-ome has ra been desatied as such. l.JliTOO strud be ci9:lnrued t ltjpersensltMty os suspectEd 
Use jn f'IJcNncy 
UPITOR Is contraiudicated dLring pregnancy (see CONT!IAINDICATIONSI. 
Altterll!l:lera os a ctrtrw; IJili'!SS <n1 cls:xllCruaoon ci lipd-bterrJ ciugS clmg ~ strud haYe 
rrca:t oo lhe u:ome ci llrQ-toon t!1eripy ci 1J111a1Y hypodde!>1eotti•oa. O'oeslilrol <nlllller IJll(tl:ls ci 
ctOeslerol bllsyrltlOSIS a'e OSSillllal aJn1)CriefiiS ,... felal deYeq)mert (R:Uirl;j synlhesiS ci Sli!llXds <nl eel 
mentJranes) Sn:e tt.1G-OlA rBiiJ::lse rtixars decrease ctOeslerol ~ <nl ~ lhe ~ ci IIIler 
bUJgicaly aaM! Slbstltces derMld frlJn ctOeslerol, lhey may caJSe la-m llllhe fei!JS v.tat 3li1nSia8d ll Jleo-
.-.nworren. 
Tlue a-ero IDta oo lhe use ci l..I'ITOO clmg ~ l.JliTOO strud be 3li1nSia8d to wanen ci ~ 
age my wl1en such pale1S a'e hi!tiY td<ely llllii!CeM! <nl haYe been l'1lonned ci lhe pocentJal hallrds • lhe 
pa becomes prBIJ1<It - takllg l..I'ITOR. lhe B'ug - be <isann.ed <nllhe patet iiR)I1Sed ci lhe 
IJ(m1!lal r9t ll feWs. 
h latS, mil< cxn:enuanons ci allrv.!Stllrl a'e srnilar ll t11Jse II plasma. liS i1Cl - wllelher 1tJs ci'ug IS excte!lld 
11 IUna1 m1t BecaJse ci lhe pocentJal n adw!rse ieaciO\S it iUSI1Q 11farls. wanen takllg l..I'ITOO strud ra 
t:reast-feed (see (X)NTRANJ(;A.Tn.!Sj. 
Ti1!11liT'St~llapeOatnc~IS lll<bsescil..I'ITOO~to!Kl~b'1year 11 8pallei1IS 
l1omozygw; famllal hypoddtseittiloa. No clncalcr ba:l1emcal alramalilleS 'Mlll! reponed 11 these 
palleniS. 
~ 
Treatment ~ II aliAs 70 years lr older =2211 W1lh <bses ci l..I'ITOO ~ ll!Kl mg/day has denmslla!Ed 
that lhe safely m effeciNeness ci at~nas~alrl 11 1t11s ~ was Sillllla' to that ci pa!BltS <70 years ci age 
~ evaklatrlll ci aDv.1S1a 11 Sliljecls rNI!flhe age ci 65 years i:tclcates a1 n:reased ALC N. a 
 measue. lhe lllwesl dose strud be aOrnstered il1illally (see PHARMAC(X_OGY ftmrt 
~ SElECTID 88..KlGW'HY) 
Plasma IXllnll1lllltl: m lll. -e o..emg e!li:acy ci l..I'ITOO was shown ., be srra 11 palJei1IS 'Mlh moderate 
nrtalllSUtfictercy ~ pa ncrrre1 nrta1 ftn:llon. ~. sn::e several cases ci ihabcbtty<tjsiS 
haYe been repm!11 palJei1IS Wi1ll a hisl>ry ci nrtalllSUtfictercy ci lrl<i1lwn sewnty, as a ~ measue 
<nl perxiJ;j fLrther ~ 11 nrtal disease. !he lllwesl dose (10 mglda)l ci l..I'ITOO strud be used II these 
patats. Srnla-~ apply 11 patJeniS Wilh severe llniiiiSUffoency (creatme c1eararce <:11 iTUmll 
(<0.5 ntlsecl): lhe lllwesl cbsage strud be used <n1 fl1)lemented C3IOlUSti (see Wl>m~. ~Effects 
~. Drug l1eraaxr$l 
Refer alsO to DOSAGE IW ADMINSTRAllON. 
Endocrine flllction 
tt.1G-OlA nlllCiase rtixars mrfBe c:hllestilrO syrftSIS <n1 as such mo;tt html:aly lUI aD'enal inW 
gorslal saod fJO(Laot Ch:al Slides - <n!Oite' tt.1G-OlA ilW:Iase rli*rs haYe Sl.ll}.leSted that 
these agons 00 i1Cl ill1l:e plasma IXJ1iSo! oornrvaiOllr ll1lilf aD'enalleseM! <nl 00 i1Cl ill1l:e tasal plasma 
tesllSleRJle an:erca:ot tbnever. lhe effeas ci tt.1G-OlA lec1case rra:rs 00 male rerti!y haYe i1Cl been su.ded 
11 adecJ,iate ll.ll'bin o! patJei1!S. Til! effects. f Blfl, oo lhe pottJtry~ axos 11 ~ wanen n l.l1roN:t 
Panems treatEd atlnaslalrl who deYelop ch:al ewlence ci enOOc:rre dysf\n:OOn strud be evakla!Ed 
3fliY!V'Itett camn strud be exerased .., tt.1G-OlA recLclase mbliX' cr 1111er agent used m kMer ct0es1ero1 
levels IS aOrnstereO to palJei1IS I1!CI!I\onJ IIIler MJgs (e g keloan!l!ile. ~ lr cmetxilel tal may 
decrease lhe levels ci erdlgerws Slerol! to1lo'es. 
O!ua lntel'actions 
Coocomitartt Therapy willt Other Lipid Metabolism Regulators: CaOOned B'ug t!1eripy strud be 3lliJOl!Ched 
W1lh caJ!01 as rtfomta:m frlJn conllOied Slides IS imlted. 
Bile Acid Sequestranls: 
P;u:nts W'lt! "*' p modera!e tMlerd!lles!emlem!a l.Dl-c reci.CIIll'l was !11l<lter ..nen L.FITffi 1 o mg aro ~ 
20 g ~ um•• -ed (-45%) 11m..nen e1111er aug was aOOns:ered able (-35'1o lor L.FITffi aro -22'1. lor 
~ 
f';Q:nls Wi1h SlM!!l! twg:ui'W>1e!t*ma. l.Dl-c re<lam was srra (-53'1o)..tlen Lffiffi 40 mg aro cDe5qD 20 g 
~ IXlilOmiSiered ..nen ttrl'!Bed " Ita WiilllJ'ITffi Ill mg able Plasma llli1B1IlilD1 ci amasw1 was -
(awoumtely 26%j..tlen lJ'ITffi 40 mg ~ cDesqD 20 g ~ IXlilOmiSiered ttrl'!Bed Wilh lJ'ITffi 40 mg 
able 
- · lhe c:orrbraiXln aug ltoerill\' was less ettecwe 11 ~ lhe il1gl',a!rlles ~:mL.FITffi ~ 11 
txxh types of ~ pa1JeniS (see f'HARMAC()_OGY Ch:al SIOOiesl 
wten lJ'ITffi IS used cxrrurerlly Willi ~ a '&"If Olller resrl. <r1 rurval ci at least 2 hem shWd be 
rrootalled - lhe I'M) <iugs. sn::e lhe aboorplicn ci L.FITffi ill!)' be mpared l7f lhe resrl 
Fib<ic Acid Derivatives (-~ Fenofibrate, Bezafibrate) and Niacin (Nicotinic Acid): Alltr:liJg1 there IS 
ill expenerce lhe use ci L.FITffi gr;en cxn:mentt,o Wi1h fin: aad denva!M!S aro roaan. lhe benefiiS aro nsks 
of Sl.dl oorrbrled ltoerill\' shWd be careflly CXlOSidered The nsk ci ll1)'0ila!hy <i.mg treatmenl Wi1h- <iugS 11 
thiS class IS roeaseo canmnt aannsuatm (see w~ Muscle Effecls). 
Coumarin Anticoagulants: L.FITffi hOO ill th:aly sqlifiC:ar'l effea on IJ(iltfllmlillllne ..nen aonnstered ill 
patJefitS receYI1!l d'l1r«: wMlm ltoerill\' (see SEl£CliD Bll.XlGIW'HY). 
Digoxin: Coaannsuaoon ci ~ <Dses ci L.FITffi aro 11gaxr1 roeaseo steady-Slate plasma 11gaxr1 
an:eooaoons tJv awoxrnately 20%. Pate1IS 1a1<11g 11gaxr1 shWd be ITOlllllled cae~y aro awqJnately 
0ra1 Con1rac:eptives CoaOrnsu1W1 ci L.FITffi iOih .., aa1 ~. !XJ1ar1r"g 1 mg rae11w10tre aro 35iJ!l 
ll!hr¥ esuadol. measro plasma~ (PI..C leYe!sl ci rae11w10tre aro ll!hr¥ esuadoltJv ~
:m~o aro 20%. respecwe~y Ttese rcreases shWd be CXlOSidered ..nen seloc:!n;l .., aa1 ~
Antlcids: Mnnsuatm ci aunn.m aro rna<;Jli!SU11 based ..-, Sl.dl as Maab<" TC Suspension. L.FITffi 
decreased plasma c:oncen!ra1D'IS ci L.FITffi l7f awoxrnate~y 35% l.Dl-c reci.CIIll'l was Jill altered tu lhe 
trlQI'IceRle-~ effea ci L.FITffi ill!)' be affecled 
Cinetidine: Mnnsuatm ci cmetDre L.FITffi lid Jill alter plasma an:eooaoons a l.Dl-c ~ etfi:acy 
ci L.FITffi. howeo.e'. lhe ~-~effect ci L.FITffi was reOJ:ed from 34%10 26%. 
Cytochrome P-450-mediated ln1l!ractions: AnvaSialrliS ll'li!tltdled bV lhe cyiXtrome P-450 ISOIW)me. CYP 
3A4 Etyttrorn)on. a CYP 3A4 mini', meased aDVaSialrl plasma leooels bV 40%. Calinr&slralm ci CYP 3A4 
riUas. Sl.dl as ~ ~ IT<Il't*le ardm:s ll'cldr!l er)1trarr,u1 aro clan1trtlrTr,CI. llllfTU'OSlWI!S 
~). 32!lle ~ agem J e ilaarez!lle. ke10cona2!lle). a lhe ~ refa2!xb'e l1liY haYe lhe 
potefllai " raease plasma ilJIB1IIa1mS ci tM:l-cM recU:tase rllliiDs. tiCI.drl;l Lffiffi (see SB.£CTHl 
l3ll.()GW'HY) CaDln shWd lll.IS be l!lleiCISed iOih aroJl'litl'l use ci these agentS (see WNHK3S. 
Plmracd<nell: n.mms. Musde Etl!as; l'lffillJ1X)!S. Aera mJ1i:IErY;y aro ErO:x:rre Ftrctm; £XJS.~« f!W 
A!M'.ISTRATnl; SB.£CTHl131l.()GW'HY) 
~ a sn.dy Wi1h l'ealtt1y SliJ!ec!s. <nOrn;natm ci maxm.m <ilses ci txxh alllMSialll (8) mg) aro Tafenach 
( 20 mg). a CYP 3A4 9bilrale. was sllaMlill pnxix:e a rrodest raease 111Bferai'e AI£. The Ole l'1teMI 
remaned li'Cimged. - sn::e .., rtera:~D~ belv.een these 1>10 <iugS cam be ellixled 11 pa:B1lS Wilh 
Jlll(isposr1g tacm lor <11t1y1tma. (e.g preexJSIIlg IJ1)01ged OT flti!MI. seYere cao:ay arterY llsease 
h)!D<alemoaj. taWX1 shWd be l!lleiCISed when these agentS in ruDnnstered (see WNNN3S. l'lamacXlkret.c 
ruraams. £XJS.~« f!W AOMNSTRATml 
Antipyrine:~ was used as a rm-speafic model for <iugS IT>!IaiJoized tJv lhe iliDOSOI11al hepatJ: enzyme 
system (CytDclircrre P-450 system). L.FITffi 1100 ill ettea on lhe ~ ci ~. lll.IS rneracoons Wi1h 
Olller <iugS IT>!IaiJoized Yla lhe same cyiiXtrome ISOZyiTleS in Jill e>peeted. 
&yttvomyan: ~ heallhy - · plasma an:et1l'a1DIS ci - meased awoxrnately 40'Io W!j!J 
umrn 511i!OOII ci L.FITffi aro eryhum)m. a 1mwn rl1bllr ci CYP 3A4 (see WAfN.lGS. Musde EtfaasJ 
Other Concomitant Therapy: ~ dirw:al 51\Jies, L.FITffi was used CXJ1COOll1<r1ll Willi arltr,lJerter&o agentS aro 
es1r0ge11 replacement ltoeriiJI' WiltoJt eYidence " date ci th:aly sognfi3lt a<tooem! rneracoons k1lerlicOOn 51\Jies 
W'1h speafic agen1S haYe Jill been cord.cted 
Patienls with Severe l!ypeu:ho!esle!o!emia: Hi!jler aug 005ages (8) mg/da)i ~ fa sane pateliS Wi1h 
seYere hyperdOesleroie {il::IJdng familal hypeichoiesteoolei I i.a) in assroated meased plasma i!M!Is fi 
ai!JVaSiall1. caution should be exercised in such patien1s who are also severely renally impaired, eldet1y, 
or are concomi!antfy being adninistered digoxin or CYP 3A4 Inhibitors (see WARNINGS, Pllannaalkineti 
Interactions, Muscle Effects; PRECAU110HS, Drug lnteraclions; DOSAGE AND ADMINISTRATION). 
Drug/l.aboratory Test lntmctions 
L.FITffi l1liY eiMI1e sen.m tr.I1SafTW'BSe aro aea1n1e ~ ~eooe~s (from- rruscle). ~me <itferenllal 
diag'a;IS ci chesl par1 11 a pa1et on ltoeriiJI' L.FITCR catiac aro roncatiac tractms ci these i!OZj!Tli!S shWd 
be delennni!d 
ADVERSE REACTIONS 
L.FITffi IS generaav wei-IOielated. ~ reaams haYe USlJaly been "*' aro llllllSii!ft. ~ aJillliJied dirw:al 51\Jies 
~ aro ~~oYe Slides iOih Olller i!Jd-UoYemg agentS) rNOiw1g 2502 patets 
<2% ci patJefltS ~ discontnJed rue 10 act.oerse expenerces anrtutallle 10 L.FITCR Of these 2502 patets, 
1721 ~ trealed fa a least 6 IT'O'IItiS are 12531or 1 YfR1 a mae 
~ expenerces llCCIIT'tg at .., llCiderce <!1"' 11 pateliS fB!iCpatrlg 11 placello<onlrol ch:al Slides ci 
L.FITffi aro '"IXJITed 10 be posstlly, ~ a defntely aug reta ed in sl1aMl 11 Table below 
TABLE 1. Associated Advelse Events Reported in <!1% of Palierrts in Placebo Conlrolled Clinical Trials 
GASTROitmSTlHAl 
Constipation 
Diart1ea 
Dyspepsia 
AatUence 
Nausea 
NERVOUS SYSTEM 
-MISCWAHEOUS 
Pain 
Myalgia 
Placebo % !n 270! UPITOR % !n 1122 1 
<1 
Asthenia < 1 1 
The folowrg --.at a<tooem! everts ~ '"IXJ(1ed 11 dirw:allnals. Jill al eYentS isted below haYe been assroated 
Wi1h a causal retato1Ship ill L.FITffi therapy: Muscle trarT'!JS, IT1)'0SIIIS, lll)q)allly, pareslhesia, pef1i1eral neuopallly, 
p;rcrea hepa • ciOestatx: jlllllOOl,-. 'oU!lllllg. ~ flM!US. rash .~. hypelgt,ocemoa. arC 
~
!'!!s!-ma1<etm !!l!!!ef!!!!lCe' Very rae repa1S ci seYere lll)q)ailly iOih a WI1IW rllabcilrn)Oysi haYe been '"IXJ(1ed 
(see w~. Musde Elfeas; I'!E'IJOOt,S, Rernl nsutDercy aro [)ug nteractms). lsolaled cases ci 
~ aro allergic reaams (i1iOO,l lllitala. <W1QD'IIllJitt edema aro ~~~a l1liY haYe ill 
causal~~~- haYe also been '"IXJ(1ed 
~ 005erVa1o1s- see PI£CAlJTl:N) 
L.alloralory TesiS n:reases 11 sen.m tr.rlSallW1aSe ~eooe~s haYe been Jllled 11 dirw:allnals (see WAIHf:iSl. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
Tlee IS ill specifi: treatmerllor atrvaSialll <M!I'OOsage Sfn*l<Wl o.oertbse OCill', ill! pa!iert shWd be trealed 
~ aro &watM! mea5IJ1!S rmuted as reqnd. DJe "e<III1SM! aug ~ 1> plasma IJOflliiS, 
tenodatjsiS IS Jill e>peCted ID Slg'lfi:atly Eri1<n:e aovastall1 cfealn:e. 
DOSAGE AND ADMINISTRAnDN 
PateliS shWd be placed on a stll1d<W1l cllllesterd-~ diet [at least lliJ,Mielt ID lhe Amerl31 tBrt As1;roatm 
(AHAl Slep 1 dieiJ before receYil!lL.FITffi. aro shWd oonlrU! on thiS diet <imQ treatment Wilh L.FITffi r 
awqJna e. a fJll!1liiT1 ciwequconl1lll aro pllysieale>lllltiSe shWd be~· 
['rmry tt.g:u;tdes!ero arcj CarOOed !Mpcedl tt.g:rtilQma. kQ.<h mia! CarOOed tM!!!!1iJoderT! 
The rearnmended 005e ci L.FITffi IS 1 o mg once a day The rnap11y ci pa ~ aro ITii!il1lan Wget 
cl'oles1arol leooels L.FITffi 10 mglday A 5q'llfi3l ifleralaJbc response IS E!'o'OeR 2 - · llld lhe 
maxm.m response IS USlJaly acheYed Wi1hl1 2-4 weelcs. The response IS mal1lalled <i.mg d'l1r«: ltoerill\' 
Doses C3l be gr.oen at '&"If 11ne ci lhe day a Wll!nl food. aro shWd ~ be gr.oen 111he IM!IWYJ Doses 
shWd be niYOJai2ed acco:OOg 1D ba5eft LDl.C aro'a TG leooels, lhe desred LDl.C aro'a TG lirge! (see lhe 
De!eclm aro Maragemert ci HyJ:ed"*">1att:~•oa. l'b1<r1!J ~on~ aro Olller Dyslpdemlas 
(Canada) aro'a me 1.5 Nai01al 01>1es1era EdJ:alm Progam [lnl'l). lhe !J)al ci ltoerill\' aro lhe paoort's response 
~ ci cb;age. if roecess..y, shWd be 111a<2 at l1leMils ci 4-a mae. The rearnmended 005e ooge lor 
rrost patJefitS IS 10 " 40 mgA:Iay The mamun 005e IS Ill mgA:Iay, whch l1liY be ~ 11 a nwoty ci patJefitS 
(See seam belolrol 
Upid le¥els should be monilored periodically and, if nocessaty, the close of UPITOR adjusted based on 
target lipid le¥els recommeoMied by guidelines. 
The 1o1owrg reru:oons 11 uatcl'oleslarol aro l.Dl-c ~eooe~s haYe been OOseMd 11 2 OOse-response sruies, aro 
l1liY 5el'le as a~" treatment ci pateliS Wi1h "*' 10 moderaie hypeid-oleiioa. 
TABLE 2.1lose-Response in Patien1s Wi111 Mild to Moderate l!)llen:holesletoleniia 
• Percenl O!a!lje from -r 
l.IPITOR Dose (mg/day) 
Totai-C: 7.1 ITllld/l' 
(273mW<lJ' 
10 
~22) 
-29 
LDl-t: 4.9 mmoiA.' -39 
(1 90mW<lJ' 
'ResU1s are pooled from 2 OOse-response siJJdies. 
'Mean baseline vaus. 
Seym Dyslioidemias; 
20 
(!i=?O) 
-33 
-43 
40 
~21 ) 
-37 
-50 
Ill 
IN=23l 
-45 
~ patJeriS seYere ~. n:ldr'g horrozygoJs aro heletozygous f3nial hypelcholesteoolei•e aro 
(T)!le 1), t'qler 005ages ~ 1D Ill mg/da)i may be~ (see WNN~. l'lamacXlkret.c 
ruraams. Muscle Effecls; PI£CAlJTl:N). D'ug nteraclionsl 
Concomitant Therapy 
See PR£CAIIT10NS, Drug Interactions. 
Dosage in Patien1s Wi111 Renal Insufficiency 
See PR£CAIIT1QNS. 
PHARMACEIJTICAL INFORIMJION 
P!l!!! SUbstance 
Pqler N<rne· Al;t'I3Sia!r1 C<icun 
Olernl:aiN<m! (R-f!"R1J-2-(4-~. ~-5-(1 -~3-phenjl-4-(~-
1 tlil\'mlfe-' .J'ietlGnlC aad. C<icun sail (2.1) Ui1)<iale 
Err4W'cal FanUa (CJ!;.FN,O,),Ca• JH,O 
lot8:IAar Welijt. 1209 42 
SlnalaiRirnlAa. r 
~: Allrvastatll C<icun IS a ID cif-wtl!e aySialile powder illat IS IJactl:aly I'ISOUlfe 11 a<JJeCl.iS 
solJIIn; ci ~ 4 aro below AllrvaSia e<icun IS oe:v 'fiiP.If SllUlle 11 - wat!>", ~ 1 4 Jta;itlare buffer aro 
ace~~JrWE sigl1ly SllUlle 11 e~~mo~. aro fre8y SllUlle 11 rnelta'd 
Tablet Composj!ion: 
Each Iailie! anar&S eslher 10 mg, 20 mg a 40 mg alOIVaSiatrl as lhe aciM! rvedieft. Each ialllel also contar1S lhe 
lobwY;j ron-rnedl:nll ~ C<icun cartmale. i31lella wax. aoscamelose scOOn, ~ atilse. 
taaose rnorn'iy<tate rna<;Jli!SUOsteaate m01lCiySialine atilse. ~~. polyelhylene 
rJyr:JJ. . tat:. utnun cbxle. pdysabate 111 aro Sll1'lellw:ale errUsion. 
S!abi!ity and S1or)ae Recommendations 
S10re at anroled roan lerr!leran.re 15 ill 25~ 
AVAILABIUTY OF DOSAGE FORMS 
L.FITffi (ataVastalll cai::uri IS available ., 005age stl'l!r¢15 ci 1 o mg, 20 mg aro 40 mg ar:rvas~a111 per Iailie!. 
10 mg: wtore, elliptx:al, ttn-coated Iailie!. coded "1 0" on one Side aro "PO 155" on ill! <m!r. AvMie 11 bollles ci 90 
ialllels 
20 mg: \'hie elliptx:al, lim-coated Iailie!. coded "20" on one Side aro "PO 156" on lhe <m!r ""** 11 bollles ci 90 
ialllels 
40 mg: \'hie. elliptx:al. lim-coated Iailie!. coded "40" on one Side aro "PO 1 '57" on lhe Olller. AvMle 11 bollles ci 90 
ialllels. 
Referentt!S 
1. LIPITOR (atorvastatin calcium) Product M~raph, Parl<e-Davis Div., Warner-lambert canada 
Inc , Oec.1998. 2. Dan A. Jerums G. eta/. A multicenter, double-blind, one-year study comparing 
safely and efficacy of alorvastatin versus smmstatin in patients wi1h hypercllolesterolemia 
Am J Gatr1io/1997;80:39-44. 3. Bertolim S, B•tlolo Bon G. eta/. EffiCaCy and safely of atorvastatin 
compared to pravastatin in patients Wilh hypercholesterolemia. Alhetosderosis 1997;130:191-7. 
4 DaVIdson M, McKenney J, Stein E, et a1: Comparison of one-year efficacy and safely of 
a1orvastat10 versus lovastatin in pnmary hypercholesterolemia. Am J Carr1io/1997; 79'14 75-81 . 
5. Hemonen TM, et al. Alorvastatin, a new HMG-CoA reductase inhiMor as monolherapy and 
combmed with colestipol. J can1iovasc Phannacli ~ 1996;1 (2).117-22. 
For a copy of the Product Monograph or fu ll Prescribing lnformatJon. please contact 
® PARKE-DAVIS 
*TM Warner-Lambert Export Lim~ed 
Parl<e-Davis Div. 
Warner-lambert Canada Inc .• lie. use 
Scarborough, DKT Mll 2N3 
Co-promoted With 
e; 
Ute IS our life~ wolk 
Pf12er Ganada Inc. 
rldand , Quebec 1!9J 2MS 
t TM Pfuer Products Inc. 
PfiZer Ganada Inc .• licensee 
FEATURE ARTICLES 
MUTAGENICITY OF SURGICAL THE 
SMOKE IN ELECTROSURGICAL 
PROCEDURES 
Recently, the safety of urgical smoke generated by electrosurgery devices has become a topic of much concern. Electrocautery is u ed to dissect ti sue or 
cauterize blood vessels with a high radio frequency 
electrical current. During the cauterizing proces , copiou 
amounts of visible smoke are produced. The smoke is 
malodorous and tends to irritate operating room 
personnel by producing burning, watery eyes, respiratory 
problems and nausea . Many animal studies have 
demonstrated the ill effects of electrocautery smoke 
plume, though its specific effects have yet to be 
determined in humans. 
SURGICAL SMOKE STUD IES 
The combu tion of animal tissues lead to the 
formation of carcinogenic amines.2 Heterocyclic amines 
have also been identified from environmental components 
like airborne particles and cooking fumes. 3• 4• 5• 6 Animal 
studie have shown that the mutagenic agents in smoke 
from cooking fish and meat cause tumor formation in 
rodent organs such as liver, lung, large intestine, and 
mammary gland? 
In recent years, electrocautery smoke has been 
demon trated to possess mutagenic properties. Analysis 
of electrocautery smoke determined that its chemical 
compo ition consisted of significant levels of benzene, 
ethyl benzene, styrene, carbon disulfide and toluene. 
Individually, these chemicals have all demonstrated 
carcinogenic effects in both animal and human studies. 
Styrene exposure in humans causes irritation of the eye 
and respiratory tracts; some studies have even indicated 
increa e in the frequency of lung and other cancers wi th 
tyrene expo ure, though the studies are considered 
inadequate by some.9 Carbon disulfide has been hown to 
cause mutagenesis of human 9erm cells and to induce 
embryonic growth retardation. 0• 11 Toluene exposure in 
humans has led to increased risks of various 
gastrointe tinal cancer a well as lung cancer.9 Benzene 
expo ure is trongly as ociated with an increased ri k of 
leukemia. 12 As well, a large Chinese cohort study linked 
benzene exposure to a greater ri k of lung a nd 
nasopharyngeal cancer. 13 
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Gatti et al. tested airborne smoke particles for 
mutagenic potential in two strains of Salmo nella 
typhimuriwn (TA 98 ands TA 100) and found that smoke 
induced by an electrocautery knife was mutagenic to the 
T A 98 strain. 14 The aforementioned study supports an 
older, similar experiment by Tomita et a1., which concluded 
that the mutagenicity of electrocautery smoke condensates 
was comparable to that of cigarette smoke. 15 
SMOKE SAFETY MEASURES 
Currentl y emplo y ed surgical masks filter 
5 micrometer size particles. 16 However, more than 77% of 
the particulate matter contained in surgical smoke is less 
than 1.1 micrometers in size.16 As a result, other methods 
are nece ary in order to diminish exposure to 
electrocautery smoke. 
The ational Institute for Occupational Safety and 
Health in the United States has demonstrated several 
methods whereby airborne contaminants generated by 
electrocautery can be controlled. It is recommended that a 
combination of general room and local exhaust ventilation 
be u ed. Smoke evacuation methods may consist of the 
simple attachment of a suction apparatus to the cautery 
hand piece or having an assistant with a high flow suction 
tip. 17 Additional means include commercial smoke 
removal systems and high filtration surgical masks I 
respirator worn by members of the surgical team.18 
Unfortunately, though several studies have proven 
the deleterious effects of surgical smoke plume, many 
members of the perioperative team are indifferent or 
negatively inclined towards the u e of protective 
ventilatory devices (general or local). 16 The most likely 
reasons for the aforementioned attitudes are as follows 19: 
• Some individual believe that smoke plume i not a 
hazard to one's health. 
• There is a perception by many surgical personnel 
that surgical masks provide adequate ventilation. 
• It is also thought by orne that evacuating 
equipment may interfere with surgical procedures 
or the surgeon's dexterity. 
• Lack of re ources available to purchase a smoke 
evacuator. 
• Lack of the availability of personnel needed to hold 
an evacuator wand. 
CONCLUSION: 
Surgical smoke plume contains known carcinogens 
and irritants, which can produce watery, burning eyes, 
dermatitis, central nervous system effects, hepatic and 
renal to xicity, and bronchitis or emphysema-like 
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conditions. · 16 Though there have been no formal studies 
determining the exact effect of inhaling mutagenic 
surgical smoke in humans, it has been proven that 
e lectrocautery moke condensates collected during 
urgery have genetically altered strain of Salmonella 
bacterin. 14•15 Further studies ought to therefore concentrate 
on the specific hazards of surgical smoke plume by 
determining the level of exposure by the surgeon and 
urgical taff; longitudinal studie wouJd also be valuable 
in assessing any detrimental effects which might be 
suffered a a con equence of electrocautery moke contact. 
Until such additional studies a re inve tigated, simple 
techniques such as high filtrat ion mask and local 
electrocautery moke uction ought to be employed in 
order to minimize electrocau tery smoke exposure in the 
operating room etting. 
ACKNOWLEDGMENT: 
The author wishe to th ank Dr. R. Holliday, 
Department of Surgery (S.S. LHSC), for hi con tructive 
suggestions. 
REFER£ CES: 
1. Kanter WR. The mutagenicity of electrocautery smoke (DisCilssion). Plastic 
and Reconstructive Surgery 1992; 89:785-786. 
2. Kataoka H, KijimaK, Mamo G. Determination of mutagenic heterocyclic 
amines in combustion smoke samples. Bulletin of Environmental 
Contamination and Toxicology 1998; 60(1):60-7. 
3. Stavric B. Biological significance of mutagenic heterocyclic amines in 
human diet: A critical review. Food and Chemical Toxicology 1994; 
32:977-994. 
4. Eisenbrand G, Tang W. Food-borne heterocyclic amines: chemistry, 
fimction, occurrence mzd biological activities. A literature review. Toxicology 
1993; 84:1-82. 
5. Felton JS, Knize MG. Occurrence, identification, and bacteria/mutagenicity 
of heterocyclic amines in cooked food. Mutation Research 1991 ; 
259:205-217. 
6. Tl1ieband HP, Knize MG, Kuzmicky PA, Hsieh DP, Felton ]5. Airborne 
mutagens produced by frying beef pork and a soy-based food. Food and 
Chemical Toxicology 1995; 33:821-828. 
7. Sugimara T. Overview of carcinogenic heterocyclic amines. Mutation 
Research 1997; 376:211-219. 
8. Sagar PM, Meagher A, Sobczak 5, Wolff BG. Chemical composition and 
potential ha:;ards of electrocautery smoke. British joumal of Surgery 1996; 
83:1792. 
9. Lynge E, Anttila A, Hemminki K. Organic solvents and cancer. Cancer 
Causes and Contro/1997; 8:406-419. 
10. Le JY, Fu XM. Human sperm chromosome analysis -study on Iutman 
spenn chromosome mutagenesis induced by carbon disulfide. Biomedical and 
Environmental Sciences 1996; 9(1):37-40. 
11. Zlrao SF, Zhang XC, Zhang LF, Zlzas 55, Zhang F, Wang QF, Wang YL, 
Bao YS . The evaluation of developmental toxicity of chemicals exposed 
occupationally using whole embryo wlture. lntemational jouma/ of 
Developmental Biology 1997; 41(2):275-282. 
12. Yin 5 , Hayes RB, Linet MS, Li GL ET AL. A cohort study of cancer 
among benzene exposed workers in China: Overall results. American jormzal 
of Industrial Medicine 1996; 29:227-235. 
13. Hayes RB, Yin 5 , Dosemeci M, Li GL, Waclzolder 5, Chow WH ET AL. 
Mortality among benzene-exposed workers in China. Environmental Health 
Perspectives 1996; 104:1349-1352. 
14. Gatti]£ , Bryant CJ, ooue RB, Murphy ]B. The mutagenicity of 
electrocautery smoke. Plastic and Reconstructive Surgery 1992; 89:781-784. 
15. Tomita Y, Mihashi 5, agata K, Ueda 5, Fujiki M, Hirano M, Hirolzata T. 
Mutagenicity of smoke conden ates induced by C02 laser irradiation and 
electrocauterization. Mutation Research 1981; 89:145-169. 
Feature Articles 
16. Ball K. Surgical smoke: is it afe to breathe?. Today's Surgical urse 1996; 
18(5):16-21. 
17. Thorne FL. The usefitl smoke sucker. Plastic and Reconstructive Surgery 
1986; 77:500. 
18. Romig CL, Smalley Pj. Regulation of surgical moke plume. AORN jozmza/ 
1997: 65(4):824-828. 
19. Giordano BP. Don 't be a victim of surgical smoke. AORN jouma/ 1996; 
63(3):520-522. Q 
GENERAL 
INTERNIST 
Quinte Healthcare Trenton Memorial requires a general 
internist (our current third internist is retireing at year end). 
Trenton Memorial is part of the new Quinte Heal thcare 
Corporation, comprising sites in Trenton, Belleville, Picton 
and Bancroft. The successful applicant will have full privi-
leges at the Trenton site and courtesy privileges at Belleville. 
Subspecialty interest in resplrology or rheumatology is an 
asset, but not essential. 
Trenton Memorial is building a new acute-care wing (comple-
tion in fall 2000) that will include four special-<:are beds and 
40 acute-care beds. We have a full range of facilities , includ-
ing a stress lab, pulmonary function testing lab and echocar-
diography. Services are provided at our site by three general 
surgeons, one otolaryngologist, three ophthalmologists, one 
radiologist, four GP{anesthetists , an aggressive group of fami-
ly physicians and a 24 hour Emergency Department. 
Trenton is located an the Bay of Quinte in an incomparably 
scenic area with excellent recreational amenities and easy 
access to Highway 401. 
Please contact: 
Dr. Yaw Twum-Barima, Chief of Medicine 
Qulnte Healthcare Trenton Memorial 
242 King St., Trenton, ON KSV 5S6 
Te1613 392-2541, Fax 613 392-2489 
--5699 
U. W.O. Medical Journal 69 (2) 1999------------------------ 27 
Fea tur e A rti c l es 
ANGIOGENIC INHIBITORS: 
NEW POSSIBILITIES FOR CANCER 
THERAPY 
BACKGROUND 
The formation of new blood vessels, known as angiogenesis, is a critical component of tumour biology, in both local tumour growth as well as 
distant metastatic spread. Without neovascularization, 
tumours have been found to be unable to grow beyond a 
size of 2 to 3 mm3 due to an equilibrium present between 
the cellular proliferative rate and the apoptotic ra te. 1•2 
Thus, the e tumours may persist for months, or even 
years, in a "dormant" state until a particular subs t of 
malignant cells converts to an angiogenic phenotype. The 
exact mechanism involved in this conver ion is still not 
completely understood . Yet, it involves some form of 
va riation in the local balance between positive and 
negative regulators of angiogenesis. 3 
Shedding of tumour cells to distant sites has been 
demonstrated to begin only after a tumour has become 
vascularized.4 In fact, it has been shown that the greater 
the vascular density of a tumour, the greater the chance 
for malignant cells to enter the circulation.5 Interestingly, 
proliferating capillaries of the tumour neovascula ture 
have been found to consist of fragmented ba ement 
membranes, resulting in these capillaries being more I aky 
than mature vessels and thus, more conducive to entry of 
malignant cells into circulation? This correlation between 
vascular density and metastasis, relapse, or mortality has 
been hown in several neoplasms, such as breast cancer 
and colorectal cancer, and has been a key factor in the 
recent intere t in angiogenic inhibitors as a form of cancer 
therapy.6•7 
Angiogenic inhibitors or antiangiogenic agents were 
first proposed as a form of antitumour therapy in 1971. 1 
Since the primary target of antiangiogenic agents is the 
proliferating endothelium, there are many advantage to 
the u e of these agents, as summarized in Table 1. One 
important advantage is that the e agents are less likely to 
result in resistance because endothelial cells are iliploid 
cells po essing a stable genome. Thus, the potential for 
angiogenic inhibitors as an effective cancer therapy is 
enormous. This article will focu on two classe of 
angiogenic inhibitors, namely tumour-derived inhibitor 
and matrix metalloproteinase inhibitors. 
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TUMOUR-DERIVED INHIBITORS 
Angiostatin and endostatin are two angiogenic 
inhibitors that have received a lot of media attention 
recently. Angio tatin is a 38 kD fragment of the precursor, 
plasminogen. 3 Although plasminogen itself i not 
antiangiogenic, angio tatin is indeed a potent inhibitor of 
endothelial cell proliferation and migration as well as a 
circulating angiogenesis inhibitor.9 Angiostatin is actually 
a tumour-derived inhibitor since it only appears in the 
serum in the presence of the primary tumour, and upon 
removal of the primary tumour, angiostatin disappears 
from circulation, resulting in growth of metastases. 10 
However, even though angio tatin is tumour-derived, it is 
not thought to be produced by the tumour cells per se, but 
instead to be the result of cleavage of plasminogen by 
protea e produced or activated by certain tumours, such 
a pro tate cancer.9•11 
Treatment of certain cancers with angiostatin has 
shown promising results. In mice xenotransplanted with 
three human cancers (breast, colon, or prostate), ystemic 
treatment with angio tatin inhibited the growth of breast 
cancer by 95%, colon cancer by 97%, and prostate cancer 
by 100%. The mechanism of growth inhibition in these 
tumour involved a marked increase in apoptotic rate in 
the treated mice, while the proliferative rates in both the 
untreated and treated mice were the same. Interestingly, 
no toxic ide effects were ob erved. However, cessation of 
angiostatin therapy resulted in relapse of the dormant 
tumours.12 
Endostatin, a fragment of the non-antiangiogenic 
precursor collagen XVIII, is another potent tumour-
derived inhibitor of endothelial cell proliferation and of 
angiogenesis. Systemic treatment with endostatin ha been 
shown to cause significant regre ion of primary tumour 
size as well a inhibition of metastatic growth, without 
development of toxicity or of drug resistance . Like 
angio tatin, the mechanism of action is via an increased 
tumour cell apoptotic rate. Discontinuation of endostatin, 
however, was shown to result in relapse. 13 lntere tingly, 
combination therapy involving both endostatin and 
angio tatin eems to cause complete tumour regression, 
even after therapy is discontinued.9 
Recent studies have investigated viral-vector 
mediated angiostatin therapy (via adenovirus or 
retrovirus) to deliver high local concentrations of 
angio tatin .14•15 This ha been termed "targeted 
antiangiogenesis" and ha been found to cause a 
ignificant arre t of tumour growth in v ivo via an 
increased tumour apoptotic rate. This will have important 
applications for the therapy of tumours that are locally 
invasive but not necessarily metastatic, such as gliomas. It 
is important to note, however, that this targeted 
angiostatin therapy did not cure the mice tested, but 
28 
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Characteristic 
• Are quiescent in normal ti ues of the adult whilst 
they are activated, proliferating and migrating within 
the stroma of invasive tumours 
• Are genetically stable, normal diploid cells that are 
required for tumour growth 
• Have similar characteristic in different solid tumors 
• Are easily targeted by sys temic administration of 
antiangiogenic agents 
• Proliferate under the stimulus of partially known 
endothelial growth factor 
• Proliferation and migration can be inhibited by 
endogenous angiogenesis inhibitors 
Table 1 
Feature Articles 
Therapeutic advantages of angioinhibitory therapy 
• Little toxicity on normal vasculature 
• Their genomic and phenotypic characteristics are 
stable in time 
• Repre ent a uniform target 
• o difficultie related to the amount of drug that can 
reach the cellular target 
• Pharmacological neutralization of the angiogenic 
peptides i a po sible therapeutic trategy 
• Therapy with endogenou antiangiogenic peptide is 
fea ible and well tolerated 
Favourable characteristics of endothelial cells as a target for anticancer therapy 
merel y prolonged their survival. 15 Improvement in 
vectoriza tion efficiency will be required for eventual 
attainment of maximal clinical benefits and hopefully, the 
ynergistic effect of angiostatin combined with endo tatin 
for complete tumour regression may al o one day be 
achieved with vector therapy. 
MATRIX MET ALLOPROTEINASE INHIBITORS 
eovascularization is dependent on not only the 
proliferation of endothelial cell but al o the migration of 
the endothelial cells through the urrounding extracellular 
matrix. Thi require degradation of the component of 
the tissue matrix via the enzyme , matri x 
metalloproteinases (MMPs) . These enzyme are 
upregulated in proliferating endothelial cells and thus, 
as i t in the neovascularization and ultimate growth of a 
tumour.3 
TIMPs (tis ue inhibitors of metalloproteinases) are 
naturally occurring MMP inhibitor and are all inhibitors 
of angiogenesis.9 TIMPs inhibit both tumour growth as 
well as metastasis, mo t likely due to their ability to 
suppre s matrix degradation.16-18 TIMP have al o been 
shown to directly block the proliferation of tumour and 
endothelial cells in vitro.9 Thu , this dual mechanism of 
action makes them very potent antitumour agents. In fact, 
one study found that retroviral-mediated transfer of TIMP 
into a limited population (only 13%) of tumour cells in 
mice was still sufficient to inhibit tumour growth and limit 
local tumour invasion. 16 These findings how the great 
potential for the e agent in cancer therapy. 
Synthetic MMP inhibitors al o exist. Batimastat and 
marimastat are two such compounds, and they act by 
binding reversibly to the zinc in the active site of MMPs. 
In the mouse model, batimastat was shown to increa e the 
survival of mice xenotransplanted with human ovarian 
cancer by 5- to 6-fold. 19 These results were supported the 
following year by an experiment demonstrating that 
treatment with batimastat cau es reduction in primary 
tumour size, local I regional inva ion, as well as metastase 
in mice xenotransplanted with human colon cancer. 20 
Importantly, no significant side effects with batimastat 
therapy were found . Ba ed on these finding , batimastat 
wa one of the first MMP inhibtors to be te ted in cancer 
patients, primarily tho e with malignant effusions. 
Unfortunately, batimastat was found to have poor oral 
bioavailability and thus, could only be given to the cancer 
patients via intraperitoneal or intrapleural suspensions.21 
Marimastat, a compound similar to batimastat, is an 
orally active drug that i able to inhibit cell inva ion, 
meta ta i , and angiogene is. This drug is currently in the 
process of clinical trials, which have shown that the mo t 
significant side effects are musculoskeletal complaint . 
Despite thi , marimastat eems to have potent biological 
activi ty in patients with advanced ovarian, prostatic, 
pancreatic, or colorectal cancer, and thereby, demonstrates 
substantial promi e for acceptance as a novel form of 
anticancer therapy in the near future.22 
CONCLUSION 
MMP inhibitors (TIMP , batima tat, marimastat) and 
tumour-derived angiogenic inhibitors (angiostatin, 
endostatin) are ju t two classe of antiangiogenic agent 
that have shown significant findings for future cancer 
therapy. In fact, it is interesting to note that several 
antica ncer agents already in clinical use (such as 
tamoxifen) have been found to have antiangiogenic 
activity.23 Even certain non-cancer pharmacologic agents 
uch as thalidomide also have demonstrated 
antiangiogenic activity and are currently being 
inve tigated as a form of cancer therapy.9•24 Although it 
eems that treatment with angiogenic inhibitors will not 
necessarily cause complete regression of tumours, 
combination therapy of antiangiogenic agents with 
conventional chemotherapy has been found to reduce 
tumour metastases to a greater degree than when either 
therapy i used alone.25 Thus, angiogenic inhibitors seem 
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to be quite prorni ing for cancer therapy, and it is po ible 
that we may soon see the incorporation of angiogenic 
inhibitor into the standard treatment protocol of various 
cancer . 
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SENTINEL NODE LYMPH 0 SCINTIGRAPHY: 
THE ROLE OF NUCLEAR MEDICINE IN 
AND TREATMENT 
BREAST CANCER 
THE INVESTIGATION 
OF MELANOMA AND 
BACKGROUND 
B rea t cancer and melanoma occur at high frequency in Canada. In fact, brea t cancer is the leading cancer diagno ed in Canadian women, accounting for about 
30% of all new cases.1 There has been a dramatic increa e 
in the incidence of cutaneous melanoma a ociated with 
damaging sun exposure during childhood. The incidence 
rate for melanoma has tripled ince the late 1960s, from 3.2 
per 100,000 population in 1969 to an e timated rate of 10.5 
per 100,000 in 1998.2 Fortunately, early diagnosi ha 
reduced the death rate from almost 90% earlier thi 
century tole than 20% today.2 
For mo t patient with olid tumour , the most 
powerful and predictive progno tic factor of one's 
urvival i the status of one's regional lymph node .3 
Patients with malignant melanoma with no lymph node 
meta ta e have a 10 year urvival rate of 70-80%, while 
tho e with nodal involvement have a 10 year 20-30% 
urvival rate.4 In brea t cancer, regional nodal meta ta e 
decrea e the 5 year urvival by 2 -40%.4 Hence, it remains 
important to identify th o e patients with nodal 
involvement in order to differentiate tho e patients that 
will clearly benefit from y temic treatment from those 
who will not. 
The management and staging of breast cancer u ually 
include an axillary lymph node di ection. Likewi e, 
melanoma patients with palpable regional lymph node 
meta ta es undergo a therapeutic nodal di ection . 
However, the approach to melanoma patients who may 
have ly mph node micrometa tases ha been quite 
controver ial- ranging from complete node dis ection to 
imply "watch and wait".4 
THE SE TINEL NODE CO CEPT 
The entinel node i that ly mph node in a given 
lymphatic ba in that fir t receive lymphatic flow from a 
primary tumour.5 As a result, the hi tology of the entinel 
node u ually reflect the hi tology of the basin. If the 
entinel node i cancer free, there i greater than 98% 
likelihood that the remaining node in the basin are 
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negative, but if there i cancer in the sentinel node there 
may _be metastatic di ea e in other nodes.4 A urning the 
entmel node can be reliably identified and 
hi topathologic exam reveal no cancer cell , the 
remaining nodes in the basin should be clear a skip 
meta ta e are rare.6 Thus a total re ection of the lymph 
node basin with its as ociated surgical morbidity ( uch a 
para thesia, wound infection, eroma, drain di comfort, 
acute and chronic lymphoedema, as well a potential 
delay~ in adjuvant therapy) can be avoided.7 Particularly, 
chrome lymphoedema can po e a significant morbidity. 
Sentinel node lymphoscintigraphy (S L) has been 
developed for thi purpose. It involves injecting 
radiopharmaceutical ( pecifically radiolabeled colloid of 
uitable ize and propertie ) ju t out ide the periphery of 
the primary tumour site where they are transported by 
lymphatics and localize in drainage lymph node . Thi 
allows one to trace the path of lymphatic from a 
cutaneous melanoma or breast le ion to the regional node 
basin. Using the nuclear images as a road map, gamma 
probe guided surgery (wi th a hand-held, wand-like 
in t_rumen~ that detect gamma rays emitted by the 
radiocolloid) successfully locate the sentinel node, 
a~lowi~g a directed di ection and minimizing tissue 
d1 ruption. When a pathologi t i given a sentinel node 
in tead of many node to examine, a thorough 
examination with more sectioning or with the use of 
specific staining method or PCR-based assays is afforded, 
which contributes to more accurate di ea e staging.6 
Furthermore, lymphatic mapping and entinel node 
biopsies direct di ection to all lymph node beds that 
potentially receive or have received tumour cells. ot 
infrequently, a sentinel node that shows micrometasta e 
i in a lymph node bed that would not have been 
pr dieted to receive lymphatic drainage from the primary 
tumour based on conventional estimates. In fact, the 
cla ic concept of a lymphatic watershed de cribed by 
S~pp~y's lines (anatomic coordinates governing the 
direction of lymphatic flow from any point on the trunk) 
has been shown by lympho cintigraphy to be inaccurate 
in many patients. 
The Ideal Radiocolloid 
Debate exist regarding the most appropriate 
radiocolloid for u e in SNL. The rate of colloid transport 
and movement through lymphatic pathway i mo t 
s trongly related to the ize and surface charge of the 
colloid. Tho e larger than 0.004,um to O.OOS,um are 
preferred, a mailer particle have been reported to 
penetrate the capillary membranes and are therefore 
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unavailable to migrate through the lymphatic channels 
resulting in ob cured images. Particles smaller than 0.1,um 
show the most rapid disappearance from the intersti tial 
space into the lymphatic vessels and have significant 
retention in the lymph node . Large colloid particles 
(-O.S,um) show a much slower rate of clearance from the 
interstitial space with significantly less accumulation in 
the lymph nodes.6 
Three important questions mus t ultimately be 
answered in the assessment of a colloid's suitabili ty for 
SNL. Firstly, is a stable, safe and efficacious product made 
during the radiolabelling process? ext, how w ill the 
body deal with a charged particulate, taking into account 
its many other physical properties? Las tly, will this 
particulate be biochemically altered, metabolized and 
excreted? Research is currently taking place at London 
Health Sciences Centre9 in the development of suitable 
radiolabeled colloids and assessing them in ca n cer 
patients after appropriate animal biodistribution studies. 
SENTINEL N ODE LYM PH OSCI NTI GRA PHY IN 
MALIGNANT MELANOMA 
In patients with malignant melanoma, the sentinel 
node(s ) is (are) resected and biopsied and, if free of 
metastases, radical nodal dissection is not required, thus 
avoiding potential morbidity which could result from 
radical nodal dissection. If the sentinel node is involved 
with malignancy, radical nodal dissection of the affected 
basin is then performed. Such an approach is currently an 
accepted practice. 
The use of a variety of radiotracer agents for 
lymphoscintigraphy and intraoperative gamma probe 
localization of sentinel nodes in patients with stage 1/ II 
melanoma (ie. no evidence of tumour spread) is firml(o 
documented in the literature. For example Berman et al 0 
reported on 135 patients with malignant melanoma of the 
head, neck, shoulder and trunk. A discordancy rate of 41% 
was found between drainage that would have been 
predicted by the surgeon based on location of the primary 
skin lesion and what was found on imaging. Surgical 
management was changed in 33% because of the 
lymphatic drainage revealed on lymphoscintigraphy. 
Uren et al 11 reported 209 patients with high r isk 
melanoma of the trunk . They found that 
lymphoscintigraphy was 94% sensitive in detecting 
sentinel nodes that contained metastases. Similarly, Krag 
et al12 reported on 121 patients with invasive malignant 
melanoma and clinically negative lymph nodes. Before 
surgical lymph node resection, these patients h ad 
intradermal administration of 99mTc sulfur colloid around 
the primary melanoma. A gamma probe was used in the 
operating room to identify radiolabeled nodes which were 
then electively removed. Patients with identified 
metastatic lesions then underwent regional 
lymphadenectomy. Radiolabeled sentinel lymph nodes 
were successfully resected in 98% of cases. Fifteen patients 
had pathologically positive sentinel lymph nodes and in 
10 of those, the sentinel node was the only node with 
metastases. 
Glass et al13 reported on 132 patients with intermediate 
thickness malignant melanoma. Sentinel nodes were 
exci ed and examined for metastases by light microscopy 
with conventional stains and immunohistochemis try. 
Only patient with micrometastases received comple te 
lymph node dissection. Sentinel nodes were identified in 
all patients while micrometastases was found in 23%. Of 
those with metastases the sentinel node was the only node 
with tumour in 83% based on subsequent complete nodal 
dissection. 
O'Brien et al14 studied 97 patients with cutaneous head 
and n eck melanoma u sing preoperative 
lymphoscintigraphy to identify sentinel nodes. Sentinel 
nodes w ere identified in 95 of 97 scintigrams. 
Lymphoscintigraphy was discordant with clinical 
prediction in 34% of cases. 
The sentinel lymph node biopsy is a particularly 
appealing surgical management strategy for patients with 
stage I/ II melanoma because of the controversy about the 
alternative surgical intervention - namely elective lymph 
node dissection (EL D). Approximately 80% of patients 
with s ta ge 1/ II disease do not have nodal tumour 
involvement demonstrated by EL D. Thus the expense 
and morbidity of the dissection would be unnecessary in 
that group.6 
SENTI NEL N OD E LYMPHO SCINTI GR A PHY IN 
BREAST CANCER 
In the case of breast cancer, surgical management, 
over the years, has evolved from radical and mutilatory 
surgery to the less extens ive s imple mastectomy or 
lumpectomy with radical nodal dissection still being 
performed on a significant number of patients. The 
sentinel node localization and biopsy should eventually, 
after val idation b y large clinical trials, lead to the 
elimination of unnecessary radical nodal resection, 
another step towards optimizing the surgical management 
of this disease. 
Uren et al15 reported on 34 patients with breast cancer 
who were studied with lymphoscintigraphy. Unexpected 
drainage across the centre of the breas t to axillary or 
internal mammary nodes was reported in 32% of patients 
with inner-or outer- quadrant lesions; drainage to supra 
clavicula r or infra clavicular nodes in 20% of upper 
quadrant lesions; drainage to ipsilateral axilla in 85% of 
cases where a single sentinel node was seen. Furthermore, 
Solin16 has shown that the frequency of internal mammary 
node metastases in breast cancer parallels metastases to 
axillary nodes and correlates with the size of the tumour. 
The implications of drainage to unpredicted lymph node 
for patient surgical management are profound. In a large 
number of centres, current management of breast cancer 
does not include lymphoscintigraphy to identify 
lymphatic drainage from the breast cancer site. However, 
it does include ipsilateral axillary node dissection for 
staging invasive breast cancers regardless of location. The 
therapeutic impact of sentinel node localization, excision 
and biopsy directed by ly mphoscintigraphy in all 
potential nodal beds involved with tumour is being 
evaluated . If the frequency of metastases to axillary, 
internal mammary, and other nodal groups is 
proportional to the frequency of lymph drainage to those 
node groups, then surgical management should probably 
be modified to include internal mammary and other nodal 
bed dissections.6 
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CONCLUSION 
Like all currently practiced radionuclide procedure , 
interstitial lymphoscintigraphy is easily performed, well 
tolerated by patients, and is free from either local or 
systemic toxicity. Patient di comfort or inconvenience 
with the procedure as well as allocated resources are small 
considerations relative to the potential benefits. Greater 
familiarity with the technique will enhance its role in the 
investigation and treatment of patients with melanoma 
and breast cancer. 
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HEALTH AND HARMONY: 
LIVE MUSIC 
REGIONAL 
AT THE LONDON 
CANCER CENTRE 
I magine you have just taken your seat on the th ird balcony, front row centre. From far below, a colourful hum of notes rises towards you as a string quar tet 
begins to play. You are impressed by the clarity of the 
ound as it fills the four-storey-high atrium. The hall with 
such remarkable acoustics is, in fact, the London Regional 
Cancer Centre (LRCC). And the musicians are participants 
in the LRCC Live Music Program. 
Music has been a part of medicine for many centuries, 
and the establishment of the LRCC Live Music Program 
shows an increasing awareness of this relationship today. 
It is the goal of this article to review the role of music in 
medicine, and to describe the LRCC program based on our 
experiences at the Cancer Centre as a piano-cello duo. 
Medicine, religion and the arts were closely connected 
in many ancient cultures. The use of music and other 
healing modalities reflected a culture's view of illness. For 
example, chants and magic songs were used by various 
ative American tribes who viewed disease as being due 
to the intervention of spiritual forces .1 Ancient Gr ek 
mythology and historical literature contain many 
references to the use of music in healing, for instance, in 
the works of Homer and Plutarch .2 During the 
Renaissance period, many philosophers tried to develop a 
scientific approach to the relationship between music and 
the human being. For example, the four musical voices 
(bass, tenor, alto, soprano) were related to the four 
temperaments (melancholic, phlegmatic, sanguine, 
choleric), and the four humours of the body (black bile, 
phlegm, blood, yellow bile).3 
The first English book on the use of music in medicine 
was Robert Browne's Medicina Musica: A Mechanical Essay 
on the Effects of Singing, Musick, and Dancing on Hu man 
Bodies (1729).4 Of significance, Browne put forth several 
postulates that still serve as a basis for music therapy 
today. He proposed that music can change and evoke 
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moods, influence physiological processes, does not require 
the attainment of a certain level of proficiency when used 
therapeutically, and could be useful in preventive health 
care. 
Music therapy is the modem term for the use of music 
in medicine . Music therapy can be defined as the 
"controlled use of music, its elements and their influences 
on the human being to aid in the physiologic, psychologic, 
and emotional integration of the individual during the 
treatment of an illness or disability."5 It involves listening, 
singing, playing instruments, improvising, and 
composing.6 
Most people have an intuitive awareness of the 
relaxing and calming effect of music. 
Background music is commonly used in hospital 
waiting areas, delivery suites, orerating rooms, and in 
occupational and physiotherapy. In the medical setting, 
attentive listening can distract from the "here and now" of 
an illness . Specifically, music can divert a person' s 
attention away from the pain, stress, anxiety, and isolation 
of his or her illness and hospitalization. 
Furthermore, it is important to recognize that illness is 
an experience that goes beyond reason and word s. 
Finding a way to express this experience may prove 
crucial to the patient's sense of well-being: "For the 
patient, expression of unspeakable concerns not 
infrequently provides renewed creative energy that is 
usually lost in the process of an illness. This not only 
enriches the quality of life at such a time but may provide 
the impetus to live."8 As such, improvising, singing, 
composing, and playing an instrument can provide an 
avenue for expression and creativity. 
At this time, it is important to point out that the term 
music "therapy" suggests a procedure that has an effect on 
the disease process itself. Is this justifiable? Physiological 
processes, to some extent, can reflect our emotions. We 
hold our breath when we are anxious and exhale when the 
moment of tension passes. We blush when we are 
embarrassed. Yet can the experience of music directly 
influence physiology and possibly disease as well? Some 
basic evidence-based research in this area has begun.9 For 
instance, in Munro and Mount's study of chronic pain, 
they found that music could decrease the intensity of the 
pain experience. Music has also been shown to decrease 
heart rate, systolic and diastolic blood pressure. 10•11 Of 
interest, music played at the tempo approximating that of 
the heart rate is thought to promote relaxation? 
In this century, music therapy was initially used in the 
mental health services. Norma Sharpe, who worked at St. 
Thomas Psychiatric Hospital in Ontario, was one of the 
pioneers of music therapy in Canada.6 In fact, some of the 
inaugural conferences of the Canadian Association for 
Music Therapy took place in St. Thomas (1974) and 
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London, Ontario (1976).6 However, mo t of the current 
literature about the use of mu ic in medicine involves the 
field of palliative care and oncology. 
Regarding the u e of music in cancer care, it i felt that 
"the diver ity of its potential i particularly suited to the 
diver ity of the challenges - phy ical, psycho ocial and 
spiritual - that these [cancer] patients pre ent."5 The way 
in which mu ic can help cancer patients at various tage 
of the disea e de erve an entire discu ion of it own. 
However, in general, mu ic help tho e afflicted with 
cancer in the proce of coping and acceptance through 
relaxation, di traction, and expre sion of feeling . 
One of the most e tabli hed music therapy programs 
in Canada i the 20-year-old program of Montreal's Royal 
Victoria Ho pita! palliative care ervice. Music u ed in thi 
etting has been shown to help patients with advanced 
malignant di ea e. In particular, case report from this 
service document the importance of the power of 
as ociation that music can invoke.5 
Specifically, "mu ic can reduce feelings of loneline s 
by producing familiar, comforting stimulation reminiscent 
of family, homeland, or pa t experience ."5 Mu ic may 
al o be beneficial as an adjunct to antiemetic agents used 
to treat chemotherapy-induced nau ea and vomiting. 12 
Mu ic not only helps to decrea e the anxiety that may 
precipitate the nau ea and vomiting, but also the degree 
and length of this unpleasant side effect. 13 
While mo t of the literature deals with adult oncology, 
the u e of mu ic in pediatric oncolo~, particulary in yhe 
United State i well documented. 4 The u e of mu ic 
therapeutically hare a imilar concept to that of art and 
play therapy - to provide a diver ion and help to enhance 
elf-expre ion of the child. The latter i particularly 
important for children who, a a group, are less capable of 
expres ing their feeling in concrete terms. Of interest, there 
has also been me documentation of potential phy iological 
therapeutic effects of music used in pediatric setting . These 
include decrea ed crying, decreased re piratory rate, and 
even increased oxygen saturation.14 onethele , a mu ic 
therapy is lowly but urely being di covered by other 
medical specialties, it is becoming apparent how music can 
benefit patients in almo tall illness ituations. 
It is intere ting to note that mo t of the literature 
written about mu ic in oncology and medicine revolve 
around its u e a tap d background music. There is little 
written about the u e of live mu ic. Yet, a live 
performance ha much to offer patients. In contra t to 
taped background mu ic, live music provides the human 
pre ence that can enhance the mu ical experience of the 
audience. A live performer is able to pre ent the music to 
the li tener in a per onal way which can be very 
meaningful to the patient. 15 Moreover, an advantage of a 
live performance i that the mu ician is continuously 
aware of the audience' respon e and can spontaneously 
tailor the choice of mu ic, and to orne extent the tyle of 
the performance, to the li tener. 
These benefits were recognized by Jan Searle, a flauti t 
and cancer urvivor from Stratford, Ontario, and Shelley 
Markland and Dr. Le lie Levin of the LRCC. 16 In 1997, 
they organized trial performance with the flute and harg 
in an attempt to make the LRCC "a after, gentler place." 7 
These performances met with an overwhelmingly po itive 
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re pon e. Although orne taff member initially found it 
more difficult to get the patients' attention when it wa 
time to ee the doctor, mo t were supportive of the live 
mu ic. The unique program developed quickly, aided, for 
instance, by the donation of a piano. The program 
currently involve mu ic tudents, community mu icians, 
and mo t recently, patient themselve , who play for one 
to two hours during clinics. 
When we fir t heard about the program, it 
immediately appealed to u but we did not quite know 
what to expect. At our fir t performance at the Cancer 
Centre a year ago, we were initially intimidated by the 
hu hed, impersonal ilence that pervade the LRCC. 
Would we dare to - or even want to - introduce orne 
ound here? Everything eemed so subdued and quietly 
functioning. However, a we gingerly began to play and 
the LRCC revealed it true acou tical qualitie , our doubt 
were dispelled . The atmo phere became lively a the 
patients, previously following variou train of thought, 
turned their attention to the new pre ence. 
Importantly, we were well aware of the fact that many 
patient were in an emotionally demanding situation and 
therefore, we would have to choo e our music carefully. 
What type of mu ic would be mo t appropriate for the 
LRCC? We played a wide a pectrum of mu ic a we 
could to cater to the different mu ical ta tes of the 
patients. A chronological progre ion eemed to work 
well, from Bach and Vivaldi, to Brahms, Schubert and 
Chopin, to the "hits" of the 1950's and 1960' and orne 
oft contemporary mu ic. 
In addition to choosing the music carefully, we 
learned that we had to pay pecial attention to the 
interval between piece . Intere tingly, we found that it 
wa e pecially important to be aware of the moments 
immediately after the end of a piece. The patients at the 
LRCC tended not to applaud by clapping. Instead, a 
remarkable, attentive ilence u ually followed the Ia t 
note. It was a if the mu ic continued to linger on in the 
mind of the patients. In particular, Brahm ' Waltz in A 
Major and Chopin' Claire de Lune were usually followed 
by uch a "li tening" ilence, completely different from the 
"frozen" ilence that preceeded the performance. 
Remarkably, it often took everal minutes before the u ual 
background noi e and movement re umed. 
Perhap one of the mo t rewarding a pects of playing 
at the cancer centre wa experiencing the patient ' 
gratitude. They appreciated not only the mu ic itself, but 
al o the fact that we were taking the time to play for them. 
We felt that the supportive miles and appreciative 
comments the patient gave us benefited them as much a 
it did us. Many patient were e pecially appreciative of 
the fact that we volunteered our time. Thi tell u what an 
important part of the live performance the musicians' 
per onal dedication is to thi audience. 
However, in our opinion, one of the greate t 
achievements of the Live Music Program i the 
involvement of the patients in the performance . As 
mentioned earlier, orne cancer patients are now 
them elves performing at the LRCC. Experiencing the 
progre ive illne , and perhap many rather imper onal, 
standardized procedure uch as MRI, Cf, chemotherapy, 
and radiation protocol , can easily give a patient a feeling 
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of powerlessness . Becoming active and creativ is 
empowering and can serve as a strong support during 
such an uprooting life experience. 
Although most patients do not perform themsel es, 
they often express an acti ve interes t in the live 
performance. How often have we been told about the 
patients' own musical backgrounds, or about a relative's 
accomplishments! It was as if the performance offered a 
much-needed opportunity for personal communication 
and conversation. 
Our experience at the LRCC has gi ven us a n 
appreciation of the tremendous potential of music in 
cancer care. As we discovered, music has the unique 
ability to fulfill a need that ari ses during an illness 
experience. Thus, we would encourage everyone to 
contribute their talent whenever there i an opportunity, 
to help secure and expand the role of music in medicin 
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FUNCTIONAL 
THE REMOVAL 
BRAIN MAPPING AND 
OF BRAIN TUMOURS 
W hether malignant or benign, tumour that lie within the brain po e a treatment dilemma. Surgical removal of the tumour may jeopardize 
urrounding brain ti ue, thu causing a profound 
neurological deficit. In order to minimize the neurological 
deficit that will re ult from a tumour's re ection, the 
function of the brain tissue urrounding the tumour must 
be identified. We shall start by briefly ketching the typical 
organization of brain functions within the human cerebral 
cortex, which provide an approxi mate guide to the 
functions that may be threatened by a tumour. Definitive 
identification of the functions threatened by a particular 
tumour is made po ible by the techniques of functional 
mapping. We hall briefly d.i cu the tandard technique 
for functional brain mapping, which involve applying an 
electric current directly to the brain' urface to stimulate 
the cortex. We shall then focu on an experimental method 
of functional brain mapping with magnetic re onance 
imaging. Finally, we shall pre ent a ingle ca e in which 
both technique of mapping were u ed prior to th e 
re ection of a cavernous hemangioma. 
The brain is the mo t complex organ in the human 
body, both in terms of structure and function. One of the 
ongoing challenge of neuroscience is to relate the 
anatomical tructure of the brain to the cognitive proce e 
that occur within it. Hi torically, there have been two rival 
theories of the relation hip between the tructure of the 
human cerebral cortex and it functionl. At one extreme i 
the view that the cerebral cortex i homogeneous, with all 
regions capable of contributing to all mental ta k 1. At the 
other extreme i the view that each mental proce i 
"localized" to a di crete anatomical area pecialized for 
the ta k. 1 The model supported by today' evidence 
combine element of the e two view . The primary 
ensory and motor functions of the brain are certainly 
localized to characteri tic area in the normal human. For 
instance, the vi ual area i in the po terior occipital lobe, 
the primary auditory area i in the uperior temporal 
gyrus, and the ensorimotor area lie on the banks of the 
central sulcu .1 Even the more abstract function of 
language ha a ded.icated area urrounding the left ylvian 
fi ure in mo t individual .1 It i worth noting, however, 
that thi characteri tic arrangement of functional area in 
the brain can be dramatically reconfigured in re ponse to 
injuries, particular! tho e that occur during development 
of the nervou y tem.1 Thi indicate that there is a fair 
amount of homogeneity between area of the cerebral 
cortex at lea t in their potential to perform variou 
cognitive ta k . 
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The area of the brain that are pecialized to proce 
motor output and linguistic activity are of particular 
concern when the urgical re ection of a tumour i 
planned, since the urgeon wants at all co t to avoid 
leaving the patient hemiplegic or aphasic. Becau e each 
brain may how ignificant idio yncrasie in the location 
of functional area , vital functions can be pared only if 
they are mapped prior to urgery. Between the 1930's and 
1950's, Dr. Wilder Penfield of the Montreal eurological 
Institute pioneered functional mapping of the brain a a 
guide to neuro urgery. 1 Hi technique involved 
performing brain urgery under a combination of local 
and neuroleptic anae thesia, o that the patient remained 
con cious and re ponsive during the operation. The 
urface of the cortex was timulated with a mall electric 
current. Motor area were identified by ob erving the 
contraction of mu de in re ponse to the current. Sensory 
area were identified by asking the patient to verbally 
de cribe any en ation that the electrical timulation 
evoked. Finally, peech areas were identified when 
timulation of the area cau ed a temporary arre t in the 
flow of a patient' peech. Once the e critical areas were 
labeled (see figure 1 upper left), urgery could proceed 
giving them a wide a berth a po ible. 
The recent development of functional magnetic 
re onance imaging (fMRI) provide another method of 
crea ting functional brain map . FMRI exploits the 
deoxygenated hemoglobin normally found in the blood a 
a "contrast agent" ind.icating brain activity.2.3.4 In magnetic 
re onance imaging, the signal emanating from each mall 
block of ti ue i produced by the prece ion of protons 
within the ti ue. The rate of each proton's prece sion i 
proportional to the trength of the magnetic field acting on 
the proton. Since d oxyhemoglobin contains iron with free 
va lence electron , each molecule of deoxyhemoglobin 
create it own magnetic field. 2•3 High numbers of 
deoxyhemoglobin molecule in a mall block of ti sue 
therefore create many small d.i tortions in the magnetic 
field within the ti ue block. In the pre ence of uch 
di tortions, the protons in the ti ue prece at different 
rate , thereby lo ing phase with one another. The resulting 
MR ignal i d.imini hed by the lo of pha e in the same 
way that two water waves of different pha e will partially 
cancel one another. The key result i that high 
deoxyhemoglobin concentration within a ti ue cau e a 
darkenin§ of that ti ue on appropriately acquired MR 
image .2.3• When an area of brain i activated, it extract 
more oxygen from it blood upply, thu creating 
deo yhemoglobin. However, an increa e in blood upply 
to the active area more than compensate for the increa ed 
oxygen extraction, o the concentration of 
deoxyhemoglobin within the venous microva culature of 
the active brain area drops.4 The net effect on MR images 
i that active cerebral cortex i approximately four percent 
U. W.O. Medical Journal 69 (2) 1999------------------------- 37 
Feature Articles 
brighter than the arne cortex at re t. If a serie of image 
are taken while a ubject alternate between re t and task 
performance, the brain areas responsible for the task can 
be identified by their significantly increased brightness 
during ta k performance. FMRI ha been used to map 
primary sen orimotor and visual activity, higher order 
motor and vi ual proce ing, and even comrlex cognitive 
functions uch as learning and language u e. 13 
The following case illustra tes the use of fMRI in 
conjunction with electrical cortical stimulation for the 
purpo e of brain mapping. A 52 year-old lady pre ented 
with a history of headaches and with simple partial 
eizures involving the left thumb. Clinical MR images 
suggested that the le ion was a cavernous hemangioma in 
the middle portion of the cen tral ulcu of the right 
hemisphere, located in the depths of the sulcus. The 
urgeon's preoperative asse sment was that removal of 
the le ion might cause a deficit in hand and arm 
movement. FMRI was used to map the brain regions 
re ponsible for left finger to thumb apposition, olo left 
thumb movement, left wri t flexion and extension, and left 
to right tongue movements. Extensive cortical stimulation 
mapping was performed at the time of surgery, locating a 
range of sensory and motor activitie in the upper limb, 
head, and neck. 
The volume rendered fMRI data was oriented to 
re emble the view of the brain obtained at surgery. The 
fMRI rendering i uificiently detailed to identify all of the 
gyral contours visible in the operative photograph. 
Comparisons of the fMRI maps to the operative data are 
made in figure 1. From figure 1, it is evident that finger to 
thumb oppo ition cau ed fMRI brain activity within 3 mm 
Figure 1. In the upper left is the view of 
the patient' s brain through a craniotomy, with 
labels on the surface indicating the results of 
cortical stimulation mapping. The prominent 
ve el running between the labeled gyri marks 
the central ulcu . Left of page is anterior, and 
bottom of page is uperior. Stimulation at the 
foUowing letters eHcited the following relevant 
re ponses: A - making grip; B - ensation in 
hand, shivering of hand, arm, and shoulder; 
C - pronation of forearm and hand ; 
G- wri t sensation; H, J, K, L, M- sensation in 
fingers or thumb; U - sensation on left side of 
tongue . The upper right shows the fMRI 
activation during left to right movement of the 
tongue. The lower left shows fMRI activation 
during finger to thumb oppo ition. The lower 
right show s fMRI activation during wrist 
flexion and extension. 
Figure 1. 
of operative label A, where electrical stimulation caused 
the patient to clench her left hand. Furthermore, finger to 
thumb opposition caused activation in the po tcentral 
gyru in the area identified with finger and thumb 
ensation during surgery. The ta k of finger to thumb 
oppo ition would be expected to activate both en ory 
and motor components of the primary ensorimotor cortex 
respon ible for the fingers and thumb. We thu conclude 
that the fMRI and cortical stimulation map agree on the 
location of the hand ensorimotor cortex. Wrist movement 
caused fMRI activation at label C, which marked forearm 
pronation and hand movement during surgery. The e are 
clo ely related movements that also involve the wri t joint. 
Tongue en ation could only be elicited during urgery by 
probing beyond the edge of the craniotomy at U. Thi 
region is within 3 mm of the activation shown by fMRI 
during tongue movement, a ta k that will also elicit 
tongue sensation. In this patient, then, fMRI and cortical 
timulation create comparable maps of the functional 
areas found along the banks of the central sulcu . 
The ability to identify the function performed by an 
area of brain tis ue is of obviou benefit to a surgeon 
considering the resection of that ti sue to facilitate the 
removal of a tumour. Cortical stimulation mapping has 
long been u ed uccessfully in this capacity . Early 
experimental results such a the case study described 
sugge t that fMRI may play a role in thi type of brain 
mapping in the future. FMRI has several feature that 
make it an attractive method of brain mapping. Fir t, since 
it i non-invasive, fMRI can be performed on patients both 
before and after neurosurgery . This gives fMRI the 
potential to how the plasticity of brain function in 
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OF PROSTATE-SPECIFIC THE ROLE 
ANTIGEN 
FAMILY 
FOR SCREENING IN THE 
OFFICE PHYSICIAN'S 
Pro tate cancer i ranked among the mo t common cau e of cancer-related death in men. In 1997, it urpas ed lung cancer as the most frequently 
diagnosed cancer in Canadian men and its estimated 
incidence per year has exceeded that of breast cancer in 
Canadian women. 1 Prostate Specific-antigen (PSA) has 
been available as a screening test in Canada ince 19 6, 
although its u e did not become widespread until the 
early 1990's. Screening guideline for prostate cancer in 
the Uni ted State include PSA testing, however no such 
guidelines have been establi hed in Canada. Why have 
creening programs for pro tate cancer, like tho e of 
breast cancer, not been implemented in Canada? There are 
no clear cut answers, however, an understanding of PSA 
as a creening tool will help physicians determine how to 
be t apply this tool in the management of their patient . 
Prostate Specific Antigen; Historical Aspects 
The earch for a pro tatic tumor marker more pecific 
and ensitive than prostatic phosphatase began in the 1960's. 
By the 1970's several groups of researchers had discovered 
antigen pecific to the prostate. Work on the e antigen 
continued in hopes of developing forensic identifiers in 
rape ca e (never very effective) as well a tumor marker 
for pro tate cancer. In 1971, Hara et al, isolated PSA from 
eminal plasma and named it y-seminoprotein. Soon 
afterwards, Li and Beling characterized El, an antigen from 
eminal plasma using a serie of protein chromatographic 
technique . In 1978, Sensabaugh identified PSA in human 
emen and called it p30. When it was discovered that 
anti era to the partially purified antigens did not react with 
extract from tissue other than the prostate, the term 
pro tate-specific antigen or PSA was coined? 
In 1981, Wang et al, reported isolates of pro tatic 
antigen from seminal plasma and prostatic antigen 
purified from prostatic ti ue were identical.3 Alma t a 
quarter of a century after the three separate antigen were 
initially di covered, inve ligation revealed that the three 
antigens where in reality a single pecific antigen -
pro tate- pecific antigen. PSA i an organ-specific erine 
protea e, produced by pro tatic epithelial cell lining the 
acini and duct of the prostate gland. Functionally, this 
protease i known to cau e liquefaction of the seminal 
coagulum.4 
Current Screening Techniques for Prostate Cancer 
There are several criteria a clinical test should meet 
before being considered a a di ease screening te t: (1) the 
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disea e must be an important health problem; (2) the 
di ea emu t have a recognizable early stage; (3) treatment 
at an early stage should be more beneficial than treatment 
at a later tage; (4) the test must be convenient and 
tolerable for the patient; (5) necessary facilities must exist 
for diagno i and treatment; (6) the cost of creening must 
be acceptable to society.5 
Currently there are four potential screening te ts used 
for pro tate cancer. The e include the digital rectal exam 
(ORE ), pro tatic pho phatase (PAP), trans-rectal 
ultra ound (TRUS); as well as, the seromarker prostate-
pecific antigen (PSA) approved in 1986 by the Food and 
Drug Admini tration for the u e as an aid in the prognosis 
and management of patient with pro tate cancer.6 
Although PAP is also a seromarker for prostate 
cancer, unlike PSA, PAP level do not become elevated 
until the disease ha reached an advanced tage. This 
gives PAP no advantage over a ORE screening exam. 
Thus, PAP is not u ed for creening but for taging the 
disea e only after it i diagno ed? Performing a TRUS of 
the pro tate as a creening te tis not an effective creening 
test because a TRUS can not differentiate many small 
cancer from urrounding benign prostatic ti ue. TRUS' 
mo t appropriate use is in directing biop ie in men who 
have abnormal findings on ORE and/ or PSA testing.7 
Although inexpensive and time tested, DRE-ba ed trials in 
pre-PSA eras showed that only 33% of ORE-detected 
pro tate cancers had pathologically organ-confined 
di ease. Thus, 67% of men were diagnosed at a stage of 
prostate cancer associated with a very poor 10-year 
progno i . If men with organ-confined prostate cancer 
undergo radical prostatectomy, they are essentially cured 
of the disea e and have a urvival rate equivalent to that 
of age-matched men without the disea e.9 In contrast, 
pro tate cancer that i not organ confined is incurable. 
PSA creen.ing ha shown it elf to be a very effective tool 
in finding organ confined and thus curable prostate 
cancer. PSA testing is convenient, tolerable and 
inexpensive. Serum PSA te ting meets most established 
criteria' for a clinical te t be con idered a a creening 
tool. 
Physiologic Reasons for PSA Elevation. 
The physiology by which elevated levels of PSA enter 
the blood stream has lead to some inaccurate assumptions 
regarding the specificity of elevated serum PSA levels. 
Serum PSA levels deviate from reference value for two 
basic rea ons: (1) an increase in PSA production, such as in 
the ca e of benign prostatic hyperplasia, which creates a 
shift in the diffusion gradient; (2) a change in the 
membrane permeability or normal physiological barriers, 
for example prostate cancer and pro tatitis. 
Early re earch indicated the potential for false-po itive 
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re pon e to change during urgery. Secondly, many 
comple cognitive ta k that cannot be inve tigated u ing 
cortical timulation can be inve tigated with fMRI. Finally, 
whil cortical timulation give acce only to the brain' 
urface, fMRl can show functional areas deep within the 
brain. Thus, there is rea on to be optimi tic th a t the 
difficult urgery currently performed to remove cerebral 
tumour will in the future benefit from advance in 
functional mapping technique 
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elevations in serum P A level after pro tatic 
manipulation and/ or ejaculation. However, Chybowski et 
al 10, via a prospective randomized controlled trial, howed 
that the median erum PSA elevation caused by ORE 
repre ented a clinically in ignificant increa e in the erum 
PSA level. Thu the author concluded that the erum PSA 
concentration in the immediate post-ORE period i 
accurate and would not com~romi e clinical value of the 
marker. Similarly, Yuan et al 1, found that ORE, pro tatic 
rna sage, and TRUS, produced orne elevations in erum 
PSA levels; however, the author concluded that the 
elevations were not tati tically ignificant and that the e 
e am had minimal effect on erum PSA level in mo t 
patient . 
PSA level may become elevated by age (therefore, 
age pecific range of value are employed), acute urinary 
reten tion and urethral catheteriza tion. The use of 
Fina teride can lower PSA level by approximately 50%. 11 
Sensitivity and Specificity of PSA 
The fact that pro tate cancer ha recently become one 
of the most prevalent cancer in our society is primarily 
due to increa ed diagno i a a direct re ult of the u e of 
PSA a a creening tool. Of the cancer now detected, 95% 
that are detected are clinically localized. While ensitivity 
i relatively high at 92%, pecifidty is lower becau e of the 
other way in w hi ch PSA can be rai ed . When other 
condition or rea ons for the eleva tion of PSA are 
u pected, the finding of a low percentage of free, 
unbound PSA increa e the pecifidty. Al o, PSA velocity 
can be followed . While it i increa ed by factors such a 
age, it hould not increa e by more than 0.75 ng / rnl per 
year. PSA density (ng/ ml / ml) can also be followed for 
creeningY Regardles of it limitation , erum PSA i 
currently the best creening tool available for pro tate 
cancer. If there is sufficient u pidon of prostate cancer 
ba ed on PSA level , then TRUS guided biop y of the 
pro tate can be performed for a d finitive diagno i . 
Management of Prostate Cancer 
There i currently orne controver y urrounding the 
wide pread use of erum PSA levels as a screen for 
pro tate cancer. A noted previou ly, PSA i currently the 
be t method for detecting pro tate cancer. It i highly 
en itive, and ince PSA te ting began, there has been a 
lower incidence of meta tatic disease at th e time of 
diagno i .15 This is important, a there i a reali tic chance 
for cure of prostate cancer only if it i detected and treated 
early in it cour e. Argument against the wide pread use 
of PSA for prostate cancer creening are not ba ed on 
Table 1 Age-specific reference ranges for serum prostate-specific 
antigen. 14 
Age 
(years) 
40-49 
50-59 
60-69 
70-79 
Serum PSA 
(ng/ml) 
0.0-2.5 
0.0-3.5 
0.0-4.5 
0.0-6.5 
PSA density 
(ng/ml/ml) 
0.0-0.0 
0.0-0.10 
0.0-0.11 
0.0-0.13 
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whether or not PSA i a reliable tool for the detection of 
cancer. Thi ha already been proven and accepted. What 
tho e oppo ed to PSA creening question, is whether or 
not there are effective treatment available to patient 
which will increa e their quantity and / or quality of life 
once the cancer has been diagno ed. 
There are currently four approache to the 
management of pro tate cancer. The first and imple t 
app roach i watchful waiting. Thi may be the mo t 
appropriate management for pro tate cancer diagno d in 
men 75 or older, a 4% of the e patient will urvive 10 
year without treatment and it a odated ri k . Another 
option for older patient i hormonal therapy uch a a 
luteinizing hormone-relea ing hormone agoni t or an 
antiandrogen. This i an acceptable option to many older 
patient who will not accept watchful waiting. While it 
may not affect their life expectancy, many patient fe 1 
that watchful waiting i an un a tisfactory treatment 
cour e for cancer. The gold tandard treatment for 
pro tate cancer i urgery. A radical pro tatectomy i 
a ociated with a 10-year urvival rate of up to 94%. 
However, this i only an option if the tumor is confined 
within the pro tatic cap ule. Finally, radiation therapy i 
an option. It i as ociated with a lower 10-year urvival 
rate than a radical pro tatectomy (74%), but thi i largely 
due to the fact that radiation therapy is re erved for 
patient with larger tumor and higher PSA levels.16 
Widespread Use of PSA as a Screening Tool 
There are everal argument that fuel the controver y 
of PSA creening. An important question that mu t be 
addre ed before creening for pro tate cancer i , "What 
grade or stage of pro tate cancer i worth treating in order 
to improve quality of life?" At 55 year of age, a man 
wi thout pro tate cancer ha a life e pectancy of 21.4 year . 
If the arne man ha a well-differentiated, micro copic 
cancer and doe not undergo treatment, hi life expectancy 
wil l till be 21.4 year . However, a moderately 
differentiated cancer will cut life expectancy by four year . 
A wide pread ere ning will identify case in which 
treatment will benefit the patient a well a ca e in which 
treatment will have no benefit, the willingne of patient 
to leave a cancer untreat d, no matter what the tudie 
indicate, mu t al o be que tioned. 
It i likely that a large number of patients, even when 
coun eled that treatment will have no effect on life 
expectancy will go forward with management to remove 
the cancer from their bodie . Thi de ire to treat pro tate 
cancer regardle of the fact that it may not alter life 
expectancy i a primary argument again t wide pread 
creening. Treatment may not only be of little benefit, it i 
as odated with several ide effect which can diminution 
a patient's quality of life. Radical pro tatectomy i 
a odated with a 30% ri k of incontinence and impotence 
a lingering patient problem . Radiation therapy i 
a ociated with tre s incontinence in 50% of patient , 
exual dysfunction in 30% and chronic proctiti in 10%. 
Hormonal therapy i a ociated with hot fla he , 
decrea ed libido, and brea t tenderne although the e 
effect are u ually hort-lived.17 Only watchful waiting i 
without treatment-induced ide effects. 
A second important argument again t PSA creening 
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i co t-effectivene . As with all a p ct of health care in 
today' ociety, co t-effecti vene i a great cone rn. 
Analy e b Krahn et al 1 and Fleming 19 found that there 
wa littl or no clinical benefit deriv d from treating 
clinically localized pro tate cancer. While the e tudie 
received a good deal of attention from the media and 
were well-cited in medical literature, their election of 
patient ha b en questioned . In their tudie , the average 
age of the men tudied wa 72 year , whereas the 
recommended age for creening i 50-70 years. AI o, 
34.2% of the men with cancer in the tudy had moderately 
or poor! differentiated di ea e, w herea in the .S., 
creening trial have shown that over 77.6% of men 
diagno d with cancer had the arne lev I of di ea e.20 A 
well, everal tudie have hown that men treated by 
radical pro tatectomy have the arne life expectanc as 
age-match d m n without pro tate cancer, whereas there 
i no available data demon trating the number of year 
lo t if the e arne men were not treat d for their cane r.21 
There ar tudies both for and against the co t-
effectivene of PSA creening; how v r, conclu ive data 
from long-term randomized clinical trial will not be 
available for another ten year .22 
Conclusions 
Wide pread creening for pro tat cancer by PSA ha 
not yet been accepted in Ontario, evidenced by our lack of 
Canadian guideline for creening, a well a the fact that 
PSA te ting i not covered by OHIP. The American Cancer 
Society, th American Urological A ociation and the 
College of Radiology (U.S.) currently recommend that 
men o er the age of 50 year hould undergo an annual 
DRE and erum PSA for the purpo e of detecting early 
pro tate cancer. Annual creening hould begin at the age 
of 40 year in African-American men or patient with a 
known famil hi tory of pro tate cancer.23 
Curr ntly in Ontario, laboratory te ting i covered by 
both public and private ector . Pri va te laboratorie 
recover th ir co t by billing OHIP fo r in ured te t 
covered by the provincial plan. Public lab ratories operate 
mainly within hospitals and te ting co t are recovered 
from ho pita! budget .24 Therefore, pati nt must pay for 
the PSA creen if it is reque ted out ide of a hospi tal 
etting (i .. in a family phy ician' office). The fact that 
PSA creening i not yet cover d by OHIP hould not be 
rea on to w ithhold it from patient in the identified ri k 
group . The controver y of PSA creening come at a time 
when co t control i a dominant cone m to the health care 
y tern . In reality, cerv ical and brea t cancer creening 
program were implemented at tim during which the 
effect of th e creening program on mortality wa not 
known.25 The fact that the burden of co t for this te t 
currently lie with the patient, coupl d with the fact that 
Canadian guideline do not currentl y upport the 
wide pread u e of te ting, leave the family physician in a 
tate of uncertainty a to whether or not to use PSA a a 
creening tool in their practice. 
One certainty remain , pro tate cancer i a highly 
prevalent problem in our odety. While the controver y 
o er creening and treatment continu , all patient must 
be educated on the ignificance of po itive test re ult , 
different mod of treatment (including watchful waiting) 
and potential benefit and ide effect of the e treatment . 
Thi educa tion mu t be fa irly comprehensive and take 
place before the option of PSA te ting is given to the 
patient. While the jury i till out regarding both creening 
and ub equent treatment, the magnitude of the problem 
i uch that inaction cannot be tolerated. PSA screening 
mu t be offered to informed patients 50-70 years of age 
and tho e with risk factor 40-70 year old. 
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METASTASES TO B 0 N E 
Bo n y meta ta e a re a hall m ark of o m inou , d i eminated di ea e. They are more common than primary bone tumour . In fact 70% of all 
malignancie in bone are meta ta e from another primary 
ource. 1·2.3 Skeletal meta ta e are pre ent in up to 85% of 
all people with terminal carcinoma.1 The e metasta es are 
frequently the pre enting complaint from which the 
disease i di covered. 
Alma t all malignant neopla m have been de cribed 
to meta ta ize to bone at orne point. 3 However, 
carcinoma of the brea t, pro tate, lung, kidney and 
thyroid comprise 90% of bon y meta tases .u 3. Le 
common primary tumour include carcinoma of the kin, 
e ophagu , oral cavity, tomach, cervix and colon. Only 
23% of terminal colon cancer ca e how bony meta ta es 
on autop y? In men, pro tate cancer i re ponsible for 60% 
of bony meta ta e and bronchogenic carcinoma i 
re pan ible for 25%.2 In women, brea t cancer produce 
70% of bony meta ta es with kidney, thyroid and uteru 
causing nearly 30%. In children under five year old, 
neurobla toma is the mo t common primary neoplasm 
meta ta izing to bone. 
The mo t common ite for bony meta ta e i the 
thoracic spine. Thi i followed by the lumbar spine, 
pelvis, femur, rib, sternum, proximal humeru and skull. 1•5 
It i rare to ee bony meta ta e di tal to the elbow or 
knees. When the e o called acral metasta es are pre ent, 
lung i the mo t common primary.1 
Tumour arrive at bone u ually via hematogenou 
pread, although local inva ion i po ible. The pine in 
particular i u rrounded by an ana tamo ing va cular 
network known as Bat on' Plexu _I.:z.s Thi rich plexu of 
veins ha no valve .3 Thi fact allow for retrograde flow 
of blood that bypa e the caval y tern and facilitate the 
eeding of tumour cell in the pine. The hematopoietic 
marrow of the axia l keleton i a l o upplied by rich 
in u aid . The e may al o play a role in meta ta es 
formation. 
In the early tage , bony metasta e are u ually 
a ymptomatic.5 They often progre to pain, tenderne 
and welling, increa ing in idiou ly for week or month _3 
Thi pain i u ually war e at night. In the much rarer ca e 
of sudden onset of pain, a pathological fracture i u ually 
re ponsible. Other po ible presenting complaint may be 
related to nerve root or pinal cord compromi e. p to 
10% of patients with bony meta ta e will develop a 
clinical picture imi lar to hyperparathyroidi m, due to the 
production of rara thyroid hormone-like 0 teoclast-
activating factor. 
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Bony meta ta e can be either o teobla tic, o teolytic 
or both.' 0 teobla tic le ion con titute 15% of all bony 
meta ta e . They carry a better progno i than o teolytic 
tumour .1 They are frequently painle and have a lower 
chance of pathological fracture . In men, pro tate and 
te ticular seminoma are mo t often the primary tumour .2 
In women, brea t, ovary and uteru are u u ally 
re ponsible for bla tic metasta e . 
0 teoblastic tumour produce cytokine that activate 
o teoblast Y There i al o an a ociation with increa ed 
alkaline pho phata e level and cau ing h pocalcemia. A 
plain film of an o teobla tic le ion may how increa ed 
bone den ity or clero i . However, a bone can i u uall 
u ed to detect the e le ions. 
Seventy-five per cent of bony meta ta e ar 
o teolytic. Common primarie of lytic le ion include 
kidney, brea t, lung, ga trointe tina) and thyroid 
tumour .3 The e le ion are more often a ociated with 
hypercalcemia. 0 teoly tic le ion re ult when tumour 
produce sub tance that cau e bone re orption uch a 
pro taglandins or vitamin D-like teroid . The tumour 
may al o produce cytokine that induce o teocla t activity. 
(eg. interleuken 1 and tumour necro i factor) . 
Most tumour may produce both ly tic and bla tic 
meta tases. Ten per cent of all le ion are ac tually a 
mixtu re of both bla tic and ly tic component .2 Some 
carcinomas, uch a hypernephroma, multiple myeloma 
and thyroid carcinoma, can induce va cu larity at a 
meta tatic ite producing an a neury mal le ion. 1 It i 
important to note the e a they may need to b embolized 
prior to urgery. 
APPROACH 
It i not unheard of for a cancer to pre ent a a focu of 
bony metasta e . In the e ca e , the pre nting complaint 
is u ually that of progre sive pine pain that may or may 
not progre to include neurological ymptoms. Le s 
often, the pre enting problem may be that of a 
pathological fracture. In either ca e, a full work-up to 
diagno e the primary le ion i indicated. 
The recommended inve tigation into bony meta tase 
of unknown origin begin with a detailed hi tory and 
phy ical exam.1.6 In the female, concentration hould be on 
the breast exam and Papanicolou mear. In the male, a 
pro tate exam and Pro tate Sp cific Antigen are of pecial 
intere t. Brea t and pro tate hould be the fir t thought in 
a diagno tic inve tigation. The thyroid gland hould al o 
be palpated thoroughly and an I-131 i otope tudy of the 
thyroid i often indicated . A complete blood count, 
electrolyte , urinaly i and alkaline pho phata e level are 
the initial laboratory inve tigations of choice.6 Pathology 
examination of a biop y of th meta ta i may provide a 
diagno is if the above inve tigation fail to yield the 
n eded information. 
Imaging i more helpful in finding the primary Je ion 
than it i at det cting bony meta ta e . A che t x-ray, 
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Prescribing Information 
Ill AREOlA* 
(pamllronate disodium for onjecbon) 
30 mo. so mo. 90 mo 
For I. V. infusion only 
THERAPEUTIC CLASSIFICATION 
Bone Metabolism Regulator 
INDICATIONS AND CLINICAL USE 
Tumor- Induced hypercalcemia following adequate saline 
rehydration. 
Prior to treatment with AREOlA. renal excretion of excess calcium 
should be promoted by restoring and mamtaming adequate fluid 
balance and unne output 
- Conditions associated with Increased osteoclast activity: 
predominantly lytle bone metastases and multiple myeloma. 
- Symptomatic Paget's disease of bone . 
CONTRAINDICATIDNS 
Known or suspected hypersensitivity to AREOlA. to any of its 
components (see COMPOSmON in PIIARMACEUTICALINFORMATION 
section), or to other bisphosphonates. 
WARNINGS 
AREOlA MUST NEVER BE GIVEN AS A BOLUS INJECTION SINCE 
SEVERE LOCAL REACTIONS AND THROMBOPHLEBITIS MAY 
RESULT FROM HIGH LOCAL CONCENTRATIONS. 
AREOlA SHOULD ALWAYS BE DILUTED AND ADMINISTERED 
AS A SLOW INTRAVENOUS INFUSION (see DOSAGE AND 
ADMINISTRATION). REGARDLESS OF THE VOLUME OF SOLUTION 
IN WHICH AREOlA IS DILUTED, SLOW INTRAVENOUS INFUSION 
IS ABSOLUffiY NECESSARY FOR SAFETY. 
AREOlA should not be giVen together with other bisphosphonates to 
treat hypercalcemia since the combined effects of Utese agents are 
unknown. 
AREOlA should not be mtxed wtth calc10m-contammg mtravenous 
inluSIOnS. 
PRECAUTIONS 
It is essenbal in the mitial treatment of tumour-indured hypercalcemia 
that intravenous rehydration be instituted to restore urine outpul 
Patients should be hydrated adequately throughout treatment but 
overhydral!on must be avoided. 
In pa ents with cardiac disease, especially in the elderly, additional 
saline ovelload may precipitate card~ac fatlure (lett ventricular 
failure or congestive heart failure). Fever (influenza-like symptoms) 
may also contribute to this deterioration. 
Although AREOlA IS excreted unchanged by the kidney, the drug has 
been used without apparent mcrease in adverse effects in patients 
with Significantly elevated plasma creatinine levels (includtng 
patients undergoing renal replacement therapy with both 
hemodialysis and peritoneal dialysis). However. experience w~h 
AREOlA in patients with severe renal impairment (serum creatinine 
>440 ~mol/l, or 5 mg/dl in TIH patients; <180 ~mol/l, or 
2 mg/dl in muniple myeloma patients) is limited. If clinical 
judgment determines that the potential benefits outweigh the risk in 
such cases. AREOlA should be used cautiously and renal funcbon 
carefully mon~ored. 
Patients with Paget's disease of the bone, who are at risk of calcium 
or vitamin 0 deficiency, should be given oral calcium supplements 
and vitamin 0 to minimize the risk of hypocalcemia. 
Patient Monitoring: 
Patients should have standard labOratory (serum creatintne and 
BUN) and clinical renal function parameters periodically evaluated, 
especially those receiving frequent AREOlA infusions over a 
prolonged penod of time, and those with pre-existing renal disease 
or a predisposition to renal impairment (e.g., patients with multiple 
myeloma and/or tumour-induced hypercalcemia). Auid balance 
(unne output, dally wetghts) should also be followed carefully. If 
there IS deterioration of renal function during AREOlA therapy, the 
infusion must be stopped. 
Serum electrolytes, calcium and phosphate should be monitored 
followmg initiation of therapy with AREOlA. Patients with anemta, 
leukopenia or thrombocytopenia should have regular hematology 
assessments. Occasional cases of mild, transient hypocalcemia, 
usually asymptomatic, have been reported. Symptomatic 
hypocalcemia occurs rarely and can be reversed with calcium 
gluconate. Patients who have undergone thyroid surgery may be 
particularly susceptible to develop hypocalcemia due to relative 
hypoparathyroidism. 
In tumour-tnduced hypercalcemia, either ionized calcium or total 
serum calcium corrected (ad1usted) for albumm should be 
mon~ored during treatment with AREOlA. Serum calcium levels In 
patients who have hypercalcemia ol malignancy may not reflect the 
seventy of hypercalcemia, since hypoalbuminemia is commonly 
presenl Corrected serum calcium values should be calculated using 
established algorithms, such as: 
I eta =tea + (0.02 x 140 - ALB)) I 
where: 
cCa =adjusted calcium concentration (mmol/l) 
tCa = measured total calcium concentration (mmol/l) 
A!.B = measured albumin concentration (gil) 
Drug Interactions: AREOlA has been used concomitantly with the 
follOWing medtcations without evidence of signtficant adverse 
interactions: aminoglutethimide, cisplatin, corticosteroids. 
cyclophosphamide, cytarabine, doxorubicin, etoposide, fluouracil , 
loop dturetics, megestrol, melphalan, methotrexate, mitoxantrone, 
paclitaxel, tamoxifen. vinblastine, vincristine, and. in patients with 
severe hypercalcemia. calCitonin or mithramycin. 
Use in Pregnancy: There is no clinical evidence to support the use 
of AREOlA in pregnant women. Therefore, AREOlA should not 
be administered during pregnancy except for life-threatening 
hypercalcemia. 
In animal experiments, pamtdronate was not teratogenic and did not 
affect general reproductive performance or fertility. In rats, 
prolonged parturition and reduced pup survival were probably 
caused by a decrease in maternal serum calcium levels. The tertii~ 
of the pups was also reduced. Pamidronate crosses the placental 
barrier and accumulates in fetal bone. 
lactation: There is no clinical experience with AREOlA in lactating 
women and ~ is not known whether AREOlA passes into breast 
millt A study in lactating rats has shown that pamidronate passes 
into the mil Mothers treated with AREOlA should therefore not 
breastfeed their intants 
Pediatric Use: The safety and efficacy of AREOlA in children have 
not been established. Until further experience is gained, AREOlA is 
only recommended for use in adun patients. 
EHects on Ability to Drive or Use Machines: In rare cases, 
somnolence and/or diZZiness may occur, in which case the patient 
should not drive, operate potentially dangerous machinery or 
engage in other activities that may be hazardous. 
ADVERSE REACTIONS 
Adverse reactions with AREOlA are usually mild and transienl The 
most common adverse reactions are influenza-like symptoms and 
mild fever (an increase '" body temperature of> 1"C, which may last 
up to 48 hours). Fever usually resolves spontaneously and does not 
require treatment. Acute "influenza-like" reactions usually occur 
only with the first AREOlA infusion. The table below shows the 
inctdence of the more commonly observed adverse effects overall 
and by indication. 
Adveru experiences by body system: Frequency estimate: frequent 
>10%, OCtaSIOnai >1-10"4, rare >0.001-1 '/o, isolated cases <0.001 '/o. 
Body as a whole: Frequent fever and influenza-like symptoms 
somebmes accompanied by malaise, rigor, fatigue. and flushes. 
Isolated cases: allerg~ reaction (swollen and ~thy eyes, runny nose 
and scratchy throat). 
local reactions: Occastonal: reactions at the infusion site: pain, 
redness, swelling, induration, phlebitis, thrombOphlebitis. 
Musculoslleletal system: Occasional: transient bOne pain, arthralgia, 
myalgia, generalized pain, skeletal pain. Rare: muscle cramps. 
Gastrointestinal tract: Occasional: nausea, vomiting. Rare: 
anorexia, abdominal pain, diarrhea, constipation, dyspepsia. 
Isolated cases: gastritis 
Central nervous system: Occasional: headache. Rare: symptomatic 
hypocalcemia (paresthesia, tetany), agitation, confusion, dizziness, 
insomnia, somnolence, lethargy. Isolated cases: seizures, visual 
hallucinations in one case 
Blood: Occasional: lymphocytopenia. Rare: anemia, leukopenia 
Isolated cases: thrombocytopenia. One case of acute lymphoblastic 
leukemia has been reported in a patient with Pagefs disease. The causal 
relationship to the treatment or the underlying disease is unknown. 
Cardiovascular system: Rare: hypotension, hypertension. Isolated 
cases: left ventricular failure (dyspnea, pulmonary edema), 
congestive heart failure (edema) due to fluid overload 
Respiratory system: Isolated cases: adult respiratory distress 
syndrome, interstitial pneumonitis. 
Renal system: Isolated cases: hematuria, acute renal failure, 
deterioration of pre-existing renal disease. 
Skin: Rare: rash, prur~us. 
Special senses: Isolated cases: conjunctivitis, uveitis (iritis, 
iridocyclitis) . scleritis, episcler~is, xanthopsia. 
0\he!$: Isolated cases: reactivation of herpes simplex and herpes zoster. 
Biochemical changes: Frequent hypocalcemia, hypophosphataseia 
Occasional: hypomagnesemia. Rare: hyperkalemia, hypokalemia, 
hypematremia, symptomatic hypocalcemia 
Isolated cases: abnormal liver function tests. increase in serum 
creatinine and urea 
Many of these adver58 events may have been related to the 
underlying dise<lse. 
Tumour-Induced Hypercalcemia and Paget's Disease: Adverse 
experiences considered to be related to AREOlA occurring in :!.1 '/o 
of patients in the specified indication· 
Adveru Tumour-Induced Paget's Disease 
Experiences Hypercalcemia 
No. of patients n=910 n=395 
('lo) ('lo) 
Fever 6.9 B.9 
Headache 0.0 4.8 
Hypocalcemia 3.2 0.8 
lnfluenza-li e 
symptoms 0.0 11.9 
Infusion site reaction 1.7 1.8 
Malaise 0.0 5.8 
Myalgia 0.0 2.0 
Nausea 0.9 2.0 
Pain (bOne) 0.0 8.9 
Pain (unspecified) 0.0 7.9 
Rtgors 0.0 2.8 
Oetenoration of renal function has been noted 1n patients treated 
with bisphosphonates. Since many patients with tumour~nduced 
hypercalcemia have compromised renal function prior to receiving 
antihypercalcemia therapy (see PRECAUTIONS), ~ is difficun to 
estimate the role of tndividual bisphosphonates in subsequent 
changes in renal function. Oeteriora ·on of renal function (elevation 
of serum creatinine of >20'1o above baseline) which could not be 
readily explained in tenms of pre-existing renal disease, prior 
nephrotoxic chemotheraptes or compromised intravascular volume 
status has been noted tn 7 cases of 404 patients treated with 
AREOlA where these data have been reported. The role of 
pamidronate disodium in these changes in renal function is unclear, 
but merits cautious observation. 
Bone Metastases and Multiple Myeloma: 
The most commonly reported adverse experiences regardless of 
relationship to therapy have been shown. 
Deterioration of renal function (including renal failure) has been 
reported following long-tenm treatment with AREOlA in patients 
with multiple myeloma. However, underlying disease progression 
and/or concomitant complications were also present and therefore 
a causal relationship with AREOlA is unproven. 
DOSAGE AND ADMINISTRATION 
Dosing recommend3tJOns differ for tumour-induced hypercalcemia, 
lytic bone metastases and multiple myeloma, and Paget's disease. 
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abdominal CT and pelvic CT are usually indicated in 
dis eminated neoplastic disea e.6 Plain films of the bone 
where metastases are su pected are often of little value. 
0 teolytic le ions tend to show up on plain films only 
after the cortex has become involved.7 Usually, tumours 
embolize to marrow fir t and only invade the cortex after 
orne growth (usually at least 1 em diameter) has 
occurred. This invasion of th e cortex produces the 
o-called "cookie-cutter" le ion on a plain radiograph.2 
Typically, 30% to 50% of cortical bone mineral must be lost 
before the lesion how up on x-ray. Therefore, bone scans 
often how po itive meta tase up to four months before 
plain film _3 
In 3% to 4% of case of isolated bony metasta e , a 
primary is not found. 6 Although most bony meta ta es are 
from pro tate or breast, tho e that remain unknown are 
not likely to be from either of the e two common cancers. 
The e are both ea ily examined and local symptoms are 
usually pre ent. Undiagno ed primaries are more likel to 
be from deeper visceral organs such a kidney or lung. If 
the aforementioned inve tigations do not yield a 
diagno is, further investigation is likely not indicated. The 
disease is severe and the progno is is already known to be 
poor. It should seriou ly be considered to treat this patient 
palliatively and pare them the di comfort of further 
aggre ive te ts. 
MANAGEMENT 
The pain cau ed by bony meta ta e hould not be 
undere timated . Palliative pain management is often 
neces ary to reduce the morbidity of the di ea e . 
Hormonal regulation plays a role in controlling the 
ymptom of bony meta ta e ! AI o effective for the e 
common tumour is local radiation therapy consisting of 
3000 cGy for ten day . More radiore istant tumour , uch 
a renal cancer or melanoma, may re pond favourably to 
4000 cGy to 5000 cGy for ten days. This ha been hown to 
ignificantly reduce pain one month po t-treatment in 0% 
of ca e ! Thi i al o a ociated with a change from an 
o teolytic picture to an osteoblastic one. 
Pathological fracture of a bone due to metas tatic 
di ea e i mo t often an indication for urgical treatm nt. 
Twenty year ago, the mean urvival followin g a 
pathological fracture was 7.8 month ... Due to the 
development of better surgical technique and 
radiotherapy, the current mean urvival following all 
pathologic fracture i 1 .8 month . Specifically, the m an 
urvival following fracture due to pro tate cancer i 30 
month , breast cancer i 22.6 months, kidney cancer is 11.8 
month . The wor t progno is follow pathologic fracture 
due to lung cancer with a mean urvival of 3.6 months. 
75% of all pathological fracture urg ry i performed 
on the hip. The most common site for fracture is 
intertrochanteric followed by the femoral neck. Often a 
meta ta i to the femur i identified befor fracture occurs. 
In this ca e it is the responsibility of the Orthopaedic 
Surgeon to decide whether prophylactic internal fixation 
i nece ary prior to local radiation. The current criteria for 
prophylactic tabilization con ist of one of: 50% cortical 
lysi ; 2.5 em diameter femoral le ion; avul ion fracture of 
the les er trochanter and f>ersi tent pain four w ek after 
local radiation therapy . Other site of pathological 
fracture that commonly require surgical stabilization 
include the hafts of the femur and humeru and the 
acetabular area. 
Metastases to the spine produce further issues in 
management. The presenting complaint of pinal 
metasta e is that of progre ive pain persisting for weeks 
to month . Mo t pinal metasta e can be adequately 
managed with local radiation therapy and medication. 
However, in the event of neurological symptoms such as 
motor or ensory changes, radicular pain or alterations in 
bowel and bladder function, more aggressive treatment 
needs to be instituted. The mid-thoracic pine is the mo t 
common ite for pinal meta ta es.1•9 The narrow vertebral 
canal in this area also make it more prone to spinal cord 
compression. This is followed by the thoracolumbar area. 
The cervical pine i more rarely affected partially due to 
the wide vertebral canal at thi level. Prostate and breast 
cancer u ually appear at multiple ite along the pine 
wherea lung cancers often metastasize to one focal 
point.s,9 
Spinal cord compre sion occurs in 5% to 10% of all 
cancer patient .5•6•1° Cord injury occurs when meta ta es 
from the vertebral body or pedicle encroach upon the 
pinal canal and compress the dura. Alternatively, it is 
pos ible for a tumour from the paravertebral area to 
invade into the pinal canal through the intervertebral 
foramina. 
If neurological symptoms pre ent with back pain, an 
emergency work-up for cord compre ion i indicated. 
Upper motor neuron finding (ie, upgoing toes, spa ticity 
and hyper-reflexia), en ory lo s and lo of autonomic 
sphincter control may all be present. MRI is the 
investigation of choice to diagno e cord compre ion. If 
cord compre ion is u pected on history and physical 
exam, dexamethasone can be given immediately (do e 6 
mg po q6h, can be doubled if nece ary).5 The goals of 
therapy are to reduce pain and to pre erve neurological 
function. This i u ually accomplished with radiation 
therapy and glucocorticoid . With thi protocol, 75% of 
tho e patient who are ambulating on pre entation will 
remain ambulatory . However, only 10% of those who 
have lo t their ability to walk will regain it. 
Surgical decompre ion and tabilization is required 
in orne ca e of vertebral collapse and cord compromi e.1 
The current indications for surgery are: a radiore i tant 
tumour; local radiation failure; pathological fracture; and 
rapidly developing neurological symptoms.5•11 •12 Formerly, 
a laminectomy alone wa the procedure of choice; 
however this led to a destabilized pine, kyphosi and 
further cord damage. 12 ow, an anterior decompre ion 
with pins and bone cement or a femoral allograft is used if 
this aggre ive anterior thoracotomy can be tolerated. Thi 
i a particularly effective procedure as most le ions are 
actually anterior to the cord it elf. In the lumbar area, due 
to the large amount of force that the spine mu t bear, 
posterior tabilization is al o nece sary. Bone grafting is 
contraindicated as local radiation therapy follows 
surgery. 11 
Cancer is a disease that no physician can avoid 
dealing with . A large component of cancer treatment 
consi t of treating the complications of the di ea e. In the 
case of bony meta ta e , correct identification, approach 
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and treatment can significantly improve the morbidi ty 
and mortality from the primary di ease. 
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OVERVIEW 
ROLE OF 
OF THE PALLIATIVE 
RADIOTHERAPY 
I TRODUCfiON 
adi~th_erapy play major roles in both radical and 
palliative cancer treatment . Radical radiotherapy i 
more aggre ive form of management that target 
cancer patient who have limited tumour and a 
reasonable chance of cure. Meanwhile, palliative 
radiotherap manage incurable patient , with the goal of 
alleviating their cancer-associated ymptom . 
Radiotherapy i further categorized by technique of 
delivery into two Proup : external beam therapy and 
internal therapy . Modern external beam therapy 
primarily utilize megavoltage teletherapy, which 
include linear accelerator that produce proton and high-
energy electron beam , and cobalt-60 units that emit 
gamma ray .1• 2 It is uitable for many uperficial and 
deep- eated malignancie . Internal therapy is divided into 
brachytherapy and y temic therapy. Brachytherapy refer 
to the direct implantation of ealed radioactive ource or 
intracavitary ource placement, 1• 3 and is mainly u d for 
urface treatment, tumor in the intracavitary pace 
(cervix, uterus), and inter titial implant within ti ue 
(brea t and tongue) .1 Sy temic therapy u e un ealed 
radioi ope . It major applications include th yroid 
carcinoma and hyperthyroidism, polycythaemia vera, and 
cancers of the peritoneal cavity.1 
BASIC PRINCIPLES 
Radiotherapy i an important palliative tool becau e 
of its ability to remarkably relieve certain ymptom of 
advanced- tage cancer . It i often pre cribed to effectively 
manage pain from bone metastases and ulceration, 
vi cera! ob truction, bleeding, neurological deficit , 
pathological fracture , and other systemic symptom .1• 4 
However, ince radiotherapy i not the only modality that 
can alleviate ymptom a ociated wi th advanced- tage 
tumour , indication and contraindication ha ve been 
outlined to guide its u age ( ee Table 1). 
Be ide directing the appropriate u age of palliative 
radiotherapy, the indication and contraindication in 
Table 1 also emphasize the goal of palliati ve 
radiotherapy. The e include achievement of rea onable 
ymptom relief with horter duration of therapy than 
radical radio therapy, complete and durable palliation, 
minimization of patient inconvenience and di comfort, 
and minimization of toxic effects and hospital tay.4• 6 
Other palliative modalities, uch as urgery, 
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chemotherapy, and analge ics, may contribute to 
ymptom management a adjuvant palliation. 
COMMO USAGES 
There are pecific clinical manife tation for which 
palliative radiotherapy ha proven to be effective. The 
mor dominant one include keletal or bone meta ta e , 
pinal cord compre sion, brain meta ta e , and 
media tina1 meta ta e . 
Skeletal Metastases 
Meta ta e found in the bone are mo tly multiple, and 
originate primarily from tumor of the brea t, prostate and 
lung.4• 5 The main role radiotherapy play in the e 
ituations i the relief of pain. Radiotherapy i u ed only 
when the patient i ymptomatic, and thi occur in three-
fourth of patient with keletal meta ta e .2. 5 Pain is th 
re ult of two proce e triggered by the tumour cell : 
o teoly i and o teo clero i .5• 6 There are two main 
mechani m of o teoly is. In the direct method, tumor 
cell either re orb bone them elve , or activate o teoda t 
through th relea e of chemical uch a growth factor , 
pro taglandin , and cy tokine . On the other hand, the 
indirect mechani m involve timulation of immune cell 
by the tumour cell to produce the arne chemical that 
induce o teocla tic activity .2• 6 Pain produced b 
o teo clero i rarely occur , and i usually limited to 
meta ta e from pro tate cancer, and in about 10% of 
brea t cancer.5 
Once the bone pain ha been confirmed to be the 
re ult of bone cancer, a therapeutic deci ion i often mad 
between urgery and external beam therapy.2 Surgery i 
required if bone ha already be n fractured, or if there i 
an impending fracture in the affected long bon . In ca 
where urgery i not required, local ionizing radiation 
alone ha proven to be very effective in managing keletal 
ymptom . Moller' 5 meta-analy i of 19 retro pective 
tudie observed that 40% to 50% of patient reported 
complete pain relief in re pon e to localized irradiation, 
while an additional 30% reported partial pain relief. The e 
re ult agree with tho e of a randomized trial conducted 
by the Radiation Therapy Oncology Group (RTOG ) 
between 1974 and 19 0. The RTOG trial found that 90% of 
all patient treated wi th local external beam therap 
received partial pain relief while 64% received complete 
pain relief. 
Although the ucce of local e ternal beam therapy in 
alie iating keletal ymptom i unque tionable, there i 
controver y over which type of treatment module i mo t 
effective and efficient.H Main variation in treatment 
plan include do age of radiation and fractionation 
chedule . Moller5 analyzed ix pro pective randomized 
tudie and concluded that there wa no con ensu on the 
optimal type of treatment delivery module ba d on the e 
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vanahons. 
In the pre ence of multiple bone le ions, local external 
beam therap become le applicable, and i u ually 
replaced b hemi-body irradiation. The upper body and 
lower bod are u ually treated quentially, with a 2 to 4 
week interval to allow for the recovery of bone marrow. 
Although hown in everal tudie to provide faster pain 
relief, thi method of delivery re ult in more prominent 
toxic effect than conventional, local irradiation.5• 6 The 
ide effect u uall involve the lung , ga trointe tinal 
tract, and mucou membrane .5 Erne i i the mo t 
common one, which affect up to 0% of patient who 
receive a ingle high do e of radiation to either half of 
their bodie .6 Pneumoniti i a po ible side effect, but can 
be avoided by u ing lower do age to the upper body.4 
Pretreatment ho pitalization with dru~ prophylaxi i also 
u ed to minimize patient di comforts. 
When bone meta ta e are too numerou , or when 
they are unre pon ive to ext rnal beam therapy, the 
patient can be managed with y temic therapy, a le 
widely u ed treatments. 6 Meta ta e from the pro tate 
and brea t re pond mo t avidl y to thi form of 
radiotherapy. Pre ently, two main type of radionuclei are 
u ed for the alleviation of y mptom a ociated with 
keletal meta ta e : pho phoru 32 and trontium 9.2.-1-6 
They are both introduced into the body intravenou ly, and 
are absorbed more efficiently by tumour and bone ti ue 
than normal ti ue .5• 6 Re ult from randomized studie 
on mptom alleviation have b en encouraging for both 
radionuclei. Approximately 70% of patients trea ted with 
pho phoru 32 report orne degree of pain relief, although 
myelo uppre ion wa a major ide effect. Strontium 9 
ha al o been a ociated with ignificantly greater pain 
relief than placebo, but with le eve re 
myelo uppre ion.2• 5• 6 One etback for trontium 89 i it 
long half-life, which re ult in a longer latency period than 
pho phoru 32 b fore pain relief b gins.5 
Spinal Cord Compression 
Meta ta e to the vertebral column that result in 
pinal cord compre ion occur in 5-10% of cancer 
patient .4-6 Like meta ta e to other part of the keleton, 
brea t, pro tate, and lung cancer are u ually the common 
primary tumour in the e ca e .5 The thoracic vertebrae i 
the mo t common ite of meta ta i , accounting for 70% of 
all vertebral meta ta e . Becau e vertebral bod y 
involvement i frequent, mo t compre ions a ociate with 
the anterior a pect of the pinal cord. Con equently, 
compromised motor functions repre ent dominant, early 
ymptom .5• 6 Other cia ical ymptoms of pinal cord 
compr ion include back pain, bladder and bowel 
dy function, and numbne .4 
Spinal cord compre sion require prompt 
management becau e a patient' s neurological function i 
at take. Radiotherapy i highly indicated a treatment 
unle the patient expre e vertebral in tability, 
compre ion due to bony deformity, high cervical cord 
compre ion that jeopardize re piratory function, or 
unre pon ivene s to radiotherapy. In the pre ence of the 
cenario , urgery i the alternate treatment.6 Prior to local 
external beam irradiation, patient are usually prescribed 
cortico teroid (e .g. de amethasone) to reduce 
neurological ymptom due to va ogenic edema .2• 4• 6 
Localized external beam therapy that include 1 or 2 
vertebrae above and below the cord block to be treated i 
extremely effective in relieving pain. From an analy i of 
everal tudie , Molle reported a 50% to 95% pain relief 
for patient treated with external beam therapy alone. 
Meanwhile, rever al of neurological deficit depend 
largely on pretreatment neurological tatus.5· 6 If a patient 
could ambulate independently at the tart of treatment, 
there i a 70% to 90% chance that mobility can be 
maintained. This contra t with a 10% to 30% chance of 
regaining ambulatory ability after irradiation for patient 
who were paretic prior to treatment.5 
Brain Metastases 
Patient with brain meta ta e have extremely poor 
progno i . Untreated, their median urvival time range 
from 1 to 2 month .4• 6• 7 The mo t common ource of brain 
meta ta e i lung cancer.4• 6 Prevalent symptom include 
headach , focal weakne , behavioural change, eizures, 
ataxia, and apha ia.4 At time , more eriou condition 
uch a hydrocephalu , herniation of cranial content , and 
va ogenic edema often complicate treatment. 2 Like 
treatment of pinal cord compre ion, initial therapy 
include cortico teroid , which i effective in extending 
urvival to about 2 to 3 month if pre cribed alone. And 
complications, uch a eizure and hydrocephalu , mu t 
be tabiliz d before radiotherapy can be initiated. 
Table 1. Indications and Contraindications fo r Usage of Palliative Radiot!Jerapi·4 
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Indications 
relief of pain 
relief of neurological deficit 
re toration / pre ervation of 
function I co mesi 
relief of ob truction 
control of bleeding 
re traint of tumor growth 
maintenance of keletal integrity 
prevention of fi tula 
relief of temic symptom 
Promotion of healing 
Contraindications 
availability of more effective therapy 
availability of more ea ily admini tered therapy 
unrea onable ri k of quelae 
low probability of ucce 
pregnancy 
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External beam therapy for the whole brain i an 
effective method in relieving symptom and increasing 
urvival time for bo th solitary and multiple cerebral 
meta ta e . Surgery i usually indicated prior to radiation 
treatment in the pre ence of olitary meta ta e . Together 
with the admini tration of cortico teriod , whole brain 
irradiation typical yield urvival time between 3 to 5 
month .~. 6• 7 Collectively, tudie have shown that external 
beam therap y a a primary treatment of cerebral 
metastases relieves symptom and improve neurological 
tatu in 50% to 90% of patient .2• ~ . 6• 7 There i al o 
indication that po toperative whole brain irradiation i 
able to increa e durability of palliation from urgery and 
median urvival time, and decrea e recurrence rate .4• 6• 7 
However, thi only applie for patient who have one or 
few brain meta ta e that are acce ible by urgery, and 
who are generally in good condition .7 One major 
imperfection in whole brain irradiation i the high 
recurrence rate , which often require patient to be re-
irradiated. Even though re-irradiation from everal tudie 
point to a 69% to 79% improvement in all patient 
treated, the concern for acute and ubacute equelae 
ari e .7 
Patient generally tolerate toxic effect of whole brain 
irradiation quite well.6 Acute adver e effect from whole 
brain irradiation include fatigue, epilation, and kin 
erythema.6• 7 Subacute toxicity u ually ari e within 3 to 10 
week after radiation treatment, and may con ist of the 
omnolence yndrome, or tran ient neurological 
deterioration that u ually re olve in an additional 6 
week .7 Late equelae are le common becau e of the 
limited life e pectancy of the patient , but dizzine , 
headache, hort-term memory lo , and severe dementia 
have been noted. Moreover, cortical atrophy, ventricular 
dilatation, and hypoden e white matter have al o been 
ob erved.6• 7 
A more aggre ive form of treatment, like tereotatic 
radio urgery, may al o be of value for patient with 
olitary or few cerebral meta ta e . It involves the delivery 
of high do e of radiation to limited volume of ti ue 
u ing a cobalt-60 gamma knife. Although further studie 
are required to tudy it b nefit and setback , tereotactic 
radio urgery ha been a ociated with high local tumour 
control, 64% to 99% in evera1 inve tigation , and with few 
morbidity.H 6 Brain toxicity becom a concern only when 
there are more than a few meta ta e to be treated.~ 
Mediastinal Metastases 
Meta ta i to the media tinum is a common 
complication of advanced lung cancer. Common 
media tina! meta ta es include ob truction of the 
e ophageal, bronchi, and uperior ena cava. Ob truction 
of the uperior vena cava i the mo t freq uently een type 
of complication, and account for 75% of all thoracic 
meta ta e . The progno is of the e patient i poor, with a 
median survival time of only 3 months.6 Being regarded a 
a medical emergency, uperior vena cava obstruction 
receive prompt interventions. 
The ymptom of superior vena cava yndrome 
include dilatation of veins, edema in the che t, neck and 
upper extremities, cough, orthopnea, headache, 
dy phagia, dizzine s, and che t pain.:z. · 6 Radiotherapy i 
Feature A rti c l e s 
u ually the fir t and main treatment for relief of the e 
ymptom . It i extremely effective, having re pon e rate 
from 70% to 0% that can begin ubjectively a arly a 3 
to 4 days, and obj ctively b tween 1 to 3 week . ~ . 6 Toxic 
effect are generally mild and tolerable, with dysphagia 
being the more prevalent one? The external beam therap 
involved begin with higher do e of radiation in order to 
illicit greater r ponse, and then turn to lower dose and 
more fractionated chedule .2• ~ At time , relief of 
ymptoms do not correlate with an increa e in venou 
drainage through the uperior vena cava. Thi i 
indicative of ob tructive thrombo i , which can b readil 
re olved if thrombolytic therapy wa prescribed 
promptly.~ In the event of recurrence or unre pon ivene 
after radiotherapy to tolerance do es, patient may be 
eligible for an intra venou in ertion of expandable 
pro the i into the uperior vena cava that ha been 
a ociated with high ucce in relie ing ymptom .6 
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PALLIATION OF INOPERABLE 
THE ESOPHAGUS WITH 
SYSTEMATIC REVIEW 
CANCER OF 
STENTS: A 
The diagno i of esophageal cancer carries a v ry grave progno i . In Ontario, the median survival i le than a year and the 5-year relative urvival rate 
i 12% for male a nd 15% for female . 1 The onset is 
in idiou and the majority of patient pre ent at an 
advanced stage with pain, evere dy phagia and weight 
lo . Cure i only po ible by urgical re ection, if the 
cancer i detected at an early tage. When the tumor i 
unre ectable, then the main objective of therap i 
palliation. 
At pre ent, there is no definitive palliative treatment 
for inoperable e ophageal cancer. Conventiona l 
intervention include e ternal radiation therapy and 
chemotherapy. Different centre worldwide apply variou 
other therapie , including imple dila tion, endoluminal 
la er therapy, brachytherapy, electrocoagulation, alcohol 
injection clerotherapy, photodynamic therapy and tent 
placement. However, mo t of the palliative therapie are 
a ociated with a ignificant morbidity and mortali ty. 
E ophageal s tent are u ed primarily to treat 
malignant dy phagia and re ultant cachexia. They do not 
directly tern the growth of th cancer. Initial endoluminal 
tent were rigid pla tic tube and had to b introduced by 
laparotom involving a high mortality rate. 2•3 The 
development of lapro copic technique allowed for a le 
traumatic placement, but the delivery y tern wa till 
cumber orne and resulted in many proced ure-rela ted 
complication .-1-6 Pia tic tent have the ad antage f a 
one-time treatment and the additional ability to eal off 
fi tula with a modified cuff. Recently, expandable m tal 
tent have been de igned for an ea ier delivery, fewer 
complication and les ened chance of migra tion. The 
deployment i guided by Barium wallow, fl uoro copy 
and po ibly endo copy. Some of the current model in 
u e include the Wall tent endopro the i (Schneider AG, 
Zurich, Sw itzerl and) 15, the Ultrafle device (Bo ton 
Scientific Corporation, Watertown, MA, USA) [16] and the 
Gianturco tent (William-Cook Europe, Bjaever kov, 
Denmark). 17 
Thi article review the literature for randomi zed 
controlled trial comparing the effectivene of vari u 
tent to other pallia tive therapie for patient w ith 
inoperable e ophagea1 cancer. The primary focu i on the 
improvement of the pa tient ' quality-of-life, especia lly 
w ith regard to the dysphagia, a significant ourc of 
morbidity and mortality. The econdary focu is on the 
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improvement of urvival. 
METHODS 
The MEDLINE, EMBASE and CANCERLIT databa es 
were earched for randomized controlled trials tudying 
the treatment of inoperable e oph ageal ca ncer. The 
MEDLI E da taba e was searched w ith the OVID 
program, through the year January 1, 1966 to September 
11, 1997. The earch parameter included the MeSH 
subject term, "esophageal neopla m" the publica tions 
term , "clinical trial , pha e III" and " random ized 
controlled trial " and the text words, " u nre ectable", 
"advanced" and "inoperable" . The EMBASE da taba e and 
CA CERLIT databa e were earched for article from 
1980 to 1997 using the MeSH term "esophagus cancer" 
a nd the publication terms "experimen tal con trolled 
tudy", "double blind procedure" and "single blind 
procedure" . The reference li t of trial and review articles 
were al o rev iewed, a w ere textbooks related to 
e ophageal oncology. 
Articles were included in thi review if they were 
randomized controlled trial comparing the u of tents 
for inoperable e ophageal cancer. Article were excluded 
if they were not limited to patient with e ophageal 
can cer, were not focu ed on palliation or treatment, or 
included urgery a part of the treatment. 
Data concerning the patient population, interventions 
and the end-point of median urvival, quality-of-life and 
the rate of complication were extracted . Quality-of-life 
data cone rning the improvement of wallowing function 
or reli f of dy phagia were u ed to gauge the effectivene 
of the therapies. 
RESULTS 
The initial method intended wa a meta-analy is of 
the publi hed trial to reach an Ev idenced-Sa ed 
Recomme ndation for the treatment of inoperable 
e ophageal cancer according to the protocol set out by the 
Cancer Care Ontario. At pre ent, thi i not fea ible with 
the numb r of publi hed trials and their heterogeneity. A 
y tematic review of the e trial was done and pre ented 
in Table 1. 
DISCUSSION 
Two publi hed randomized trials compare the efficacy 
of plastic tents and e pan ile metal t nt in the palliation 
of malignant d y phagia are reviewed. Kny rim et al' 
compared the Wil on-Cook pla tic s tent to the Wall tent 
expan ile metal stent and found no significant difference 
in urvival, nor in the improvement of d y phagia or 
Karno£ ky core . Both the pla tic and metal type of tent 
improved dy phagia cores significantly. The advantage 
of expan ile metal stents was that complications uch as 
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TABLE 1. Randomized Controlled Trials with Oesoehageal Stents in the Palliation 
of Malignant D ysphagia 
Investif(ator I 11 terven tion ( # ) Median Survival Swallowillf( Score Complications 
Knyrim 1993 7 WiJ on-Cook (21) 146 ± 29 d . 3 -+1 43%* 
Wallstent (21) 167 ± 28 d.· 3 -+1e 0%** 
DePalma 1996 8 Wilson-Cook (20) 6.2mo. 3.0 -+ 1.0 22.2 %* 
Ultraflew (19) 6.6mo. 2.9 -+OS 0 %** 
Adam 1997 '0 Nd:YAG Laser (18) 56 d . 3 -+ 2 11%* 
Uncovered Strecker (19) 60 d. 3 -+1 5%* 
Wallstent or Gianturco (23) 48d. 3 -+ 1e 9%* 
Alderson 1990 9 Nd:YAG Laser (20) 12 wk. 85% 20 %* 
Celestin or Atkinson (20) 16 w k. 85%r 5%* 
Reed 1991 u Atkin on (10) 119 ± 82 d. + 2.3 ± 1.1 50%* 
Atkinson + RT ( ) 72 ± 62 d . + 1. ± 1.0 100%* 
Nd:YAG Laser+ RT (9) 169 ± 92 d .. + 1.4 ± 0.58 0%* 
I Nicolaou 1982 11 Cele tin + CT' (12) i82 d . (not recorded ) 100 %b 
Celestin (12) 117 d . (not recorded ) 
Alberts 1992 13 Cele tin or PL + IT + RT (10) 11 wk. (Semi- olid) 70%* 
Celestin or PL (10) 19 wk. (P=0.03) (Semi-solid) (not recorded) 
Schmid 1993 14 Cele tin or PL + RT (41) 9wk. (not recorded) (not recorded) 
Cele tin or PL + cr<l (40) 11 wk. 
Cele tin or PL (46) 9 wk. 15wk. 
(PL: Procter-Living tone plastic stent; RT: radiation therapy; Cf: chemotherapy) 
a expressed as mean urvival 
b Doxorubicin 40 mg / m2+ Cyclophosphamide 700 mg / m2, Complications related to chemoto icity uch as alopecia, nausea, vomiting, leukopenia, thrombocytopenia, 
fi tulas, weight loss, esophagitis 
c 5-Auorouracil 500 mg / m2+ Ci pia tin 15 mg/ m2 
d Trimetrexate 12 mg/ m2 or, ifosfamide 1.2 g / m2 + Mesna 20% or, %-Auorouracil 425 mg / m2 + Leucovorin 20 mg / m2 
e Median dy phagia score (pre- ® post-treatment) 
f Swallowing scale (post-treatment): 0 (normal) - 0 (dietary modifications) 
g Mean increase in swallowing score 
• Complications include perforation, migration, aspiration pneumonia, ob truction and hemorrhage. 
.. Other complications not included were tumor ingrowth and overgrowth 
perforation, migration and a piration pneumonia occur 
le frequently . The only major reported complications of 
the metal tent were tumor in-growth and outgrowth. 
DePalma et al compared the Wil on-Cook plastic stent 
with the Ultraflew Ti-alloy metal tent and a! o found that 
there wa no ignificant difference in median survival or 
in the improvement of dy phagia. Pia tic stent were 
hown to have a higher rate of complications, and a higher 
mortality related to tent placement. Major complication 
encountered with the plastic tent included migration, 
perforation and hemorrhage. Tumor in-growth was the 
only major complication to occur more often with the 
metal stent. The e limited numbers of trials demonstrate 
that expansile metal tent are equally effective treatment 
for malignant dy phagia and a safer, more effective 
alternative to pia tic tent . 
Two publi hed trial comparing stent to la er therapy 
are reviewed . Alder on et a/, 9 tudied the endo copic 
treatment of e ophageal cancer with Cele tin or Atkinson 
pia tic tube and d :YAG la er ablation. Unfortunately, it 
hould be noted that thi trial wa under-powered. Both 
group were found to have imilar improvement in 
wa llowing function and low complication rate . The 
authour make the sugge tion that Ia er ablation and stent 
placement hould be con ider d a complementary rather 
than mutually exclu ive treatment . 
A trial by Adam et a/ 10 compared three treatment 
modalities, d :YAG Ia er therapy, the Strecker cov red 
metal tent, and the Wall tent or Gianturco uncovered 
metal tent. o urvival advantage wa demon trated for 
any of the three modalitie . Improvement of dy phagia 
wa imilar for the two type of tent , covered and 
uncovered, and both provided uperior relief to Ia er 
therapy . Patient rece iving the uncovered tent were 
found to have sub tantially fewer complications than the 
other two group . Covered tent were prone to reflux, 
an d to migration if placed in the lower e ophagus. 
Uncovered tent were prone to tumour in-growth that 
was amenable to treatment with Ia er ablation, showing a 
role for adjuvant laser therapy in stent placement, a a) o 
sugge ted by Alder on e t al. Although the evidence in 
favour of tent place ment i not unequivocal , the 
improvement of tent technology, a wa u ed in the trial 
by Adam, should be accounted for a a ignificant 
advancement from the Alder on trial . A pia tic tent wa 
u ed in the Alder on trial wherea an expan ile metal 
tent wa u ed by the Adam trial, po ibly ugge ting that 
a metal tent may provide uperior palliation to Ia er 
therapy, while a pia tic tent i comparable to Ia er. 
The focu of the other trials publi shed studying 
e ophageal tent is on improving the palliation of the 
tent with chemotherapy, radiotherapy or a combination 
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of both. icolaou et al 11 conducted a randomized trial of 
intubation u ing the C le tin tube alone ver u 
intubation with combination chemotherapy (Doxorubicin 
and Cyclopho phamide). A mall increa e in media n 
urvival wa noted in the group receiving the additional 
chemotherapy. However, the results are not ignificant 
becau e the tudy wa under-powered. The chemotherapy 
wa well tolerated with minimal ide effect , although the 
complication of the control group were not recorded. 
A trial by Reed et al12 divided the patient population 
into three group , intubation with the Atkin on tube 
alone, with radiation therapy, and Ia er therapy wi th 
radiation therapy. It wa found that the po t-treatment 
wallowing core were imilar for all three group . The 
addition of irradiation offered no urvival advantage over 
intubation alone and had the added complication of 
radiation toxici ty. 
A trial by Alberts et a/13 had significant negative 
finding . The addition of combination chemothera py 
(with 5-Fluorouracil and Ci platin) and radiation therapy 
to a Cele tin tube re ulted in evere to lethal toxicity and a 
decrease in the median urvival as compared to intubation 
alone. Thi trial wa terminated early. 
A trial by chmid et a/14 al o found that there wa no 
difference in urvival or degree of palliation of dy phagia 
between the group of intubation with Cele tin tube alone, 
with adjuvant chemotherapy and with adjuva nt 
radiotherapy. either of the adjuvant treatment regimen 
were found to alter the natural cour e of the di ea e and 
are not justified b cau e of additional toxicity. 
CO eLUSION 
The current tate of re earch into the treatmen t of 
inoperable e ophageal cancer i in ufficient to upport a 
meta-analy i and an Evidence-Ba ed Recommendation. 
There are impl y not enough homogeneou trial to 
provide ignilicant tati tical power. 
The management of malignant dy phagia ha een the 
emergence of expansile metal tent . The lirruted number 
of trials how that they are a clinkally effective a the 
previou generation of pia tic s tent in the relief of 
malignant d y phagia . The ad vantag are in an ea ier 
deployment, and ignificantly fewer functional and 
technkal complications. 
tudie have hown that Ia er a blation of the 
ob tructi ve tumor can be clinically effective . One 
di advantage i the multiple e ions reqwred to maintain 
patency. An increa ed morbidity and a prolonged ho pita) 
tay rna not be ju tified in a patient who e median 
urv ival is le than one year and receive no urvival 
benefit from the treatment. One ugge tion made by two 
of the inve tigator [9, 10] merit orne attention: A role of 
Ia er ablation a an adjuvant treatment of expan ile metal 
tent that e perience complications of tumour in-grow th 
and overgrowth, with Ia er ablating cancerou ti ue 
e tending into the lumen of the tent. Thi complementary 
role require further re earch to clarify the clin ica l 
effectivene of Ia er u ed in the pre ence of tent . 
The literature al o hows that other adju ant 
treatment such a radioth rapy and chemotherapy do not 
improve the efficacy of stents. They in fact may negatively 
affect morbidity and mortality becau e of the a ociated 
toxicity re ulting in more complications. 
De pite many treatment options being available, none 
of them ignificantly improve upon the di mal median 
survival of e ophageal cancer patient . A the incidence of 
thi type of cancer increa e , re earch hould encompa s 
extending urvival time , effective palliation and 
improving diagno i at an early tage. 
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MALIGNANCY AND 
OF CHRONIC 
THE ANEMIA 
DISEASE 
A nemia, defined as a decrea e in red cell mas , i often associated with cancer and cancer treatrnent. 1 Indeed, anemia i the mo t common hematological 
aberration occurring in cancer patients, ranging in everity 
from a ymptomatic to life-endangering, and can re ult in 
a decrea e in the patient' overall quality of life. 1 All of this 
occur at a time when the patient, along with hi or h r 
family and loved one are trying their be t to cope with 
thi utterly deva tating di ea e. Many cau es for anemia 
have been postulated, including: blood lo (acute or 
chronic); bone marrow involvement by the cancer; 
chemotherapy or radiation therapy re ulting in marrow 
upfres ion; red c~ll apia _ia; he~oly ~ includi~~ 
autotmmune hemolysts and mtcroangwpathic hemoly t -; 
hyper pleni m; folate or 812 deficiency; and a di ea e 
entity known a the anemia of chronic di ea e.1 
Anemia of chronic di ea e (ACD), al o named the 
anemia of cancer, refers to a pecific type of anemia mo t 
commonly een in patient with malignant condition . 
Current e timate reveal that over half of all patient with 
orne form of neoplastic di ea e are anemic during the 
cour e of their illne , either a the re ult of ACD or iron 
deficiency, and almo t all patients under oing 
chemotherapy or radiation therapy become anemic. 1 Like 
myelophthi ic anemia, iron deficiency econdary to blood 
lo , and megalobla tic anemia, ACD i a form of 
hypoproliferative anemia re ulting from decrea ed red 
blood cell (RBC) production .2 However, with it 
characteri tic change in erythrocyte urvival time and 
iiOn metaboli m, ACD is quite different from the e other 
form of anemia. Specifically, ACD mo t likely involves 
the accelerated destruction of erythiOcyte , suppre ion of 
erythropoie i , and dimini hed iron utilization by the 
erythron, leading to hypoferremia de pite adequate or 
even increa ed iron tore .1 The exact pathogene i of 
ACD i not completely understood although ugge ted 
mechani m include decrea ed RBC life pan, impaired 
reutilization of hemoglobin iron, erythropoietin 
deficiency, impaired re pon ivene , and ineffective 
erythropoie is. ~ Intere tingly, ACD ha many clinical 
imilarities to anemia pre ent in patient with chronic 
inflammation or infection, including chronic renal , 
hepatic, and endocrine di ea e .5 ACD i a! o one of the 
mo t common anemia pre nting in general practice}, 
and i the mo t prevalent form of anemia in the 
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ho pitalized patient population. 2 Thus, a clear 
under tanding of the mechani m underlying ACD, along 
with treatment uch a human recombinant 
erythiopoietin, i crucial not only to the phy icians caring 
for cancer patient , but tho e in a more general etting a 
well. 
CLI ICAL FEATURES 
U ually mild and nonprogre ive, ACD i often a 
diagno is of exclu ion, developing in idiously within the 
fir t 1 or 2 month from the on et of the illne .1 Due to it 
mild nature, ACD i commonly overlooked in the clinical 
evaluation 2, and many patient , even those with 
hematocrits a low a 30%, are often asymptomatic.1 It i 
believed that the patient' inactivity, as well a the body' 
natural ability to increa e oxygen delivery to the ti ue , 
re ult in this lack of ymptom .2 In the etting of 
advanced malignancy, weakne , pallor, and fatigue are 
often een, and can be the result of ACD or the cancer 
it elf. 2 More evere manife tation of ACD include 
d y pnea, peripheral edema, angina, palpita tion , and 
other igns of cardiova cular insufficiency, but are rarely 
en in patients with packed cell volume (PCV) below 
25%.2 Skin temperatur i often reduced, and the kin, 
mucou membrane and conjunctivae, are pale.6 
LABORATORY FEATURES 
ACD i u ually a normocytic, normochromic anemia, 
althou~h microcytic, hypochromic red blood cell can be 
n.2. In fact, up to on third of patient may have slight 
to moderate microcyto i .1 Unlike iron deficient anemia, 
however, hypochromia develop before microcyto i in 
ACD.2 When the physician i contemplating the diagno i 
of ACD, the other common cau e of normocytic and 
microcytic anemias mu t be ruled out, including: blood 
lo ; nutritional deficiencie ; infection; renal in ufficiency; 
and malab orption .2 In term of pecific laboratory 
characteri tic of ACD, hemoglobin i u ually between 
and 12 g/ dL, and the PCV i u ually between 26% to 
3 %?· ·9 Studie have al o hown a reduction in the Mean 
Cell Hemoglobin Concentration (MCHC) of 44-64%.5•10 
The ab olute reticulocyte count i normally not increased, 
and the white blood cell (WBC) and platelet count are 
normal or even lightly increa ed. - Bone marrow is 
normocellular or hypocellular, and the erythroid/myeloid 
ratio is often normal or lightly decrea ed.u ,n Although 
body iron tore are normal or increa ed in patient with 
ACD, erum iron level are often ub tantially decrea ed, 
along with transferrin.25•7·12 Indeed, tran ferrin aturation 
in ACD normally falls b tween 5% and 16%, compared to 
value of 20% or higher een in healthy individual .w A 
erum ferritin concentration i u ually increa d in ACD, 
thi provide an ea way to help di tingui h it from iron 
deficient anemia.5' 1 ~' 1 ' 16 
U. W.O. Medical Journal 69 (2) 1999------------------------- 55 
Feat ur e A rticl e s 
PATHOPHYSIOLOGY 
ACD i thought to be the re ult of a number of fact r , 
including accelerated erythrocyte de truction, and an 
inadequate bone marrow re ponse to thi lo s of RB in 
the form of deficient erythropoei is .' ormally, the 
life pan of a red blood cell i approximately 120 day . In 
ACD, however, erythrocy te urvi va l time i greatly 
reduced, ranging from only 60 to 90 day .1•17•1 Although 
the exact mechani m behind the increa ed erythrocyte 
de truction remains unclear, hyperactivity of the reticular 
endothelial y tern (RES) has b en propo ed as the likely 
cau e for the hortened RBC urvival time. 2 It is thought 
that red cell rna be damaged , perhap by tumour 
va culature or inflammatory cell , re ulting in their rapid 
de truction b an activated RES. ' Interestingly, red cells 
from ACD patient have been found to urvive normally 
when transfused into normal ubject , ugge ting that the 
ultimate cau of the increa ed erythrocyte de truction 
mu t be a property of the cell' environment and not the 
cell it elf. ' ormal bone marrow can increa e 
erythropoie i at lea t three time the ba al rate, however, 
o the increa ed lo of RBC alone hould not lead to 
anemia. 2 Thu , a key factor in the pathophy iology of 
ACD i an inappropriate or lack of increa e in RBC 
production to compensate for the increa ed lo of 
erythroc te .2 
Many theorie have been hyp the i ed to explain the 
in ufficient bone marrow re pon e: decreased iron 
availability to the marrow; dimini hed erythropoietin 
level ; and immune uppre ion or erythropoiesi .1 Recent 
tudie , however, have hown that red cell turnover is 
normal in ACD patients, and that the idea of blockade of 
iron to the erythron i not upported,'·' 21 making the fir t 
theory an unlikely explanation. Furthermore, neither oral 
nor intravenou iron given to alleviate h.)'poferremia in 
ACD patient help to correct the problem.-
In term of erythropoietin production in ACD, recent 
radioirnmunoa ay tudie for erythropoietin have found 
relativel y normal level in ACD patients. 1•22•23 Alexian 
imilarl)' reported normal erythropoietin level in ACD 
pati nt .2. 10 Thu , the notion of in ufficient erythropoietin 
production al o i an unlikely rea on for the impaired 
bone marrow re ponse in ACD. In tead, re earch now 
reveal that inadequate or deficient erythropoie i may 
play an integral role in the pathophy iology of thi 
di ea e.' 
Thi concept wa fir t propo ed by Zucker et al in 1974 
who found that erythropoietin induced a significantly 
lower amount of erythropoie i in patient with cancer 
compared to normal patient with anemia re ulting from 
infection or inflammation .9 They concluded that the 
functioning of cell re pon ive to erythropoietin and 
re pon ible for increa ed red cell production mu t 
omehow be dimini hed by a humoral and/or cellular 
immune interaction with malignant cell .2 In upport of 
thi theory, immune cytokine uch a interferons alpha, 
beta, and gamma, along with Tumour ecro i Factor 
(T F), are known to be produced in the etting of 
malignancy and have been demon trated to decrea e 
erythropoei i .1.2us Furthermore, an anemia very irnilar 
to ACD ha been hown to develop in mice following 
chronic exposure to TNF. t.26 A a result, it would appear 
that the impaired marrow re pon e in ACD is there ult of 
an activated immune y tern leading to a decrea ed 
re pon e to erythropoeitin. 1 Thi , combined with an 
inability to compen ate for increa e red cell destruction, 
ultimately culminate in a nonprogressive, mild , 
a ymptomatic anemia.' 
CO CLUSION 
In the pa t, treatment of ACD has focu ed on the 
underlying malignanc(' with little attention being focused 
on the anemia itself. However, exciting new therapies 
provide hope for the future, including epoetin alpha, a 
form of human recombinant erythropoietin which may be 
beneficial in improving the patient's symptom and 
quality of life .27 In tho e patient resi tant to epoetin 
therapy, blood tran fu ion provide another treatment 
option.6 Clearly, until we have a better under tanding of 
the etiology and pathogene i of ACD, it will remain one 
of a plethora of unpleasant and potentially life-threatening 
effect of cancer and it treatment. 
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EMERGENCIES: ONCOLOGIC 
FEBRILE NEUTROPENIA 
INTRODUCTION 
I nfectiou complications in the neutropenic host are a major medical i ue. Cancer patient receiv ing chemotherap are at ri k of neutropenia due to the 
toxi.c eff~ct antineopla tic agent e xert on rapidly 
proliferating bone marrow cell . The neutropenic patient 
who develop a fever i at ri k of developing rapid and 
fatal ep i . Prompt admini tration of empiric antibiotic 
therapy is, therefore, tandard practice in the management 
of the e epi odes. A variety of regimens have been shown 
to be effective, including a multidrug approach a well a 
monotherapy. Controver y exi t a to which method i 
uperior. 
THE EUTROPE IC HOST 
The neutropenic patient who become febrile has a 
60% or greater chance of being infected.2 However, f ver 
often pre ent without clinical signs of localized infection 
in the e patients. The dimini hed whit count preclude 
ign of inflammation uch as edema, erythema, a nd 
purulent di charge. In a tudy of over 1000 febrile 
epi ode in neutropenic patient with cancer, the phy ical 
exam was unable to reveal any ign of infection in 55% of 
patient with known bacteremia.3 The febrile tate i 
defined a a core temperature > 3 .5 C or an axillary 
temperature > 3 .0 C. Se ere neutro~enia, defined a an 
ab olute neutrophil count < 500 I mrn , i the single mo t 
important ri k factor for developing infection. The 
duration and rapidity of on et of neutrop nia are al o risk 
factor . eutropenic epi ode of < 7 day have been 
hown to confer a better progno i than tho e with longer 
duration? 
The ri k of infection i al o increa ed in the pre ence 
of other predi posing factor . The e include mucou 
membrane damage econdary to cytotoxic chemotherapy, 
kin le ions pre ent at intravenou injection ite , th u 
of indwelling central venou catheter , and neopla tic 
ob truction complicated by secondary infection of 
colonizing organi m . The ri k of infection i al o higher 
in patient with hematological malignancie than in tho e 
with olid tumour . Po t-mortem tudie e timate that 
infection i the direct cau e of death in up to 50- 0% of 
patient with acute leukemia and up to 50% of tho e dying 
with malignant lymphoma . In patient with olid 
tumour , infection is the primary or an a ociated cau e of 
death in about 50% of ca e . 
The infecting organi m involved in the neutropenic 
ABOUT THE AUTHOR 
Ian MacDonald is a third year medical student at the 
University of Western Ontario with an interest in 
emergency medicine. 
By Ian MacDonald, MEDS 2000 
patient are cia ically the endogenous Gram-negative 
bacilli ari ing from the GI tract, primarily P. aerugino a, E. 
coli, and Klebsiella. Mortality in neutropenic patient with 
Gram-negative bacteremia can approach 40%due to the 
tendency toward y temic di emination.4 Empirical 
antibiotic therapy i tailored to providing broad pectrum 
coverage again t the e pathogen . However, Gram-
po itive organi m have emerged in the past decade as a 
co~mon cau e of infection in the febrile neutropenic 
patient. In particular are 5 . epidermidis, 5. aureus, and 
Streptococcus specie . Recent tudie have hown that at 
pre ent Gram-positive organisms account for 60% of 
bacter mia .5 
INVESTIGA TIO 
The phy ical exam of the febrile patient i often 
unremarkable in light of the ab ence of localized finding . 
However, it i important to consider the common ite of 
infection in febrile neutropenic : mouth and pharyn 
(25 %), the lower re piratory tract (25 %), kin and 
intrava cular catheter (15%), and the ga trointe tina! tract 
(15%). 3 The remaining proportion is made up of the 
perineal region, the urinary tract, and the nose and 
inu . Oropharyngeal infections can occur in the patient 
being treated with chemotherapy a bacterial flora 
colonize muco al ulceration . Local invasion in the e 
patient are at ri k of becoming y temic rapidly. The 
phy ical e am hould al o a e for the pre ence of any 
long- tanding intrava cular catheter which can be the 
ource of catheter-related infections. 
Inve tigation in the febrile neutropenic patient 
should include a CBC and differential, BU I Cr, and 
electrolyte . Before tarting antibiotic , blood culture 
hould be drawn on ample taken from both the 
indwelling catheter and a peripheral vein. The threat of 
catheter-related bacteremia is increa ed when the catheter 
i heavily colonized. Culture from a pre umed ite of 
infection include a urine culture and ensitivity. Sputum 
~ultu~e ~ay be included if produced and pulmonary 
infection 1 u pected. However, che t x-ray in the early 
tage of fever or in very neutropenic patient may not 
reveal ignificant lung finding . 
TREATME T 
The concept of tarting antibiotic therapy before 
knowing the re ult of blood culture is based on the high 
mortality a ociated with Gram-negative bacteremia. 
Therefore, empiric therapy i directed at providing broad 
spectrum coverage against the e organisms. In particular, 
any empiric regimen hould provide antip eudomonal 
activity in light of the ignificant morbidity and mortality 
a ociated with thi organi m. Antimicrobial therapy 
hould imultaneou ly produce high erum 
concen_trations of bactericidal agent , while di playing 
good h ue perfu ion and po e minimal toxicity to the 
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patient. In terms of approach, there is still much debate 
about optimal empiric treatment with re pect to 
combination versus single-agent therapy. 
Combination therapy is a widely adopted approach 
in the management of the febrile neutropenic patient. The 
traditional combinations involve an antip eudomonal 
~-lactam plu an aminoglyco ide. The e include either an 
extended-spectrum penicillin, uch a piperacillin, or a 
third generation cephalo porin, uch a ceftazadime, plu 
gentamicin or tobramycin. The main argument in favour 
of combination therapy i that it provide broad pectrum 
coverage, limiting the potential for econdary 
uperinfections and the emergence of re i tant organi m . 
Combination therapy al o provide a ynergi tic effect 
that i greater than either agent alone. The major 
drawback a ociated with thi therapy is the increa ed 
likelihood of toxicity at therapeutic levels, specifically 
nephrotoxicity and ototoxicity a ociated with 
aminoglyco ide admini tration. At thi point, the 
compari on of clinical trials ha failed to demonstrate any 
ignificant difference in respon e rate between the 
different combination regimens. 
The concept of empiric monotherapy i relatively new 
in the treatment of febrile neutropenia. The e agent 
include the third-generation cephalo porins and the 
carbapenems, which offer coverage against gram-po itive 
and gram-negative organism , including Pseudomonas 
pecie . The theoretical advantage of monotherapy over 
combined therapy include reduced toxicity and improved 
ea e of admini tration . Among the third generation 
agent , ceftazadime i employed for monotherapy due to 
it ignificant antipseudomonal activity and low toxicity. 
Several tudie have indicated it effecti ene s in the 
empirical treatment of fever in neutropenics ba ed on 
re pon e rate . A recent concern with ceftazadime 
monotherapy i the potential for the emergence of 
re i tant organi m . The carbapenem , a new cia of 
potent beta-lactam antibiotics, offer a broader spectrum of 
activity than the third-generation cephalo porin . 
Randomized trials have demon trated that empirical 
monotherapy with imipenem i a effective a ceftazadime 
alone. 1 The primary concern with imipenem therapy i its 
a ociation with seizure in patients with C S di ease 
and / or renal failure. 
The controver y between monotherapy ver u 
combined therapy continue . Pre ent evidence ugge ts 
that at the end of the neutropenic period there i little 
difference in term of urvival between febrile neutropenic 
patient given empiric monotherapy and tho e who 
received combination therapy. The European 
Organization for Re earch on Treatment of Cancer 
(EORTC) Trial XI wa de igned to answer the que tion of 
the efficacy of monotherapy ver u combination therapy. 
The re ult publi hed in 1996 demonstra ted that among 
the 95 randomized patients, treatment ucce rate were 
similar in both arms of the tudy.5 A recent international 
trial howed that ceftazadime was as effective but a! o 
safer than the combination of piperacillin and 
tobramycin.4 Available data ugge ts that mono therapy 
appear to be a uitable option at lea tin low-risk patient 
(neutropenia> 500 / mm3 with expected duration< 7 day ). 
Featu r e Arti c les 
M ODIFICATIO OF THERAPY 
Given the increasing prevalence of gram-positive 
bacteremias in the febrile neutropenic ho t, the addition of 
the glycopeptide vancomycin to the empirical regimen 
may be indicated. Thi trategy may be beneficial in light 
of the increa ing incidence of MRSA in certain institutions, 
the election for gram-po itive up rinfection a ociated 
with ceftazadime monotherapy, and in neutropenic 
patients at high ri k for gram-po itive ep i , uch a tho e 
with indwelling central venou catheter . However, 
EORTC Trial V showed that in neutropenic patient with 
gram-po itive infections the u e of vancomycin from the 
onset of fever did not re ult in a more rapid 
deferve cence. Thu , it ha been ugge ted that the 
inclusion of vancomy cin in empirical regimens i a 
rea onable approach for individual patient , patient with 
ign of infection at the va cular catheter ite, and upon 
documentation of infection with MRSA. 
The optimal duration of therapy in febrile neutropenic 
patient i controver ial, although the ab olute neutrophil 
count i con idered the mo t important mea ure . The 
afebrile patient with a negative blood culture and 
neutrophils ~ 500 I m.m3 may discontinue antibiotic after 5 
to 7 day of therapy.2 However, orne author sugge t that 
antibiotic can a! o be topped in the presence of 
persi tent neutropenia (< 500 / mm3) if the patient i 
afebrile and blood culture are negative. In the ca e of 
fever per i tence or recurrence even day after 
commencement of antibiotic , there i a general agreement 
r garding additional treatrn nt with empirical antifungal 
therapy uch a amphotericin B, even in the ab ence of 
ymptom or ign of y temic myco i . Sy temic fungal 
infections have been found in up to 33% of febrile 
neutropenic patient who remain unre pon ive after 1 
week of therapy and thi approach ha been shown to 
decrea e the incidence and mortality of the e epi od 2 
CONCLUSIO 
Significant progre ha been made in the treatment of 
febrile neutropenia in the past 20 year . Recognizing the 
value of initiating empirical therapy in the neutropenic 
patient with a fever and the availability of new 
antimicrobial agent ha had a ignificant impact on 
urvival rate in thi population, reducing mortality 
figure by infection to a low a 6%.6 However, infection 
remains the principal cau e of morbidity and mortality in 
febrile n utropenic patient . The management of the e 
epi ode has been complicated by the changing pectrum 
of pathogen from gram-negative to gram-po itive and 
concern for the emergence of re i tant pecie , fuelling the 
debate over combination therapy ver u monotherapy. 
Con equently, the approach to empirical therapy i 
determined by the circum tance urrounding the 
individual patient and knowledge of local pattern of 
infection and re istance. 
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AT RISK FOR BREAST CANCER: THE 
UPS AND DOWNS OF GENETIC 
BREAST CANCER TESTING 
The following information regarding genetic tes ting fo r 
individuals at high risk was obtained through an interview with 
Dr. Peter Ainsworth, Director of Molecular Genetics, Victoria 
Ho pita/ Campus, LHSC. 
W ith recent advance in genetic technology, we are reaching a point where individual ma y determine their ri k for developing a di ease one, 
ten or fifty years in the future . The field of oncology i no 
exception. Individual with a strong family history of 
brea t cancer can be creened to determine if they carry a 
mutation in one of two brea t cancer susceptibility gene , 
BRCAl or BRCA2. If found to carry uch a mutation, 
female may have a high as a 50-85% lifetime risk of 
developing breast cancer, about half this ri k of ovarian 
cancer and, for both males and female , a mall but 
definite increa e in the ri k of colon and other cancers. 
As always, with advancement come risk. We are 
facing a ituation in which otherwise healthy individuals 
can be told, with orne degree of certainty, that they may 
have up to an 85% chance of developing breast cancer in 
their lifetime. As future phy icians, we need to be aware 
of the whole picture urrounding this type of revelation, 
and what may be ahead for these individual . 
Who should be screened? 
A with all medical te ts, the cost, effectivene s and 
predictive value of a test i related to the level of risk of 
the group being te ted. Family medical hi tory guideline 
exi t to determine which individual are at high ri k, and 
thu uitable for creening. However, many individuals 
may wi h to be screened even if they are not at high ri k, 
to put their mind at ea e. This type of creening may not 
be covered and would only be performed at the patient' s 
expense. It is al o important that screening of lower risk 
individual should not interfere with creening of tho e at 
high risk. 
Individual hould be referred according to the 
following guideline (adapted from Ontario Cancer 
Genetics etwork): 
3 or more do ely rela ted individual on the arne ide 
of the family 
Early age at diagno is (<50 year ) 
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Multiple generations affected 
Multiple primary tumour (e.g. bilateral brea t cancer, 
or both breast and ovarian cancer) 
One or more ca of ovarian cancer 
Men with brea t cancer (BRCA2) 
Jewi h ethnic background (approximately 1:50 carry a 
mutation compared to 1:400 in the general 
population). 
What are the medical and non-medical considerations of 
detecting a BRCA mutation? 
Genetic te ting of member of a family known to have 
a BRCAl or BRCA2 gene mutation that has been 
characterized, would divide them into two group : tho e 
that carry the familial mutation and tho e found to be 
non-carrier . For the latter group, genetic creening would 
erve a a rea urance that they are not plagued by the 
arne genetic fate a their relative who may or may not be 
already affected b y cancer. For mutation carriers, 
screening erve to allow for increa ed urveillance and 
hopefully early detection and treatment. For each family 
member there would be a 50% chance of falling into either 
group, by virtue of genetic inheritance. 
Increa ed urveillance involve early mammography, 
starting in the late twentie or early thirtie and thi hould 
be combined with regular clinical and self-examination of 
the brea t . The value of ovarian urveillance technique i 
more controver ial and prophy lactic surgery may be 
considered in the peri- and po t-menopau al period, while 
pre-menopau al women may be placed on birth control 
medication to decrea e the ri k of ovarian cancer. ewer 
treatment uch as prophylactic tamoxifen may be u ed to 
reduce brea t cancer ri k in the future, and for some 
women, there may al o be the po ibility of prophylactic 
rna tectomy. The increased ri k of colon cancer in mutation 
carrier hould be addressed by colono copy which ideally 
would begin at age 45. 
However, what eem to be an obvious and imple 
management plan for early detection and urveillance 
carrie the additional burden of the extent of prophylactic 
or preventive treatment which a patient hould or could 
undertake. Oophorectomy i recommended to post-
menopau al women, but i not an option for women of 
childbearing years intending to extend their family . Birth 
control can be pre cribed to decrea e the incidence of 
ovarian cancer in pre-menopau al women but cannot be 
u ed while a women i attempting to conceive. There i 
al o the controver ial que tion of prophylactic 
rna tectomy: will a women feel compelled to remove her 
brea t without which her ri k of cancer i nearly 
decrea ed to that of the general population? Will he 
blame herself for not accepting a more radical prophylaxi 
if he i later diagno ed with brea t cancer? Will he feel 
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aliena ted from the part of her body which make her 
uniquely fe male? The e questions, which may arise upon 
determining one' genetic risk, cannot be answered and (je 
out ide the realm of medicine to addre . 
In addition to the medical controver y urrounding 
genetic creening, a patient' potential ri k for brea t 
cancer can be u ed out ide the medical realm a a ource 
of di crimination. Although current law forbid medical 
information to be di do ed to employment center , bank , 
or life in urance companie without the patient' consent, 
it doe not forbid the qu tioning urrounding the e area . 
Thu , once an individual ' genetic statu ha been 
determined, tho e individual applying for life or h alth 
insurance may be di criminated again t for rate or even 
accep tance to the policy. An individual' ability to 
immigrate may be denied. Bank loans or mortgage may 
be refu ed if the client is high ri k. Fu rthermore, the 
children of high-ri k patient rna be denied acce to 
education loans and fund on the ba i that the e fund 
may not be repaid if the individual develop the di ea e. 
On another per pective, early detection of a high 
genetic ri k may make an individual he itant to marry and 
have children, for fear that their life pan may b hort ned 
and that their family will be burdened with the di a e. 
Other may fear pa ing on the mutation to their children 
and feel that it i morally irre ponsible to have children 
when there i a 50% chance that they will be ubject d to 
the arne fa te a them lve . In addition, ince this type of 
te ting is till relativel y new, there i little evid nee 
regarding the long term effect of pre- y mptomatic 
te ting, in which an individual can find out potentially 
year in advance, their ri k for developing a disea e in the 
future. A minority become more su ceptible to depre ion 
and may require a i tance from a social worker. 
Currently all individual who are referred for 
coun eling regarding genetic creening are allowed ample 
time and everal visit before making a decision to be 
screened. In general mo t individual do choo e to 
undergo the screening, but the informa tion they are 
provided with, and the amount of time allotted, protect 
again t making a ha ty deci ion on the part of the patient. 
Patient found to be at high ri k h ave everal re ource 
available to them to guide them through their plan of 
action. Mo t patient take a pro-active role in their health 
care and tend to improve their lifestyle, when found to be 
at high ri k for cancer. 
In the next few year , we will all be faced with advance 
in genetic technology which will allow individual to know 
years in advance their potential for developing a terrifying 
di ase uch as cancer. There are several known, and Hkely 
many more unknown, consequ ences to de(jvering thi type 
of information to the patient. However, the va lue of 
increa ed urveillance and early detection ca nnot be 
undere timated in relation to it potentially life- aving 
ability. As a society, we need to ensure that there will be a 
y tern in place to deal with the non-medical consequ nee 
of determining one' gen tic tatu . 
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THE FREE FIBULA FLAP FOR 
RECONSTRUCTION OROMANDIBULAR 
By joe A. Mni, MEDS 2001, Dr. Jonathon Trites, Dr. john Yoo, LHSC 
INTRODUCTIO 
The mandible i e ential for oral function and facial ae thetic . Partial or complete los of the mandible may have severe phy ical and emotional 
con equence . The management of patient with 
oromandibular malignancies ha evolved with advances 
in s urgical technique . Mandibular resection po e a 
formidable recon tructive challenge. While many tumour 
of the oral cavity can be removed leaving the mandible 
intact, egmental mandibular re ection is often required 
for advanced stage tumour 1 (Figure 1). Previou ly, 
re ection of the mandible for cane r commonly re ulted in 
ignificant di ability with regard to rna tication, 
swa llowing, peech and co me i .2 Micro urgical 
technique ha revolutionized the current approach to the 
management of patients undergoing mandibul ar 
resection. Mandibular reconstruction u ing free 
va cularized bone transfer at the time of oncologic 
re ection i now the treatment of choice for th e e 
patient Y It ha minimized many of the wound healing 
problems a socia ted with previou methods of 
recon truction that u ed pro the es, non-va cularized 
bone graft or pedicled o teomyocutaneou flap . With 
immediate wound problem largely overcome, attention 
has shifted to improving functional and ae thetic results 
for the patient.3 
OPTIONS FOR RECONSTRUCT! G THE MANDIBLE 
Initially, oromandibular defect were addres ed with 
no bony recon truction. Soft ti ue was repaired either 
primarily or with a skin graft or local flap (e.g. tongue, 
buccal muco a). Large anterior mandibular defects 
managed in thi fa hion were referred to a "Andy 
Gump" deformities. Free bone gra ft s and allopla tic 
prosthe e were later attempted in order to improve 
functional ou tcome. However, these procedure were 
a ociated with poor wound healing, high rate of 
infection, extru ion of plate and crew , and con iderable 
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oft ti ue contraction, e pecially when performed as 
econdary procedures5 (Figure 2). The jaw often required 
prolonged period of immobilization. For the e rea ons, 
bone graft currently enjoy only limited u e. 
Continued improvement in cure rate following 
abla ti ve cancer surgery provid d a timulus for a 
reconstructive era beginning in the 1960s. In addition to 
metal plate and free bone graft , tray devices which 
hou ed particulate bone graft were u ed in order to 
restore jaw integrity. The advent of the pedicled 
myocutaneou flap in the 1970 provided well-
va cularized oft ti ue coverage for the e bony bridge . 
Regional flap uch as the pectorali major, lati imu 
dar i and trapezius con i t of mu cle and overlying kin 
rotated about their constituent arterial and venou supply. 
The e flap permitted ing le s tage recon truction of 
virtually any head and neck defect.5 
In the late 1970 , autogenou bone such a rib and 
clavicle b gan to be incorporated into myocutaneou flap 
and became the predominant method used in mandibular 
recon truction. Autogenou bone wa recognized a the 
material least likely to be extruded, and its u e became 
more widespread . Rea onable s ucce s rate could be 
expected in limited ca e , uch a hart defects in non-
irradiated patient . However, their di sa dvantage 
included limited pedicle length and arc of rotation, 
exce ive oft ti ue bulk and donor ite morbidity. 
Furthermore, the inability to provide bone of ufficient 
length with a reliable blood upply timulated a earch for 
alterna tive technique .1 • 
The establi hment of a reliable blood upply via 
microva cular anastomo i wa made po ible by the 
advent of microva cular urgery in 1973. Con equently, 
ti sues di tant from the defect and ba ed on an 
appropriate axial blood uppl y could be ucce fully 
tran £erred for recon truction. Such "free flap " emerged 
a a new approach for mandibular recon truction. The 
rna t important advantage of the free tis ue transfer i it 
uperior va cularity and improved ti ue urvival. The e 
flap are free from a di tinct limitation of myocu taneou 
flap , namely their va cular pedicle length and arc of 
rotation. Moreover, the wide variety and ver atil ity of 
donor tis ue allow customization of the reconstruction to 
the pecific requirement of the defect. The e refinement 
in ~rimary reconstruction provide the cancer ~anent with 
optimal functional and co metic rehabilitation. 
FREE FLAP DONOR SITE SELECTION 
The requirement for optimal recon truction of the 
mandible includ adequate bone length, con i tent hape 
along the length of the bone, and a vigorou and 
predictable blood upply. There is u ually al o a 
requirement for the bone to have adjacent muscle and kin 
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of the proper volume and in etting flexibilit to allow 
reconstruction of a ociated oft ti ue defects. Common 
donor ite for this application include the iliac ere t, 
radiu , capula, and more recently, the fibula flap .4 There 
is no ingle donor ite that can be u ed for all ituation . 
Donor ite election hould be determined by the pecific 
bone and oft tis ue requirement of the defect. 
The length of bone supplied by the radius usually 
doe not exceed 10 em and i of poor quality. Donor ite 
morbidity from radial fracture i a major di advantage. 
The capula prov ide up to 14 em of bone and an 
abundant kin flap which lend it elf to three dimensional 
contouring. The bone is wider and longer but thinner than 
the radiu . However, flap harve t require repo itioning 
the patient intraoperatively, precluding a imultan ou 
two-team approach. The iliac ere t supplie an abundant 
Figure 2. 
Figure 1. 
Oromand ibular 
defect following 
urgical resection 
for cancer. 
Patient with e truded plate following reconstruction of egmental 
mandibuJectomy. 
amount of quality bone which do ely approximate the 
height of the native mandible. However, contouring the 
bone may be le preci e than with other flap . A major 
di advantage of thi flap i the a ociated oft ti ue, 
which ha exce sive bulk and an unreliable blood supply.3 
The fibular free flap ha b come the flap of choice for 
mandibular recon truction. The flap i ba ed on the the 
peroneal artery, a terminal branch of the posterior tibial 
artery, and its venae comitante . The caliber of the ve els 
and length of the pedicle allow for reliable microva cular 
ana tomo i . The ver atility of this bone flap re t on it 
dependable feeding perio teal blood supply. Thi allow 
multiple o teotomie , which are required to reproduce the 
thre -dimensional hape of the re ected mandible. It i the 
only free ti ue tran fer that provide a bone tock up to 
24 cm.6 This allow near-total mandibular defect to be 
Figure4. 
Reconstructed 
oromandibular 
defect u ing free 
fibula flap. 
Figure 3. 
Harvested fibula fl ap with adjoined oft ti ue paddle. 
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repaired u ing a ingle flap. It has a consi tent hape 
throughout it entire length, and ufficient bone tock to 
upport o teointegrated implants for dental 
rehabilitation. 3 The fibular flap can incorporate a kin 
paddle from the lateral a pect of the leg that mea ure up 
to 25 em in length and 5 em in width6 (Figure 3). The flexor 
halluci longu mu de lie adjacent to the fibula and thu 
can be harve ted for oft ti ue recon truction . Other 
advantage include minimal donor it morbidity and it 
di tant location which facilitate a two-team approach . 
The e di tinct advantages have made the free fibular 
o teocutaneou flap the raw material of choice for 
egmental mandibular recon truction.7 
OUTCOME 
Free tis ue transfer i a highly reliable method of head 
and n ck recon truction. Shpitzer et a! recently reviewed 
their erie of mandibular recon truction u ing fibular 
free flaps in 47 patient . Succe ful flap tran fer wa 
achieved in 95% of patients. There were no perioperative 
death however nine patient had perioperative 
complication that required medical or urgical 
intervention. 2 
Accurate long-term a e ment of diet, oral 
con tinence, peech and co me is wa po ible in 39 
patient . Dietary habit were normal in 5 %, 32% tolerated 
a oft diet only and 10% were dependent on a fe ding 
tube. Oral continence wa normal or almo t normal in 
55%. Thirty-five percent had moderate drooling and tho e 
who remained dependent on a feeding tube had evere 
drooling (10%). peech wa easily intelligible in 90% and 
under tandable with effort in 10%. Co m tic re ults were 
evaluated by both the patient and the treating urgeon. 
Sixty-two percent were categorized a having excellent 
re ult , 33%, acceptable, and 5%, poor. 
The fibular donor ite healed adequately with minimal 
morbidity in 46 of the 47 patient .1 Immediate 
po toperative donor site infection occurred in one non-
compliant patient becau e of in istence on early 
ambulation and discharge. Patient were able to ambulate 
b twe n 2-10 week with 5 week being the average. On 
follow-up, all patient were able to engage fully in daily 
recreational activitie . Eight patient (17%) had mild lower 
e tremity mu cle and joint weaknes , tiffne , or 
in tability. One patient reported donor ite pain. It wa 
concluded that long-term morbidity wa minimal and 
their life tyle wa not altered.9 
CO CLUSION 
Head and neck urgeon mu t addre two ba ic 
i ue when planning the urgical treatrn nt of advanced 
oromandibular carcinoma. The fir t i ue i the extent of 
re ection required for oncologic clearance. The econd 
i ue concern the optimal method of functional and 
ae thetic re toration. The resection can be performed more 
confidently ba ed on the ability to recon truct complex 
defect involving bone and oft ti ue. In particular, the 
ability to recon truct large mandibular defect ha 
improved the functional and aesthetic outcome for 
patient with advanced di ea e (Figure 4). 
Free ti ue tran fer ha dramatically enhanced the 
Feature Articles 
quality of life for many patient undergoing re ection for 
head and neck cancer. Although no one flap i ideally 
uited to repair all def ct , the fibular flap is arguably the 
be t method for r constructing anterior or large defect of 
the mandible. 
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WHILE MERLIN 
A • rev• ew 
SLEEPS: 
of the 
CAMELOT YIELDS 
biology of 
neurofibromatosis type 
merlin as a tumour 
2 and the role of 
suppressor 
By David Skidmore, MEDS 2000, & Gregon1 M. Kelly, Assistant Professor, Department of Zoology; UWO 
INTRODUCTIO 
Neurofibromata i ty pe 2 ( F2) i a r a re, dominant! inherited genetic di ea e which ha become the ubject of con iderable intere t; 
po ibl di proportionate to the medical ignificance of 
the di ea e it elf. Excitement over F2 i due in part to the 
di covery that the di ea e i cau ed by the lo of 
expre ion of a tumor uppre or gene dubbed mer lin. 
Merlin, a widely e pre ed protein, i al o at the centre of 
evera1 type of poradic malignancie . The tudy of the 
genetic and molecular biology of NF2 provide u w ith 
the opportunity to arrive at an improved under tanding of 
the role tumour uppre or play in cell homeo ta i and 
how thi control break down in leading to the 
development of a malignant tate. 
The F2 gene wa di covered independently by two 
group .2 3 The gene at chromo om 22q12 encode m rlin, 
a protein with ignificant homology to member of the 
Protein 4.1 up rfamil , e pecially Ezrin, Radixin, Moe in 
(the ERM ubfamily). The homology to Protein 4.1, the 
prototype in a up rfamily of protein as ociated with the 
cyto k leton-pla rna membrane interface, wa a urpri e 
ince mo t other tumour u ppre or gene were known to 
be nuclear protein . Since merlin ' di covery, other 
cytopla mic tumour uppre or protein ha ve been 
identified . How merlin a nd the e pro tein act in the 
cytopla m to directly and I or indirect! regulate gene 
transcription and cell cycl ha b en given a great deal of 
attention. In ight from thi re earch will undoubtedly 
increa e our comprehen ion of both F2 and the 
mechani rns by which tumour uppre or act. 
Neurofibromatosis Type 2 
S mptom of F2 which manife t them elve during 
middle age con titute the le evere Gardner ub pe, 
wherea patient with the di ea e in their mid-twentie 
(the evere Wi hart ubtyp ) u ually do not urvive pa t 
40 year of age4. NF2 i the mo t commonly mutated gene 
in benign tumour of the human nervou y tem.5 Of the e 
ca e , approximately half occur in familie with no prior 
hi tory of the di ea e. Due to the high p netrance of thi 
di ease, it i held that poradic ca es are due to de novo 
mutations, and uggest that thi region (a hotspot) of the 
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genome ha a relatively high rate of pontaneous 
mutation. The hallmark of F2 i the development of 
bilateral acou tic chwannomas (al o called acous tic 
neuroma ). The e tumours are benign and low growing, 
but due to their location can be very difficult to treat 
urgicall y. Affected indi vidual are al o at ri k of 
developing multiple tumour of other ti ue of ectoderm 
lineage, e pecially pinal chwannoma , meningioma and 
l common ependymoma . A high incidence of po terior 
len opacitie ha also been reported. 6 Pathological 
examination of afflicted individual ha demonstrated that 
pinal ne rve root are studded with a y mptomatic 
tumourlets. The e tumourlet are e pansile le ions which 
are imilar to chwannoma , yet hi tologically di tinct. 
Whether the e tumourlets, which are unique to the F2 
yndrome, repre ent developmental le ion or are a 
precur or tage in the development of full- cale 
chwannoma i a point of orne debate.7 It hould be 
noted that while F2 tumour are benign, th e 
compre ion the cau e can lead to ignificant functional 
impairment, regardle of the indi idual' age. In 
reference to F2, Gu ella et al. ta ted that the resulting 
morbidi ty i of uch ignificant magnitude to re ult in a 
mea urably reduced life pan. 
TUMOUR SUPPRESSOR GENES 
A n opla m develop when a tumor suppre or gene 
lo e it function. The e gene play a role both in familial 
cancer and also in many poradic neopla ms. At least 25 
tumour uppre or gene have been cloned in the ten 
hort year ince the di covery of the fir t tumour 
uppre or, RBI (a ociated with familial retinobla toma ). 
Familial cancer a ociated with tumour uppre or gene 
are, a a rule, inherited dominantly. Intere tingly though, 
tudie have revealed that the pre ence of a ingle copy of 
a tumour uppre or gene in a cell i enough to in ure 
normal, wi ld typ function. Thi ob ervation contradicts 
the Mendelian theory which tate that for domina nt 
inheritance, the expre ion (or lack of expre ion) of any 
mutant allele hould re ult in the di ea phenotype. 
To explain the di crepancy and al o the eemingly 
random nature of tumour development, Knud on 
propo ed hi famou "two hit" theory. It hold that for a 
neoplasm to develop there is an inactivated copy of a 
tumour uppre or gene in the germ line, the "second hit" 
inactivate the other copy in omatic cell leading to 
tumourg ne i . Therefore, in familial cancer the "first hit" 
would occur via germ line inheritance of one non-
functional copy of a tumour uppres or and ometime 
during the individual ' lifetime a cell will lo thi 
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heterozygo it , e ither through non-disjunction during 
mito i or a random mutation, which inactivate the wild-
type allele; "th econd hit". 
Since the likelihood of a ingle omatic cell having two 
inactive copie of a pecific gen i low, tumour would be 
very unlikely to occur with any regularit unle there 
wa an inherit d "hit" already pr ent. Since the timing 
and the frequency with which the econd hit occur i 
random, thi imple but eloquent "two hit" model would 
account for the variance in everity (expre ivity) and time 
of on et een among family member who inherit one 
copy of a mutated gene. Data fr m m any yndrome 
upport the theory that there i a change from 
heterozygosity in non-neopla tic tissue to homozygou 
lo of expre ion in actual neopla tic ti ue .9 
To fru trat matter , evidence exist to indicate that a 
mutated tumor uppre or gene, who e inherited lo 
cau e a familial yndrom with it well-defined 
ymptom , may be re pon ible for generating multiple 
poradic neopla m in ti ue unaffected in the familial 
yndrome. For example me oth lioma , in which the 
homozygou lo of F2 i reJ'orted, do not occur with an 
increa d frequency in F2. 1 Thi inconsi tency i like! 
explained by the exi tence of oth r factor which play a 
permi ive role in tumourigen i . Th e factor may be 
con titutively pre ent in ti ue characteri tically affected 
by the inherited yndrome, and ab ent in other without a 
econd timulu to induce them. In a me othelioma, it i 
propo ed that the inflammatory re pon e to a be to 
alter gene expre ion of one or everal unknown proteins 
which interact with merlin. In th e ca e me othelioma 
develop when F2 e pre ion i homozygou ly lo t (it i 
al o believed that a besto incr a the rate of mutation) .11 
Study of other tumour uppre ors in F2 will help 
delineate the perrni ive factor and may highlight orne 
that are amenable to prevention. 
MERLI AND NEOPLASM 
The neoplasms mo t commonly a ociated with 
merlin' ab ence are chwannoma . The tumour are 
benign nerve heath tumour compo ed of Schwann cell 
w hich can form along any peripheral or cranial nerve. 
Schwannoma form with particular frequ ncy in dor al 
nerve root and in the eighth cranial nerve . Multiple 
tumour of thi kind are e pecially common in individual 
with F2 . In an immunocytochemical tudy Stemmer-
Rachamimov et a!., 12 creen d pathological pecimen 
(both poradic and from NF2 proband ) of chwannoma 
and found merlin wa completely ab nt. In a follow up 
tudy the author reported that merlin' ab enc in the 
tumourlet , characteri tic of F2, might not only be 
ab olute, but an early re9uirement in the progre ion to 
chwannoma formation. 3 It i intere ting to note that 
independent tudie have hown that merlin i ab ent in 
only 7 % of chwannoma .14 Thu , while the evidence 
clearly indicate that merlin expre ion i alt red in 
chwannoma , more re earch i needed to determine the 
ab olute frequency. 
Di crepancie in the tudie de cribed above are 
trouble orne for tho e u ing genetic te t to identify 
patient with F2; a lo of merlin mRNA in only 50-60% 
of chwannomas i in marked contra t to Stemmer-
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Rachamimo and colleague ' ab olute (100%) lo .15 In 
orne ca e , wild type m rlin mRNA wa d monstrat db 
rever e transcription polym ra e chain reaction analy i . 6 
This di crepancy ugge t that orne form of a genetically 
undetectable tran la tional or po ttran Jationa l 
modification to merlin rna pia a r Je in up to 40% of the 
chwannoma . In contra t, Gutmann found that while 
merlin was pre ent in orne chwannoma , that the 
ab ence of merlin mRNA correlat d with the ab ence of 
the protein . In thi ca e one would ha e to agree that 
current t t are adequat , but obviou ly further tudy i 
needed .17 Meanwhile, the conflict in the frequency of 
merlin lo between variou tudie pre nt u from 
determining the en itivity of g netic te t for F2. 
Therefore, unle the pecific Je ion a ociated with a 
family inheritanc ha been identified, current method of 
genetic t ting for F2, while e tr mely p cific, ar not 
e1 itive in up to 40% of all case . 
The ab ence of merlin ha b n noted in other typ of 
tumour . Merlin e pre ion i often ab ent in 
meningioma in a ubty pe pecific pattern. ormal 
e pre ion, how ver, wa ob erved in 0% of poradic 
mening thelia) meningioma , indicating that merlin ha 
no role in the gene i of thi typ of tumour. Conver ely, 
merlin ' ab ence in poradic fibrou and anapla tic 
meningioma , ugg t an involvem nt of m rlin in the 
tumour ubtyp . In upport, Hitot umat u et al. reported 
that mo t meningioma in F2 pati nt are of the fibrou 
ubtype. 17 In contra t, d pite th occa ional occurrence of 
ependymoma and oth r a trocy toma in F2 patient , 
merlin expre ion in poradic tumour of the fibrou 
ubtype wa normal in the vast maj rity of. The author 
ugge t that oth r tumor uppr or are re pon ibl for 
the e condition . In thi regard, orne have noted that in 
many ca of color ctal cancer, deletion have occurred 
on chromo orne 22q in th r gion wh r F2 i located.19 
In the majority of ca e , however, merlin e pre ion wa 
unaffect d thereby ugge ting a minimal role in colorectal 
cancer.20 
De pite the ab ence of me othelioma in the pectrurn 
of tumours ob erved in F2 patient , it appear that 
merlin i ignificantl ab ent in malignant me othelioma . 
Although it role in the lung ti ue i not known the data 
would ugge t a pecific role for merlin in preventing 
uncontrolled hyperpla ia of lung pleura .21 Determining 
w hat fraction of th e tumour are due pecifically to 
merlin' ab enc i an urgent re earch objective. Once 
e tabli hed we can then ad quatel u e genetic t t to 
creen for NF2, but if the current di crepancy betwe n the 
pre ence of merlin mRN and the ab ence of the merlin 
protein can be hown, then we will have to earch for 
po ttran criptional event that influence tumourigene i . 
If the di crepancy lie in the inability to det ct the protein 
u ing currently availabl antisera then diagno tic re arch 
may depend on generating a battery of antibodie to 
detect everal epitope in th protein it 1£. In any event, 
the e area warrant furth r investigation. 
MERLIN A D ERM FAMILY PROTEINS 
Merlin and the ERM subfamily of the Protein 4.1 
uperfamily are a group of evolutionary con erved 
protein that di play considerable equence homolog 
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aero the animal kingdorn.22 All of the e proteins po e 
two di tinct component . The domain located at the H3-
terminu form a globular region which is known to 
interact with integral proteins of the pla rna membrane. In 
particular, the ERM protein and merlin bind the 
hyaluronic acid receptor, CD44.23• 24 Variou i oform of 
CD44 exi t, orne of which are a ociated with a poor 
prognosi in malignancy, a they indicate an e a rly 
meta tatic cour e. Of note, immunohi tochernical tudie 
have hown that aberrant expre ion of merlin re ult in 
an alteration of CD44 i oform expres ed in 
chwannorna .25 Thi information ugge t that merlin and 
perhap the other ERM proteins may not only bind CD44, 
but may regulate its function and ultimately its ability to 
bind to thee tracellular matrix. 
The econd component hared by ERM protein i the 
COOH-doma in which bind to cortical a ctin 
microfilament of the cyto keleton.26 The ability of ERM 
protein to bind two fundamentally different target has 
led to the propo al that ERM protein erve a dynamic 
bridge , connecting the cyto keleton with integral pia rna 
membrane protein . Irn.rnunolocalization tudie reinforce 
thi notion ince the ERM proteins localize to region 
under the pia rna membrane, particularly to tho e regions 
rich in actin.27 Merlin also localize to region just under 
the pia rna membrane and in orne studie to perinuclear 
regions. By proxy, merlin probably act like the other ERM 
proteins albeit the ERM ubfarnily ha not been granted 
tumour suppr or tatu . 
How merlin behave in vivo i till poorly under tood, 
but the e interaction are likely influenced by e era) 
other protein . At lea t two member of the Protein 4.1 
uperfarnil bind calmodulin in a calcium-dependent 
manner.2 All member of the Protein 4.1 uperfamily 
consensu equence for both tyro ine and erine 
kina e _'l!J The epidermal growth factor (EGF) receptor can 
pho phory late ezrin and when this occurs, both zrin 
localization and cell morphology are altered .30 Merlin 
po e e consen u pho phorylation ite , how ver, 
unlike the ca e with ezrin, ti ue culture cell expre ing 
merlin are not affected by EGF stimulation.31 These re ult 
indicate that merlin i likely controlled by other 
heterophilic interaction . Recently, the ERM-rn rlin 
ubfamily of protein wa hown to participate in 
homophilic interaction .32 Intramolecular bond would 
allow two molecule to bind in a head to tail fa hion 
thereby rna king the ite for actin and I or integral pla rna 
membrane protein like CD44 . Sub equent po t-
translational modification by growth factor-induced 
pho phory lation w ould induce an a llo teric h ift, 
interrupting the horno-dirnerization and expo ing the 
binding site to other proteins.33 Much work in this area is 
needed to full y comprehend how merlin behave w ith 
it elf and with other putative binding partner . 
Studie with tis ue cultured cells expre ing merlin 
transgenes have revealed orne intere ting features of the 
protein's ability to act a a tumour suppre or. Merlin i 
known to affect cell cycle and rever e malignant 
phenotype . An increase in levels of both phosphorylated 
and depho phorylated merlin in cell confluency tudie 
can be correlated to the decrea e in mitotic rate indue d by 
the e condition . On the other hand, overexpre sion of the 
carboxy-terminal half of merlin induces cell death in 
IH3T3 cell .34 Lutchrnan and Rouleau reported that 
merlin e xpres ion can decrease rnitosi in a do e -
dependent rnanner. 35 In the arne cell line, but now 
transformed with the Ra oncogene, merlin has the abili ty 
to re cue the Ra phenotype of anchorage independent 
growth.36 Thi anchorage independent growth, erving a 
a model for rnetasta is, is the epitome of what happens 
when a tumour uppre or protein is lo t. It hould be 
noted that in the tis ue culture tudie the phenotype wa 
dependent on the expre ion of both domains of merlin, 
either in ci or in tran , again upporting the notion that 
the function of thi protein i affected by hornophili c 
interactions. 37 
CONCLUSION 
Several studie uggest that the careful regulation of 
merlin play an important role in controlling cell cycle. 
Given merlin's tructural homology to ERM proteins it is 
tempting to peculate that lo of merlin expre ion alter 
the link between the cy to keleton and the pia rn a 
membrane-ex tracellular m a tri x. The lo s of tructura l 
integrity ha dramatic consequence on cell hape, due in 
part to the inability of merlin-deficient cell to adhere to 
each other or to a ub trate. The lo in a cell' ability to 
adhere to a target may be the fir t step in tumour 
progre ion, but many que tions remain. In any event, 
what on needs to find i an Excalibur to watch over our 
cells whil t Merlin leeps in Camelot! 
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ENDOCRINE THERAPIES 
OF ADVANCED BREAST CANCER 
IN POSTMENOPAUSAL WOMEN 
Sine the initial therapeutic u e of ovarian ablation b Beat on in 1 96, hormonal manipulation ha been the mainsta of the palliative management of meta tatic 
brea t cancer,1 and i the olde t form of temic brea t 
cancer treatment.2 Since e tr gen pia an important role 
in the development and promotion of human brea t 
carcinoma , the inhibition of e trogen in e trogen 
dependent brea t carcinoma (e trogen ablation ) ha 
become an important form of therapy. Treating brea t 
cancer by decrea ing e trogen upport ha fewer ide-
effect than cytotoxic drug , and i more effective in mo t 
ituation .3 E trogen ablation con i t of either (a) blocking 
the ynthe i of e trogen , or (b) b locking e trogen 
receptor in the tumour. Blocking the synthe i of 
e trogen i accompli hed through oophorectom (via 
radiation or urgery) or the u e of compound that inhlbit 
aromata e, the enzyme involved in the conver ion of the 
adrenal androgen , andro tenedione and te to terone, to 
e trone and e tradiol, re pectively, the major ource of 
e trogen in po trnenopau al women. The other major form 
of therapy, antie trogen , are compound which bind to 
e trogen receptor and competitive! exclude e trogen. 
Other endocrin therapie that are le frequently u ed 
include e trogen , androgen , proge tin and 
antiproge tin , and gonadatropin-r lea ing hormone 
(GnRH) agoru t . 
A TIESTROGE S 
Antie trogen act through the e trogen receptor to 
regulate gene transcription. When an antie trogen bind to 
the e trogen receptor, the receptor i no longer available to 
bind e trogen, and thu fail to effective! timulate gene 
expre i n and D A ynthe i . The antie trogen-receptor 
complex doe , however, enhance production of orne 
growth inhibitory factor , including tran forming growth 
factor ~ (TGF-~), thereb preventing brea t cancer growth 
and meta ta i .4 Becau e antie trogen act via binding to 
th e trogen receptor, the pre ence of e trogen receptor in 
the brea t cancer cell ha proven to b very important in 
pr dieting re ponse to antie trogen therap . 
Tamo ifen, a non- teroidal competitive e trogen 
antagoru t, ha b en in u e for over 20 y ar , and i the 
mo t common! pre crib d drug for the treatment of 
brea t cane r. 45 It i con id red th 'gold tandard' for 
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antie trogen treatment of meta tatic brea t cancer in 
po tmenopau al women6. Approximately 40% of brea t 
cancer patient benefit ub tantially from tamoxifen 
treatment, and treatment ha b en hown to reduce the 
ri k of development of contralateral brea t cancer by 
alma t one-half.v Tamo ifen binding to the e trogen 
receptor inhlbit cell proliferation by a mechani m part! 
due to the antagoni tic effect on e tradiol regulated 
proteins with growth regulatory function . Studie have 
hown the following effect of tamoxifen: increa ed ex 
hormone-binding globulin, increa ed number of natural 
killer cell , decrea ed level of tumour- timulating 
autocrine growth factor (tran forming growth factor-a 
and in ulin-derived growth factor), and increa ed TGF-~ 
(a tumour- uppre ive growth factor). 7 
De pite the effectivene of tamoxifen, many women 
eventually suffer relap e, becau e some brea t cancer 
tumour invariably develop re i tance to tamo ifen/ 5·q 
which leads to tumour progre ion and death. Although 
tamo ifen is predominantly an e trogen antagoni t in 
brea t cancer cell , acquisition of i.ncrea ingly dominant 
agoru t activity over time may re ult in clinical re i tance 
becau e of the acquired ability of the drug to timulate, 
rather than inhibit, tumour growth. In addition, although 
tamo ifen i mo tly inhibitory in its function a an 
e trogen antagoni t in brea t cancer cells, it ha orne 
e trogen-like activity in other cell of the bod . 
Stimulatory effect of the agent on the uteru and liver 
may underlie the increa ed incidence of endometrial 
hyperpla ia, and alteration in liver function een in 
women on prolonged therapy.7 Tamoxifen u e ha al o 
been a ociated with di comfort uch a hot fla he , 
vaginal di charge, thinning of the hair, brittlene of the 
nail , dryne of the kin, dizzine , nau ea, depre ion, 
and thromboembolic phenomena.' On the other hand, the 
e trogen-like activity of tamoxifen i beneficial in term of 
enhanced bone mineral den ity in postmenopau al 
women, enhanced bone maintenance, and reduction in 
erum chole terol level, with an a ociated decrea ed ri k 
of coronary problem . 1•7 
A new antie trogen, toremifene, wa recently 
approved for the treatment of po tmenopau al women 
with m ta tatic brea t cancer. 10 Toremifene i a chlorinated 
tructural analogue of tamo ifen and pharmacologically 
related to it. Toremifene cau es growth inhibition in breast 
cancer cell by uppre ing mito is and inducing 
apopto i , po ibly via induction of TGF-~ and inhibition 
of in ulin-like growth factor-111. Although primarily an 
antiestrogen, it al o ha orne e trogen agoru t prop rtie 
in po tmenopau al women. Mo t of the adver e effect of 
toremifene are related to thi e trogeruc effect, and include 
hot fla he , vaginal di charge, and nau ea. 11 In pha e III 
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clinical trial , toremifene ha demon trated an efficacy 
against metastatic breast cancer that i comparable to that 
of tamoxifen.10 However, torernifene is potentially afer 
than tamoxifen, in relation to carcinogenic effect . In 
contrast to tamoxifen, in pre-clinical trials, high-dose 
torernifene wa not found to be hepatocarcinogenic in rat 
and, thu far, no carcinoRenic effect of torernifene have 
been noted in human .1•10• 
More recently, newly developed "pure" teroidal 
anne trogen , uch a ICI 164,3 4 and ICI 1 2,7 0, have 
been found to be complete e trogen antagoni t , by 
binding and inactivating the e trogen receptor, and 
exhibiting no e trogen agoni tic activityY · It ha been 
uggested that "pure [steroidal] antie trogen may have a 
therapeutic advantage over tamoxifen in reducing the 
probability of treatment failure due to regrowth of 
tumour from resi tant cell ". The pure an tie trogenic 
activity and the high potency of steroidal antie trogen 
ugge t that the e compounds are uperior to tamoxifen 
both with re pect to complete initial re pon e and long-
la ting re pon e .9 However, they are not effective in 
preventing bone lo and may have detrimental effect on 
the cardiova cular y tem.7 
ICI 1 2,7 0 i a 7a-alkyl ulfinyl analogue of e tradiol 
that po e ses a greater ability to uppre e trogen-
ensitive gene expre ion and greater anti-tumour activity 
than the partial e trogen antagonist tamoxifen.5 However, 
a with tamoxifen, mo t tumour eventually became 
re i tant to ICI 1 2,7 0 and grew independently of 
e trogen.5• ICI 164,384 i more effective than tamoxifen in 
inhibiting e trogen becau e tamoxifen bind to the 
e trogen receptor with an affinity of le s than 5% of the 
binding affinity of ICI 164,384. 
AROMATASE INHIBITORS 
In premenopausal women, the main source of 
e trogen i the ovary, where it i ynthe ized from 
androgen under pituitary control. In po trnenopau al 
women, estrogen is produced mainly by peripheral 
aromatization of andro tenedione and te to terone, and i 
mediated by the enzyme aromatase.12•13 About two-third 
of human brea t carcinoma contain detectable level of 
aromata e. 14 Since aromata e catalyze the final, rate-
limiting tep in trogen production, it therefore has been 
the principle target of inhibition of e trogen ynthe i .15 In 
po trnenopausal women, the aromata e enzyme complex 
i not regulated by a feedback mechani m, and o it 
inhibition ultimately cau e an appreciable decrea e in 
ti ue e trogen level , which ha therapeutic effect.1 
Therefore, estrogen deprivation through aromatase 
inhibition provide effective therapeutic treatment of 
advanced, hormone-dependent brea t cancer in 
po trnenopausal women. 
There are two main group of aromata e inhibitor : 
uicide inhibitor (exclu ively teroidal) and competitive 
inhibitor (either teroidal or non teroidal). 13 Suicide 
inhibitor eem to be a better choice than competitive 
inhibitor , ince they ar highly pecific, and the 
continued pre ence of the drug i unnece ary to maintain 
inhibition. With both types of inhibitor the inactivation of 
aromata e can be prevented by the pre ence of high 
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concentrations of ub trate relative to the inhibitor during 
the reaction.3 
Aminoglutethimide wa the fir t aromata e inhibitor 
to be u ed in brea t cancer therapy. It i a competitive non-
teroidal aromata e inhibitor. Unfortunately, 
aminoglutethimide lack pecificity, and al o inhibit 
adrenal corti ol production and interact with ynthetic 
glucocorticoid , accelerating their metabolic clearance.15 
Thi therefore nece itate hydrocorti one 
supplementation . Important ide-effect of 
aminoglu tethimide appear at the level of the central 
nervou y tern, the major ymptoms being lethargy, 
vertigo, ataxia, mental depre ion, and in omnia. 15 
Forme tane (4-Hydroxyandro tenedione) i the fir t 
teroidal compound to be tructurally de igned a an 
aromata e inhibitor. It i an analogue of andro tenedione, 
and it i a teroidal, irrever ible inhibitor of aromata e. It 
ha been hown to be 30- to 60-fold more potent than 
aminoglutethimide, and to ignificantly reduce pia rna 
level of e trogen .16•17 Forme tane i very pecific and 
require no glucocorticoid replacement. It mu t be 
admini tered via intramu cular injection, and i well 
tolerated in patient , the major complaint being local pain 
at the injection ite. 1 
Ana trozole and letrozole are the fir t elective, oral, 
non- teroidal competitive aromata e inhibitor .19 
Ana trozole reduce circulating e trogen level by more 
than 0%, letrozole by 79%.20 Ana trozole ha a low ide-
effect profile (low occurrence of hypertension, 
thromboembolic event , weight gain, dy pnea, vaginal 
hemorrhage, weating and diarrhea).21 It i currently u ed 
to treat women a econd-line treatment after tamoxifen 
and as fir t-line treatment after tamoxifen ha b n u ed 
a an adjuvant therapy . It may al o be used when 
tamoxifen is not tolerated.22 Letrozole i a potent, highly 
elective competitive inhibitor of aromata e. The high 
electivity ha been demon trated by the lack of 
compromi e of glucocorticoid and mineralocorticoid 
production or thyroid function. 23 Letrozole is able to 
achie e total e trogen deprivation in animal , imilar to 
that produced by urgical oophorectomy.23 While it ha a 
imilar ide-effect profil to anastrozole, it i le likely to 
cau e thromboembolic event . Both ana trozole and 
letrozole are contraindicated in women who are pregnant, 
brea t-feeding or premenopau al, and in patient with 
evere liver di ea e. Ana trozole i al o contraindicated in 
patient with moderate liver di ea e or severe renal 
im pairrnen t. 20 
OTHER E DOCRINE THERAPIES 
Surgical attd Radiation-Induced Endocrine Ablation 
Therapies 
The main therapy in thi category i oophorectomy. 
Beat on fir t u ed urgical oophorectom in 1 96, and 
described dramatic po t-surgical tumour hrinkage in 
three women with locally advanced brea t di ea e .1 
Radiation-induced ovarian ablation wa introduced in 
1922. Oophorectom work b eliminating the ovarian 
e trogens, the main ource of e trogen in premenopau al 
women, and i therefore of therapeutic value mainly in 
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premenopau al women w ith e trogen- en itive brea t 
tumour , with les benefit reported for po tmenopausal 
patient . Two other urgica l therapie u ed are 
adrenalectomy and h pophy ectom . Adrenalectomy 
eliminate adrenal timulation of the o arie , but require 
upplementation with corti one after urgery to maintain 
the other non- trogenic effect of adrenal hormone . 
H y pophy ectomy re ult in a reduction of 
adrenocorticotropic h o rm one, LH a nd FSH (and thu 
adrenal androgens and ova rian e teroid ), but a l o 
require upplementati on of hormone replacemen t for 
glucocorticoid, mineralocorticoid and thyroid defici ncy. 
Wherea urgical adrenalectomy and hypophy ect my 
have been alma t compl tel abandoned sine the 
di cover of pharmacological mean to achieve imilar 
effect on target ti ue, urgical oophorectomy i curr ntly 
u ed to treat premenopau al women with advanced brea t 
di ea e} 
Estrogens 
E trogen were introduced in the early 1940 a an 
effective treatment for ad va nced brea t cane r in 
po tmenopa u a l wome n . They appear to work by 
occupying e trogen rec ptor and thu reducing e tr gen 
effect ; the are probabl y al o cy toto ic. 1 The mo t 
common e trogen u ed wa DES (diethy l tilbe trol). 
Prolonged u e of estrogen , howeve r, ha potential 
harmful effec t , including increa ed ri k of 
thromboembolic complication , fluid retention, t res 
incontinence, and withdrawal bleeding. U e of the e 
compound i generally re erved for a Ia t attempt at 
hormonal therapy in po trnenopau al women! 
Androgen 
Although androgen have been u d ince the 1940s, 
their mechan i m of action is till unclear. 24 In 
po tmenopau al women, androgen appear to suppre 
LH and FSH (thu reducing e trogen l vel ), and occupy 
androgen rece ptor w ith a ub equent reduction in 
e trogen receptor, limiting the effect of e trogen _l In 
recent year , the most widel y u ed androgen ha been 
fluoxyme t ron acetate. The adver e effect of androgen , 
which include virilization, nau ea, hepatotoxicity w ith 
chole ta i , increa ed libido, acn , and, in orne in tance , 
hy percalcemi a, a nd the decrea ed ffectivene of 
androgen compared to e trogen , have limited their u e 
to third- or fourth-line therapy. 1•24 
Progestins and Antiprogestins 
Proge tins ccupy proge terone receptor and reduce 
e trogen receptor and e trogen action . They may al o 
produce direct inhibition of brea t cancer c ll _I 
M droxyproge terone acetate (MPA), mege trot acetate 
(MGA), and norethine terone ( ES) have all been te ted 
in advanced di ea e. The u e of ES ha been aband ned 
in recent year , but MPA and MGA are currently u ed, 
with MGA being the more wide! pre cribed.24 Alth ugh 
generally well tolerated, orne patient receiving thi 
therapy have e perienced h perten ion, fluid retention, 
thromb emoli m, weight gain, withdrawal bleeding, and 
dy pnea?·24 
Antiproge tin al o occupy progesterone receptor 
and bring about reduced proge terone action . 
Mifepri tone (R 4 6) i a potent proge terone-receptor 
blocker currently in clinical trial . In addition to binding 
proge terone receptor , it al o bind to glucocorticoid and 
androgen receptors, bringing about more compte ide 
effect , uch a fatigue, hot fla he , nau ea, anorexia, and 
brea t tend erne . 24 
GnRH Analogues 
GnRH i relea ed from the hypothalamus in a 
pul atile fa hion, and stimulate ecretion of LH and FSH 
from the pituitary gland. A continuou level of tirnulation 
of the pituitary gland by a GnRH analogue lead to an 
initial elevation in LH and FSH level , followed by their 
uppre ion, which ultimately lead to a lack of gonadal 
endocrine timulation and to level of e trogen irnilar to 
tho e een after oophorectomy.• GnRH analogues are 
con idered the medical urrogate to urgical 
oophorectomy.7 Four uch drug te ted in the etting of 
meta tatic breast cancer a re bu serelin, leuprolide, 
go erelin, and triptorelin, admini tered via intramu cular 
or ubcutaneou injection . Toxic effect of the e 
compound include hot flashe and other effect o f 
menopau e, a well a discomfort at the ite of injection. 
The e drug have been u ed ucce fully in the treatment 
of premenopau al women with breast cancer, but less 
optirni tic re ult have been reported in po trnenopausal 
brea t cancer patient .25 
CONCLUSION 
It i currently recommended that the majority of 
patient with advanced brea t cancer receive endocrine 
therapy a their fir t mode of treatment, although it i 
po trnenopausal patient with e trogen receptor po itive 
tumour who are likely to gain the mo t benefit from thi 
approach .25 Although numerou endocrine treatment 
have be n hown to be ucce ful in treating ad vanced 
brea t cancer in po tmenopau al women, it mu t be 
mention d that brea t cancer i a highly meta tatic di ease 
and it ha been found that different meta tatic ite vary in 
their re ponse to endocrine treatrnent. 17 
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DYSPLASTIC NEVI-A CLUE 
INCREASED CUTANEOUS 
MELANOMA RISK 
TO 
The characterization of the clinical and pathologic feature of dy pla tic nevi (heritable melanocytic le ions) by Wallace Clcuk et. al in 197 allowed the 
recognition of the e le ion a mcuker of melanoma ri k 
in a pecific ub et of patient .1 Dyspla tic nevi cue now 
known to occur in two major epidemiological conte t . 
The were fir t de cribed in the setting of melanoma 
prone fainilie where the pre ence of a ingle dy pla tic 
n vu wa hown to be a n itive phenotypic rncuker of a 
trong gen tic tendency to develop melanorna. 2 It wa 
later di co ered that even out ide of thi familial etting, 
the e nevi were important mcuker of a mailer and a yet 
incompletely defined ri k for developing melanorna.1 The 
dramatic ri e in the incidence of melanoma, coupled with 
the clu tering of other ri k factor that i often e n in thi 
population, irnplie that there cue enormou public health 
benefit to the eculy recognition of dy pia tic nevi. 
CLINICAL FEATURES OF DYSPLASTIC EVI 
Dy pla tic nevi (D ) are clinically atypical nevi that 
maybe important marker for the development of 
malignant melanoma. 3 Clinically, they may have a 
maculcu compon nt, irregular and indi tinct border that 
fade into the urrounding kin, variable color (tan, brown, 
pink), and a diameter greater than 5 rom and often greater 
than 10mrn. 1 Dy pia tic n vi occur more typically on un-
e po ed area (e.g. the back and che t) but the can 
appear on normally protected area uch a , t~e calp: 
buttocks, groin, and brea t , where common acqwred n VI 
occur le often. Patient with the d pla tic ne us 
yndrome will often have from twenty to over ~ hundred 
I ion , which are often larger than u . ual nevt ~d may 
occur ingly or clu tered together In group . . Al ?, 
typically, the d pia tic ne i are not pre ~nt at b1rth ~n 
tho e with the yndrome. In tead, they begm to app cum 
mid-childhood year when they rna re emble common 
mole . The e patient u ually develop melanoma at a 
younger ag and tumor may be multiple and cue often of 
the uperficial preading type.5 
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HISTOPATHOLOGIC FEATURES O F DYSPLASTIC 
NEVI 
Benign nevi are divided into three subtypes -
junctional, compound and dermal nevi. This cia ification 
i ba ed on the location of nevu cells in the epidermal 
and dermal layer of the skin. The three type repre ent 
sequenti a l developmental stages in the life cycle of a 
nevu . Flat junctional nevi, with nevu cell located at the 
dermal-epidermal junction, cue the fir t to be een. The e 
evolve into cornpund nevi when orne of the nevu cell 
begin to percolate into the papillary dermis. Continued 
migration of all of the nevu cell into the dermi w ith 
di app cuance of the intraepiderrnal component re ults in 
the dermal nevus. 
The majority of D , clo e to 0%, are compound in 
nature. There cue many lightly vcuying criteria in u e for 
the hi tologic characterization of a D . Generally 
speaking, the epidermis show elongated rete ridge that 
cue often club- haped, with increa ed melanocyte at the 
ba al layer. Spindle haped and epi thelioid melanocyte 
often form horizontal bridge between ne t at the dermal-
epidermal junction and nests may al o form in the inter-
rete pace or at the edge of the rete ridge in tead of 
from the rete tip , a is normally een in benign nevi. The 
ne t , in cornpari on to tho e een in typical nevi, will 
often vary in ize, hape and pacing (they are not at 
equidi tant interval ). At the edge of the le ion, a houJder 
of e clu ively intraepidermal growth often how more 
pronounced cuchitectural atypia and thi lateral exten !on 
can b u eful in identifying D particularly at cannmg 
magrtification. In the papillary dermi , both lamellar and 
concentric eo inophillic fibroplasia can be een.6 There 
may a l o be an increa ed number of blood ve el ! 
pigment incontinence, and a potty lymphocytic infiltrate. ' 
At high r rnagrtification, cytologic dy pla ia i en when 
the indi v idual nevu cells randomly di play enlarged 
nuclei, hyperchroma ia, and contour angulation, forming 
rectangular or rhomboidal hape . Cell w ith the e 
charact ri tic will often how coar ely granulated 
(muddy) cytopla mic melanization. 7 Histologicall y, 
everely dyspla tic nevi may be difficult to di tingui h 
from in- itu or even inva ive melanoma, unle detailed 
hi tologic criteria cu rigorously applied. 
GE ETICS AND EPIDEMIOLOGY 
The full development of malignant melanoma eem 
to re ult from multiple genetic al terations, occurring in 
equence, in the neopla tic cell . Many of the e alterations 
cue recognizable as chromo ornal alterations. 
In the context of acquired rnelanocytic nevi, a focal 
proWeration of tructurally normal cell may progre ses 
to a D , with abnormal hyperpla ia of melanocyte and 
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atypia. Alternatively, D may appear de novo a in the 
dy pia tic nevus syndrome. Following this tep come 
primary melanoma, first as the radial growth pha e, 
which pread centrifugally within the epidermal layer 
and doe not have the capacity to meta ta ize, and then as 
the vertical growth pha e, which invades perpendicular to 
the epidermal surface and i capable of progre ing to 
meta tatic di ea e. 7 Dyspla tic nevi in the setting of the 
dy pia tic nevu yndrome and melanoma appear to be 
pleotropic effect of a ingle auto omal dominant gene 
wi th high penetrance, that may be situated on 
chromosome band 1 p36 .1 However, non-random 
karyotypic change involving chromo orne 6, 7, 9, and 10 
have al o been identified by everal group .9 Interestingly, 
the well-known oncogenes p53 and K-ras have also been 
identified by molecular tudie to be involved in 
melanocytic tran formation. There i evidence that RAS 
gene mutation may be important in the progre sion of 
the radial growth pha e melanoma to the vertical growth 
pha e melanoma.9 
In addition to genetic tudie , the ri k of melanoma in 
tho e with dyspla tic nevi ha been evaluated. I olated 
d y plastic nevi are found in 2-5% of the population, 
wherea the incidence of the dy plastic nevus syndrome is 
probably le than 1%.3 The lifetime ri k of developing 
cutaneous melanoma among the Cauca ian population in 
the United States is about 0.6% (1 in 150). Persons who 
have a D and no family hi tory have a 6% ri k of 
developing melanoma. Persons who have D and a 
hi tory of melanoma have a 10% risk of developing a 
econd melanoma; per on who have D and a family 
member with melanoma have a 15% ri k. The lifetime risk 
of melanoma approache 100% for individual with D 
from familie with two or more first-degree relati ve 
having cutaneou melanoma.5 
Halpern et. al found that tho e with dy plastic nevi 
often had a clustering of other risk factors as well. 
Con idering a number of risk factor (ie. freckling, greater 
than 50 nevi , blond or red hair, a tendency to burn 
everely, little ability to tan, and a hi tory of multiple 
painful or blistering sunburns) their group found that 46% 
of tho e with dy pla tic nevi had at lea t three or more of 
the e additional ri k factor .2 Thi finding ugge t that 
" the identification of people with D tran late into the 
iden tification of people likely to po es multiple 
independent risk factor for melanoma."2 
MANAGEMENT 
There i till orne controver y regarding th e 
management of dy plastic nevi . In 1983, the ational 
In titue of Health recommended cla ifying the patients 
into one of two group after an accurate family hi tory 
and evaluation of parents, siblings, offspring, aunts and 
uncle and grandparent : indi vidual with D and a 
family hi tory of melanoma or those with D and no 
hi tory of melanoma.5 
A thorough hi tory and physical which include 
examination of the scalp, intertriginous regions, muco al 
urfaces and eyes is necessary for initial detection of 
melanocytic dysplasia. In patients with the dysplastic 
nevus syndrome it i recommended that the phy ical be 
repeated twice a year or more often depending on the 
F e a t u r e .A r t i c I e s 
pa tient ability to monitor their own lesions and the 
s tability of the les ions. 3 In the e individual , it i 
advantageous to take clinical photograph or computer 
can of larger or more clinically atypical nevi to monitor 
change.3 Biop y of at lea t one or more dy plastic nevi is 
genera lly performed to establish the diagnosis. evi 
undergoing udden change, a well a le ion that are 
otherwise su piciou hould be removed . There i no 
place for the whole ale urgica l exci ion of all D , 
however. Prophylactic exci ion of D of the calp or other 
potentially hidden area is often recommended since the e 
le ion are difficult to monitor.5 It i prudent for the e 
patient to avoid sun expo ure as there i evidence that 
this will increa the number of nevi and their activity, a 
well a the general ri k for development of melanoma 
and other kin cancer .3 
In the etting of i olated dy pla tic nevi (non-familial), 
excisional biopsy is often performed if a) the le ion i 
perceived a changing in ize, hape, or color either by the 
patient or the phys ician; b) the le ion ha becom e 
ymptomatic (ie. itching); or c) the le ion has clinical 
ambiguity with early melanoma. 
The incidence of malignant melanoma i rising at an 
alarming rate, as is the mortality a ociated with thi 
di ea e. The increa ed melanoma ri k in tho e patient 
with dy pla tic nevi upports the need for targeted 
education in thi high-ri k group. Early recognition and 
urgicaJ cure are two way in which we can hope to better 
control the morbidity and mortality as ociated with 
di ea e. 
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MEDICAL STUDENT 
MISTREATMENT AND 
STRESS, 
WELLNESS 
INTRODUCTION 
Sir William 0 ler tated that it i "in the tudent pirit you can be t fulfil the high mis ion of our noble calling." He goe on to define the components f the 
tudent' pirit: humility, confidence, pride and hop .1 It i 
thi enthu ia m and dedication that incoming m dical 
tudent bring with them a they embark on their m dical 
training. omewhere along this path, tudent will face 
unique tre e : enormou volume of material to rna ter, 
call- chedule not conducive to adequate sleep, a well a 
challenging and potentially abu ive interper onal 
experience with faculty , hou e taff, re ident and 
patient .2• 3 Recognizing the reality of many of the e 
tre e and providing trategie to promote tre s 
management early in a tudent' career may translat into 
better coping kill a a re ident and ultimate) a a 
practicing physician. 
Evidence indicate that the e tre or impact on the 
attitudes of tudent toward their educational experience 
and their future a phy ician .~ Furthermore, the effects 
of mi treatment and abu e have been identifi d a 
stre or influencing medical tudent health, both 
p ychologically and emotionally.5•6 Th re i al o evidence 
that experience with mi treatment in undergraduate 
training have even impacted on the wellne s of phy icians 
in a po t-graduate etting.7 In fact, parallel have b n 
made betw n the abu e experienced by m dical tudent 
and the abu e experienced by children in dy functional 
farnilie . It ha been hypothe ized that the cynicism and 
lack of caring that an abu ive medical chool environment 
can create translate into potentially adver e interactions 
with patient later in life . Hence, the abu ed ma y 
demon trate abu ive behaviour and thi may begin a 
early a cl rk hip. Thi di turbing theory obviate the 
need for further re earch into the area of t re , 
mi treatment and the evolution of tudent attitude 
toward th ir profe ion a they progre through the 
many level of training. 
Ultimately, preventative mea ure mu t be tak n to 
minimize tress and rna imize tudent wellne and 
health. That i , medical chool hould aim to be a afe 
learning en ironment that i conducive to tudent well 
being. De cribed a a culture unto it elC educator and 
curriculum developer mu t realize the unique exp rience 
of the medical tudent. Many tudents enter their program 
in their early 20 and require an adju tment period to 
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acculturate them elve with the demand of medical 
chool. By directing trategie to ensure, promote and 
maintain tudent health and a po itive attitude tudents 
can benefit from program and supports immediately. 
Pre ented here i a brief account of the literature 
concerning medical tudent stres and mi treatment. 
!here wi ll be a di cu ion of potential trategie to 
tmprove health and treatment of student with an 
introduction to the WHIMS (Wellne and Health 
~mpairment in Medical Student ) p ilot project to be 
Implemented at the Univer ity of We tern Ontario 
Medical School in addition to the other medical chool in 
Ontario. 
MEDICAL STUD ENT STRESS AND MISTREATMENT 
Unque tionably, medical tudent are faced with 
tre e unique to their curriculum. For example, the 
expectation to rna ter large volume of information, 
dealirlg with the challenge that patient experience with 
their illne , attempting to meet the diver e need of the 
public, 10 and ultimately choosing a field to train and 
practice in upon graduation 11 are all part of the medical 
tudent ' realm. A Univer ity of Briti h Columbia (UBC) 
appointed advi ory group determined the following 
tre or that medical tudent face over the course of four 
year (Table 1). By examirling the unique feature of each 
year, an adequate need a e ment can be performed and 
the appropriate upport offered. 12 
The tre e li ted in Table 1 may be unique to UBC, 
but would pre umably be reflective of the issue 
concerning tudent at mo t Canadian medical chool . 
However, with each chool boa ting a different cultural 
flavour , thi type of as e ment would need to be 
performed at each institution in order to tailor workshop 
and offer appropriate upport to tudents. 
Currently counselor , both academic and per onal, are 
availabl to medical tudent at the Univer ity of We tern 
Ontario (UWO). Students are aware that they can speak 
freely with the e individuals about any per onal i sue of 
concern; however no formal tudent wellne program i 
in place. A well, extracurricular groups intere ted in 
educating peer about attaining a balanced life tyle have 
taken the initiative to give tudents a chance to a k 
que tions and expre feeling of tre s 
A tudy of 318 Briti h medical tudent employed a 
General Health Que tionnaire to a ess medical tudent 
tre level and to further identify which area of stre 
tudent found to be mo t difficult. Compared to 
employed individual , graduated non-medical tudent 
and non-medical tudents still enrolled in chool, medical 
tudent were identified to have a higher mean score 
indicating a higher ranking of stressful experiences. 
Relation hips with academic taff and consultant as well 
a talking to termirlally ill patient were identified to be 
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the mo t tre ful experiences. 10 In con trast, Lloyd et al. 
determined that the mo t tressful aspect of medical 
school was the volume of material students were expected 
to master. Demands of academic excellence and lack of 
lei ure time were also considered stre ful. 
Lloyd et a/. also demonstrated the evolution of tre 
throughout the four years of medical school, with women 
coring higher total stress scores than men.3 The mean 
total stress score increased year to year, but decrease in the 
fourth year. Stre s attributed to lack of leisure time wa 
consistent throughout the four years although the volume 
of material to learn became a less stre sful is ue by the 
senior year. In contrast, the most prominent concern of 
practicing physici~s in UBC was remaining current with 
medical education. b Whereas tudents move away from a 
theory based learning approach toward the end of their 
undergraduate tudies, as a practicing physician, the 
learning process is critical to remaining aware of the late t 
trends in medicine as are essential to the practice of 
medicine. 
Although an a e ment of tudent tre s has not been 
performed at UWO, it would be intere ting to determine 
what students find particularly stre ful about the new 
curriculum versus the old curriculum. Have the stres e 
increased or decrea ed? Doe a more integrated approach 
organize material in uch a way that the volume of 
material does not seem as overwhelming? Is a patient 
centred approach more conducive to successful patient 
interaction sooner? If the Univer ity of We tern Ontario 
Faculty of Medicine is to champion the movement toward 
addressing the issue of student wellne s, an accurate 
a e ment of the unique need of our students would be 
important in developing stre management and health 
promotion programs. 
Throughout the non-Canadian literature, the 
uncertainty of post-graduate training and choosing a 
pecialty were no t identified a sources of stress. 
However, in a recent issue of MediScan, 11 tre related to 
the Canadian Re ident Matching Service (CaRMS) proce 
experienced by student were identified. Seventy-eight 
Table 1. 
First Year: 
Second Year: 
Third Year: 
Fourth Year: 
gender issues 
performance expectations 
"keener envy" 
emphasis on facts 
emphasis on hard facts 
lack of intimacy of small group 
little emphasi on attitude/ human issues 
anxiety, depression 
academic anxiety 
lack of academic support 
bum out; overworked 
phase of apathy; 
ovenvhelmed on rotations 
inadequately prepared for career decisions 
Feature Articl e s 
per cent of the 2500 tudents surveyed found choosing a 
future discipline in medicine to be extremely difficult. A 
similar number confirmed that it was an inadequate 
expo ure to the variou pecialties that made the CaRMS 
experience particularly tre sful. Furthermore the lack of 
opportunity to change fields of training was identified a a 
flaw in the system. Sixty-eight per cent indicated that 
there was a great deal of tress related to making their 
career choice. The fact that thi choice i virtu ally 
inflexible make the proce s all the more stressful. 11 The 
new curriculum at We tern ha modified the clerk hip 
program in third year to allow student more elective time 
and therefore more time to gain exposure to the specialtie 
of interest. Student training in the old curriculum have 
applauded this modification. 
Recently, student from the Manitoba Medical 
Student ' As ociation re ponded to the three suicide of 
medical students and re idents in the Faculty of Medicine 
at the University of Manitoba. They wrote: 
W1wt do third-year students know about what sort of 
specialty they would be interested in? Once accepted in a 
particular program, residents are locked into this field for 
the rest of their lives. What if they hate it? What if they 
want to change fields? Unfortunately this is impossible the 
way things stand. 13 
Dr. Jacyk, coordinator of the Manitoba Medical 
A ociation Phy icians at Risk Program commented on the 
perceptions of re idents once placed in their respective 
program, stating that they "don' t want to be perceived as 
being vulnerable ... [and] resident are too afraid to access 
[help] for fear of reprisal." .13 The e hindrances mu t be 
explored and viable option to eek help must be provided 
through an employee a istance program run through the 
hospital. 
It i important to understand what ervice are 
available to residents and medical student . The CFMS 
(Canadian Federation of Medical Students) has made a 
erie of recommendations to addre the issue of tudent 
stres . A "comprehen ive mental health care plan" has 
been uggested which would include multip le entry 
points for student and be visible, acce sible as well as 
confidential. Proactive program including tres and 
career management in clerk hip wa al o sugge ted, and 
that support should be available at all point in a tudent's 
education, not exclusively to tho e in their fir t year. 14 
It is, however, in thi first year of medical chool that a 
student's attitude and health can begin to be influenced 
adver ely. Wolf et a/. determined that medical tudents 
reported a decrea se in elf-e teem, and increased 
expre ion of cynical attitudes after their fir t year 
compared to their feelings upon entry in to medical 
chool. By employing a number of psychological 
as e ment cale , thi group looked at lifestyle, 
nutritional, physical, and emotional changes among fir t-
year students before chool began and then at the end of 
their fir t year. In an anaJy i of the adjustment of students 
to a medical chool environment, it was found that 
psycho ocial functioning and self-esteem decrea ed while 
depre ion and ho tility, a a-called negative mood, 
increa ed. Under tandably, a tudent' ability to cope 
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within medical chool is influenced by their prior level of 
function, but knowledge of the deterioration in attitude 
and feeling of the medical chool can have implications for 
prevention. Wolf suggests that stre management and the 
establishment of realistic expectations in medical chool 
are po ible way of promoting health in the medical 
student. Improving mentoring programs with more 
empha is on role modeling and life tyle management may 
also be beneficial. 
Wolf et al. al o determined that mistreatment wa 
positively a sociated with an increa e in cynici m and 
hence a negative evolution of tudent attitudes. In fact, a 
number of studie identified abu e (verbal, physi cal or 
exual) to be a ignificant ource of s tre . The tudy 
reported that of 87 graduating medical tudents, 98.9% 
experienced some type of mistreatment during their four 
year as a medical tudent. inety-two per cent of the e 
tudent were yelled at with the greate t ource of 
mistreatment coming from residents and interns. In this 
particular tudy, the term mi treatment wa defined to 
include: shouting, belittling, being assigned punitive task , 
physical harm, sexual haras mentor exploitation.5 
Similar re ult were found by Baldwin et al. who 
surveyed third and fourth year tudents across the nited 
States and determined that mi treatment was most 
commonly manifested in the form of humiliation. Sixty-
five per cent reported having received negative or 
disparaging comments about their choice of m dical 
career or the practice of medicine. The majority of students 
implicated re ident in these cases. Seventy percent of 
tudent felt the e comment were bothersome . In 
determining the degree of effect that such mistreatment 
had, being threatened with an unfair grade was the most 
concerning form of abu e with humiliation being econd.16 
WHIMS 
The Wellne s, Health and Impairment in Medical 
Students (WHIMS) project was created to addre s the 
issue of "loneline and helple ne s which can facilitate 
the development of dy functional behaviour" .9 By 
recognizing the unique demands of medical school and 
the various opportunitie to offer prevention trategies, it 
is felt that cultivating po itive attitude early in medica] 
chool can steer s tudent away from ubstance abuse, 
depression and despair. The learning module designed to 
be implemented into the curricula aero all five Ontario 
medical schools focu es on s ubstance misu e amongst 
phy ician . The overall goal , however, include increasing 
awarene of illne e in medical tudent , the importance 
of maintaining wellne p r onally and professionally and 
offering education about the resources available to 
students in need of support. By incorporating addiction 
medicine i ue into the LMCC exam, medical school will 
be compelled to educate students about impairment i sues 
The evidence pre ented by Richman et al. provide an 
example of how mi treatment can lead to depres ion and 
sub tance abuse. Informing tudents about the warning 
signs of the impaired colleague and how to inform the 
appropriate authoritie is part of ensuring quality of care 
and maintaining the integrity of the profession, a 
re pon ibility belonging to all health care professionals. 
Taking advantage of certain teachable moment : entry to 
medical chool, preclerkship and during clerkship, 
students are empowered with the knowledge and 
resources that will hopefully lead to a heightened 
awareness of addiction that will extend into the post-
graduate years. 
When considering ways to addre student stress and 
mi treatment, it i important to think of trategies that 
implement measure for prevention versus rescue. 
Enhancing student wellne s and offering an outlet for 
tudent ' tresses and concerns can be both therapeutic 
and beneficial to the maturation of a medical student. 
Mo t schools have a mentor program where students are 
paired or grouped with a community physician, usuaJly 
for ocial interaction. Having an academic faculty advisor 
allows s tudent to address i sues of cholastic nature, be it 
exams, career choice or CaRMS. A predominantly ocially 
oriented mentor group ma y not be conducive to 
di cu ing a student' concerns. Perhap if tudent have 
an option to address concerns early, faculty advisors can 
discover where they falter and offer upport. Finally, 
mentor hould ideally be role models. Physicians that 
reach out to students, sharing their per onal experiences 
and coping mechanisms further enforce the reality of 
juggling personal stresses in a highly demanding 
professional environment. Positive role models that 
demonstrate enthusiasm for the profession as well as 
balanced life tyles may influence medical students to seek 
and maintain similar goals. 
Clinical vignette have already been designed to 
address boundary is ues in medicine between patients, 
medical students, and clinicians. Demonstrating typical 
medical tudent stres or and boundaries may be equally 
beneficial. Because the stresses medical students 
experience are dynamic, different cenarios for each year 
can be u ed to generate discussion and help introduce 
support programs available to tudents at each phase of 
their career. It is important that any strategies to improve 
student wellness be met with enthusiasm from faculty. 
Strong, weU-e tablished programs that allow for student 
involvement will create an environment where students' 
needs are met. 
Medical chool can be a challenging and rewarding 
experience. The learning environment must be a safe and 
healthy one in order to preserve positive attitudes about 
elf and others. Furthermore, maintaining respect for the 
profe sion and the value tudent will take with them 
into their professional careers should be considered an 
essential element of the medical school experience. Ideally 
medical schools should boast a zero-tolerance policy 
regarding tudent intimidation and mistreatment. 
However, with the complexities of interpersonal 
communication, thi i clearly impractical. It is important 
for all schools to have a code of conduct, which should be 
included in student handbooks as well as resident training 
/ teaching manuals. Educating tudent and faculty about 
the exi tence of policy on mistreatment, its enforcement 
and the available re ource , however informal, that 
students can use should be a priority if progress in this 
field is to be made. 
78 
------------------------- U. W.O. Medical Journal 69 (2) 1999 
REFRE CES 
1. Osler W. Canada Laucet 1905;39:121-138. 
2. isker ]A. The yellow brick road of medical 
education. CMAJ 1997;156:689-691. 
3. Lloyd C, Gartrell K. A fur ther assessment of 
medical school stress. joumal of Medical Educatiou 
1983;58:964-967. 
4. Wolf TM, Vou A/men T K, Faucett JM et a/ . 
Psychosocial clrauges duriug the first year of 
medical school. Medical Educatiou 1991; 
25:174-181. 
5. Wolf TM, Randall HM, Von A/men K, Tynes LL. 
Perceived mistrea tmeut and at titude chauge by 
graduating medical students: a retrospective study. 
Medical Education 1991;25:174-181. 
6. Richman ]A , Flaherty fA, Rospenda KM, 
Christen en ML. Men tal healtlr con equences aud 
correlates of reported medical student abuse. JAMA 
1992;267:692-694. 
7. Rosenberg OA, Silver HK. Medical student abuse: 
An r111ecessary aud preventable cause of stress. 
JAMA 1984;251:739-741. 
8. Silver H K. Medical students aud medical school. 
JAMA 1982;247:309-310. 
9. WHIMS/Project C. R.E.A. T .E Module: Report 
from Gleneri11 lim. 
10. Firth ]. Levels and sources of stress in medical 
studen ts. British Medica l j ournal 1986; 
292:1177-1180. 
11. Theodorou M E. Early career decis ious take toll 011 
students. MedicScan 1998:159-10. 
12. Proceedings fro m Projec t C REA T E meeting: 
October 17, 1996. 
13. Williams LS. Manitoba suicides force consideration 
of s t res es faci ug medica l resideuts. CMA J 
19971156:1599-1602. 
14. Tepper ]. CFMS puslriug for support programs. 
MediScan1998:159-7-8. 
15. Piercey ML, Waymouth V. Managing performance 
distractors project . The College of Plryscians and 
Surgeons of British Columbia 1998. 
16. Baldwin 0, Daugherty SR, Eckeufels Ej. Student 
perceptious of mistrea t men t and harassmen t 
during medical school: A survey of ten uuited 
sta te schools. The Westem journal of Medicine; 
August 1991;155:140-145. Q 
PRESCRIBING INFORMATION 
NAME OF DRUG: PREVACID' I~ and 30 g llonsoprazole delayed-release 
capsules I 
TNERAPEUnC CIASSIACATION: H" ,x--ATPASll tor 
NOTE: WilEN USED IN COMBINATION WITM ANTIMICROBIAlS FOR THE 
ERADICATION OF HfUCOBACTfR PYLORI, THE PRODUCT MONOGRAPH FOR 
TNOSEAGENTS SHOULD BE CONSULTfD. 
INDICATIONS AND CUNICAL USE: PREVACID llonsoprazole delayed-release 
capsUesiiS Indicated "'the treatment of cond where a redUC1JOn of gaS!nt 
acid secreoon IS reqwed. such,,. 
II duodenal ulcer. 
2) gastntulcer. 
31 reflux esophagitiS 1ntlud1ng patents W'th Barrett's esophagus, and panents 
poor1y responsiVe 10 an adequate ,.,..... of erapy W'th llsta H,-recep-
10< antagoruts; 
41 pathologiCal hypersecreiO<y coocflllOnS 11< .xl1ng Zolinger.£1ison Syndrome 
iSeeDOSAGEANOAOMI ISTRATIO t. 
~~ eradlcaoon of Heir:obocter P'!fon. 
Trip~ Tlteropy. PREVACIO lioi\SOI)I1ZOie delayed-release capsules!.'" combona· 
oonW'th clarntvo:nycllplusa i astnplethenpy,ISmdiCatedforthe treat· 
ment of patients wnh H pylon in'ecnon and actJYe duodenal ulcer d1sease 
EnditabOrl of H.P'I*Jn has been -10 roduco the nst of duodenal u cer rec'"· 
rence. ISee OOSAGE AND ADMI ISTRATIO I 
(fo< additiooal iolonutioo oo lriple lloorapy lor 1ilo - of H. ,orloriioledioo 
and ac:1iYe duodeul olcer recu,.._ rtfet 10 1he Hp-PAC" Prodoc:t Mooogoaph.) 
Dual Tlloropy. PREVACID llansoprazole delayed-release capsules), In comb~na· 
non With amo111c l~n as dual therapy, IS ~nd,cated for the treatment of pauents 
Wl1h H.fJ'IIon rtfet110n and actM! duodenal ulcer disease who are erthr a giC 
or mtolerant to clanthromycm or '" whom reststance IS known or suspected 
Endica11011 of H.P'I*Jn has been -ID reduce the nstofduodenal ulcer rtCIJ'· 
rence.ISee DOSAGE AND ADM I ISTRA no I 
In panents Wl1h a recem hiStory of duodenal ulcers who are H. pr1on1)0SitlYt, 
erad1cauon then1py may reduce the rate of recurre1ce of duodenal ulcers. The 
opnmal timing forerad;cauon thenpy for such pa ents rem11ns 10 be determmed 
In panents who fai a therapy cornb<'labOn ContaiWig tfarntvornycm, suscepnbity 
estmg should be dor1e If resastance to clanthromycm ts demonstrated or 
suscep btlny terung 1s not poSSib e, an 11 ernauve therapy comb,nanon as 
rec nded. Reststance m a c has not been demonstrated ., clir'lltal 
stiJdieswnh PREVACID and a lion. 
Table I summanmthe eradiCabOnratesforthe H P'fon T~· and Dual-Therapy 
treaunent regJmens. 
TABU! 
Enodica1ion Rates for die H. pylori Triple- and Dual-Therapy 
Treatment Regimens 
Study Eradication Rates 
l'f.IIIV'N I 
T rip/e Tllerapr' 
Evaluable Patients 
Tnal IIIM93·1311 92( 481 
T nai•2IM95-392) 86(57~1 
Combmed 891101/1141 
m IAII Available Dallll 
Tnalrl (M93·1311 911471501 
Tnall2 (M95-392I 871581671 
Comb~ned IIIIIY.>'I171 
Dual Therapy' 
Evaluable Patients 
Tnaltl (M93-13II 761391511 
Tnall4 (M95-125I 661311158) 
Comb~ned 71ln/109) 
m IAII Ava ilable Dahl) 
Tnal•l (M93-1311 781421541 
Tnall4 (M95-125I 67141/till 
Combmed 72 (8311151 
Du•l TlteranJ 
Evaluable Patients 
Tnal II (M93-131) ~12&'511 
Tnaii31M95-130) 651~1 
Comb1ned 61183{136) 
m IAII Available Dallll 
Tnal rliM93-131) 5612&'50) 
Tnai13(M95-I:Il) 68156183) 
Combmed 63IIWI33l 
m = mtent·to-treat panents. 
1 Tflllle Therapy: PREVACID30mg b.i dJtfarrthromycll500 mg b1dJ amo10c m 
I gbu1 
I Dual Therapy PREVACID 30 mg tidJamoxdrll g tid. 
I Dual Therapy PREVACtD 30mg b.idlclanthromyan 500mg bid 
Pa ents were ~ncluded m e analysiS d they had documented duodenal ulcer 
lacweland H. fJ'IIon infecnon at baseine defined as at least two of three po5111Ve 
endoscopiC tests from CLOtest'. r.stology and/or cuture. 
CONTRAINDICATION$: PREVACIO llansoprazole delayed-release capsu esl IS 
contraindiCated 11 pa nts Wl1h inow!l hypersensi!Mt'f 1D any compone of the 
fomwlanon. 
Amollc• •n IS contra,nd•cated 10 pauents WI a known hypersens ty to any 
penockiPiease re er 10 the 1111 Product Monograph before prescnbong I 
Clarrthromycin 1s contramdicated m pa ents wrth known hypersenSilMty 
to clanthromycm, erythromycm or other macrolide anttbactenal agents 
Clanthromycan cs also contn•nd•ca ed an !)~Dents recBMng concunent dlerapy 
wtth utemllOfe. terfenad•ne. CJsapnde or ptmoz1de. (Please refer to the 
Clarrthromyc11lllliets Product MonograJlll before prescnbong) 
WARNINGS: Clarithfiiiii\'Cil slootld IOIIIe aed io ,.egnancy except when 10 
allerutive therapy is ap,ropriaa. plllitalorly dwiwg die firsl3- of ,.19" 
lloty. H pregnancy OCCUB wloile lllkiog die drug. die patient should fie apprised 
of die potential hazard to die fotiS. Clarithromycio has demonstrated adverse 
oHects oa pregoaacy outc- •dlor embryo-felll developmeot io moakeys, 
mice. rats aod rabbits 11 doses thai prodoced plasma levels 2to 17 times the 
.....,!nels obtained io "-us lrealed II liloiiiUimam retOmiHded doses. 
IS.. WARNI GS sectioo io 1ilo Ooridorornycio Prodlltl Mooograp&j 
Pseudomembranous cot s has been reponed With nearty an anttbactenal 
ogents,1ncluding cia f11111\'CN1 and a c• n. and may range., ,...nty from 
m1ld to life·threatenmg Therefore, It IS Important to cons1der ttus d1agnos•s tn 
panents who present With d1arrl'lea subsequent to the adrruntstranon of ann· 
battenalagents. T rea Wl1h antibactenalogen:s alteB the nonmal ora of the 
colon and may pe overgmwth of clostncl,. Studii!S Indica e thau10 pro· 
dxedbyCios11ldrum · aleiSapmarycauseof-a t·assotlltedcofitJs-
Aher the d'agnoSIS of pseudomembranous co has been established, thera· 
peunc measures should be IMlated. M1ld cases of pseudomembranOlJS coh s 
usualy respond 10 diStontJnuaoon of the drug alone. In modera e to severe cases. 
cortslderooon shot.ld be gM!n to maragement Wl1h ftuds and electrolytes, pro e10 
supplementa on, and treatmen With an an bactenal drug eftecuve agamst 
Oostndlum d . 
AllergiC reacnons llnclud111g anapl¥11051 have been reponed 11 panents ret!IY· 
lll!l cllrntvomycll oraDy Senous and occaSIOOIIy fatJI hyperseflSl!Mty (anaphy· 
lactJcl reactions have been reported 1n pa ents on pen1ciftin therapy These 
rea coons are more apt 10 occur 111 mdMduals Wl1h allstory of pem:ilin hypersen· 
SllMIV and/or a hiStory of sei\SilMty 10 multiple anergen~ There haw been wei 
doc urnented repor.s of lndrvlduals With allstory of pe cilin hypersensitivity reac · 
nor15 who have expenenced severe hyperseflSl!Mty reacoons when treated Wl1h 
acephalospom. Before ung therapyW'th any penocilin. carerw· trt should 
te made conce'l'llng pr!VIous hypersens reacnons o perucl ms, 
cephalosponns, and other a ergens Han anerg•c reaction occurs, amoXtclllin 
shot.ld be diSc ued and the appropnate therapy IIStJllfled. 
Serioa aaaplrylactic reactions reqaire immediate emergency treatmellt Mth 
epitephriae, oxygn, corticosteroids, aad airway management. including 
. . 1Sioditate4. 
1\11en gastnt ulcer IS SIJS!ltCted. the possibity of malignancy shot.ld be exclud· 
ed before therapy Wl1h PREVACID (lansoprazole deloyed-release copsulesiiS 
ed as treatment thos drug may alleY~ ate sympiO<ns and deloyd~agiiOSIS. 
Use ia Pregnancy: There are no adequate Of weD-controled studies m pregna 
women. Therefore. PREVACID should be used dunng pregnancy only n the poten· 
Dal benefn jusuf;es the potenual nst 10 the fet!JS. Reproducnve Sllldies conduct· 
ed m pregnant rats at oral doses up 10 1~rr¢!11dav!40nrnes e recommended 
human dose baste! on body surface area), and 1n rabbitS at oral doses up to 
30 rr¢91day (16 ttmes the recommended human dose based on body surlace 
areal, did not disclose any .....tence of ateratogeroc e ect Maternal lt'f and 
a S>gntfitant 11crease 11 fetal mortally were observed 111 the rabbit stlldy at doses 
above 10rr¢!11dav. lnrats,rnaternal Clt'fand a sf9itreducoon11 ersufVIYII 
and W1J9hts were no ed at doses above 100 rr¢g/day. 
Use i1 N1rsi1g Mothers: It ts not known whether lansoprazole 1s excreted 
11 hl<nan Because drugs are e.meted in human PREVACID shot.ld not 
be g,...n 10 nursmg mothers unless Its use IS consodered esse al 
Pediatric Use: Sa ety and effecnveness m children ~ ... not been established 
Use io Patioots with Hepatic lmpairmetlt tt IS reconvnended that the al dosmg 
ragunen need not be a ered for pa nts Wl1h mild or moderate liver disease, but 
for panentswnh moderate 1mpalfl!lent. doses l"ogller than 30 mg per day should not 
be a ered idess there are compelling clinical ndicaoons. 
PRECAUTIONS 
Geoerat: Symptona response 10 therapy Wl1h lansoprazole does not preclude 
the presence of gastriC maignancy 
H.1'flori Eradicatiot and Compliaoce: To avoid fa ure of the erad1caoon treat· 
ment Wl1h a potel'tlal for di!Y1!1opong a crnb!al res>stance and a nsk of failure 
Wl1h subsequent therapy, panents should be instructad 10 follow closely the pre-
scribed regunen. For the erad1caoon of H. pylon. amo10c in and clanthromytln 
should not be ad · ered 10 panents Wl1h renal alftnent smce the appropn-
atedosagell pa ntpoptJiaooohasnotyetbeenestablished. 
Cln:ioogeoitity: Analysis of gastriC biopsy spec ns from pallerltS after short· 
term treatment of proton pump llilbru>rs have not detected ECL eel effects srniar 
to those seen lf'latlmal stud1es.l.onger term studies m humans revealed a sighl 
mcrease in the mean ECl-cell denstty, although there was no microscopiC 
eY'Idence d eel hyperplasaa Slmiar resu were seen .n the mavnenance treat· 
ment studoes. where panents receiYed up 10 l~ mon:hs of lansoprazole therapy 
Serum gastnn Yalues 10creued ~gmficantty frora the1r baseline Yalues but 
reathedaplo eauaftertwo of therapy Byonemonthpost·treatment.las!· 
mg serum gastnn va ues returned to lansopJazole erapy baseline. Moreover, 
resutts from gasmc biopSies from shon·tenn, long-term and maintenance treat-
ment stud1es md1cate that there are no climcalty mearungfuf effects on gastriC 
mucosa morphology among lansoprazole-treated panents. 
Retioal Alroplly: PREVACID studies are not stJ99estve of any drug~nduced eye 
lt'f 11 hl<nans.ln humans. there are presently no concerns for ocular safety 
W'th short·terrn lansoprozole treat:nent and the nsb aSSOCiated Wl1h long-term 
use for nearly five years appear 10 be neghg1ble. The find~ng of drug-~nduced 
reunalatrophy "'the albmo rat IS considered 10 be spetii!S·spetific with ittle rei· 
evance for humans. 
Leydig Cell Hyperplasia/l.eydig Cell TUIIIOIIfS: In the 24-month IOICICologystudy II 
rats. a her 18 mon of treatment. Leydig eel hyperplaSia 10creased above the 
concurrent and hlstoncal controllnelat dosages of I~ rr¢g/day or h1gher 
Tesbcular'" erSbtlal ceft ade~a also occurred 10 I of J) rats treated WI' 
~ rng/'<Wdayll3 the recommended lunan dose based on bodysuface areal 
"'a one-year IOIOCII'f study These changes are assoc11ted with endocnne a er· 
aoons wllc:h have not been,IO date, observed 11 humans. 
Dnog lnteractiom: t.nsop<llole IS metabolized througli the cytochrOI'le P .. svs· 
tern. specifically through CYP3A and CYP2C19 Stud•es haw - thatlanso· 
prazo1e does not have cinocaly S>g111ficant era coons Wl1h warfann. antJpynne, 
lldome ac11, asponn. ibuprofen. phenytorn. predfiiSOIIO, antacids (Mia and 
pan"). d1azepam. clanthromycm, propranolol, amoJOCIUJn or terfenadme '" 
healthy subjects. These compounds are metaboized oughvanous cytOCivome 
P.,.ISozymes 1nclud1ng CYPIA2. CYP2C19, CYP2116, and CYP3A. When lansopro· 
zole was admonostered concomnandy Wl1h theophylne ICYP1A2. CYPJAI, a m1110r 
11<rease IJO'J(,I 111 the clearance oftheophylne was seen, which IS urill.ely 10 be 
of cfonlcal concem one eless, lldnndual pa ents may requKe adjustment of 
thelf theophytl1ne dosage when lansoprazole IS staned or stopped to ensure 
cinoca enecM blood levels. 
In a Stngfe-dose crossover study when 30 mg of lonsoprazole was adrnlrostered 
concomnantty wr one gram of sucralfate 10 healthy volunteers. absorpoon of 
lansoprazofe was delayed and Its bloovailab was reduced. The value of lan· 
soprazole AUC "as reduced by 17'4 ond that for C.. was teduced by 21ll. 
In a snnilar stlldy when 30 mg of lansoprazole was ad niSiered concomnantly 
Wl1h 2 grams of sucralfate. lonsopruole Aut and c_ were reduced by 32\and 
55ll. respecnvely When lansoprazole dosmg occurred 30 moootes pnor 10 sucraf. 
fate admllliStraoon. C.. was reduced by only M and there was no sta ally 
S>gntficant d erence., lonsoprazole Aut. Therefon.lansoprazole may be g,...n 
concomitantly W'th antacids but should be ad red at least 30 utes poor 
to sucra ate t.nsoprazole causes a profound and oog lasnng 1nM•non of gas· 
tnc acid secretiOn, therefore, n lS theore catty posSJbfe that lansoprazole may 
11terlere Wl1h the absorpllon of drugs where gastriC pH IS an portant deterrnt-
nant ofblo..mabityle g.. ketocO'lazole,ampocilllesters,""" sahs.tf'90111fll 
IAmbiNriH aera, witJI C/arilflrDiR'(Cillli,lor Anouici/lio: f1lf more 1nfor· 
manon on drug tnteracnons for clanthromyem and amo din, refer to the1r 
respect>ve Product Monographs, LIIder PRECAUTIONS. Drug InteraCtiOns. 
AlftibKitit Resist1ttee in Rtlltio• to H.. pylori &Hic1tio•: Three panents 1'82 
13 7lll who had ISOlates susceptible to clanthromyc10 pretreatment and were 
treated Wl1h thetnple therapy reglf10n rema1ned H.fJ'IIon·poSitive post-treatment. 
None of the ISOlates from these three panents had suscep · resuks avaiable 
after trea Wl1h tnple therapy: therefore, • IS uoinow!l whether or not thesa 
pa nts developed reSistance o clonthrornyc111. Sixteen perc em of the panents 
treatedwnh the dual therapy reg1men developed clarntvomyc111 reSISillnce post· 
treatmen Therefore, development of clanthromycm res1stance should be 
conSidered as a fiOSSible nsl 
Use io Patients with Reoallmpaiment o dosage moddicaoon of lansoprazole IS 
req..-ed 11 panents Wl1h renal ~ency 
Use io Eldofly,_ Uicer healing ra es r~ eldertypa nts m SI!Urtolhose 
younger age groups. The ooc:odeoce rates of adverse rventsarod laboratory test 
abnonnaioes are also or to 1hose seen 11 othtnge groups. The al dos· 
reg oeed na1 bu red for elderty pa buuubsequent doses logher 
an 30 g per day should oo be ad i ered unless add al gastnc acod 
_.....,ISoecossory 
Use io w-o: Over IDl n were treated wrth lonsopiJlOie Ulcer healrlg 
ra es m femafes l!e ar o those M1 ales. The 11ctdence ra:tes of adverse 
rvems are also r to those seen in males 
ADVERSE REACTIONS: Worldwide, over 7tDl pa nts have been ueated wrth 
!'REV ACID llansopiJlOie delayed-release capsules) dlmg Phase II-III short-term 
and loog-ttnn clincaltJUis lllYOIW1g vanous dosages and dura of~~~ 
lngeneralPfiEVACID ea~hasbeenweltolerr. d 
Sllotr-TilliiSIJMiia 
The following adverse Mnts were reponed tD have a poSSible or probable refo· 
llllfOShoptodrugasdescribed bythe~eabllg physoclln •n '" oriT10fe ofPREVACID· 
treated pa ents who participated in placebo· and posruve-controled tnals 
(T abies 2 arod 3, respecovely). umbers "' parentheses Indicate the percentage 
of the admse MntS reponed. 
TABL£2 
lacideoce of Possibly or Proballly T ruweat-Related Ad-terse beats 
io Short-T e.._ Placebo-Controlled Studies io TAP Solety Dotobase 
Body Syst..V PREVACID Placebo 
Ad-terse beat' IN = 11 n N ('II.) IN = 254~ N ('II.) 
Body an Whole 
Headache 
a! Pam 
O~gestJYt System 
D11rrhea 
Nausea 
Vornrung 
l.JYer Funcoon 
Tests Abnormal 
Nervous System 
Dlllmess 
63(7 7) 31(1U) 
19(2.3) 3(12) 
29(35) 6(2.4) 
9(11) 5(2.0) 
7(0.9) 3(12) 
2(0.2) 3(121 
8(1 0) 2(0.8) 
bents reported by at least 1" of panents on enher treatment ore 1ncluded 
lo tho TAP Solety Database, al short- Phase 11/111 studies. one or moreueat-
ment-e ergent AEs were reported by 71!i/1359 (52.6"1 PREVACID-ueated 
pa ms; ollhose considered to be possibly or probably trea -rela ed AEs, 
oneor-.-e reponed bylN1359(2!).3ll) PREVACID-uea·edpa lnal 
short-tlml. Phase 11/111 studies. one or more trea -emergen~AEswere report· 
ed by 150/254 (591 'I placebo-treated panents; of 1hose considered to be pclSSI-
bly or probably uuunent-related AEs. one or more were reported by SE/254 
122.~1 
The most frequent AEs rl!poned r11he Et.upean short ·term studies were diarrhea 
(3~). boratory test aboonnal (2.3'11.1. headache 115"1. consnpa0011 11~1. 
astho0111 (ll"l dimness (1 "'l.arod abdomonal par~ fl.~). The most lrequent 
AEs reported 10 lhe Aslin short-tera1 studies werl! ll'tspec ed labora ory ll!st 
a!lnormalines (7~1. fOSifiQPhia 11ft). arod ooc:reased SGPT (1ft) 
TAB I£ 3 
Incidence of Possibly or Probably Treatmeat-Related 
Adverse beo!S io Sbort·Tena. Positive-Controlled 
Studies in TAP Safety Database 
Body Systelll/ PREVACID Ranitidine 
Adverse bent~ (N=647t NI'!I.) IN = 393~ N f'!l.l 
Body as 1 Whole 
Headache 2!i(4.0) 14(36) 
AbdQf111011 Pall 8(1.2) 3(01) 
D~gestMI System 
D11rrhea 27(4.21 8(~01 
IUSII 7(11) 4(1 01 
Nervous System 
Ollltness 81121 3(011 
s arod Appendages 
Rash 7(11) 1 (0.31 
t Events reported by at ast "'of pa ems oo erthor treaunenure Nlcluded. 
MoiateOHCI Stlldies 
U.S. Slvdits 
Trl!atment-eroergemAEs wrth an ""ldence of at least~"' artyUea group 
of e mamtenance treatmen studiEs occumng from the start o mam:enance 
trea ent to lhe forst recurrence of disease are chspla~d by body system and 
CDSTARTterm.arodbytrea groupr~Tablel 
There -e no frequently reponed R m ~~<odeocel severe AEs"' lhe treat-
mem-omergem or lhe possibly I probably treatment-related ovem categones 
onset at any pomt from the stan of 11n enance treatment to the nme of first 
recurrence of dlSease 
TAB I£ 4 
T reabMot·EJnerveot AEs Reported by ~ 2'!1. of the Placebo 
and lauoprazole Patieats to tbe Time of First Aec•rreace 
of Disease• i• the MailltHance T reat.eat Stu4ies 
Tr11tmentGroup Placebo lanSOjlrllOie 
CUM CUM 
(N=236) (N =316) 
Mean Exposure (Days) 105.4 2615 
Body SystenVCOSTARTTenn 
"''"' 
'!l.(n) 
Total Panents 
Any Event 39 4 (93) 705(2n) 
BodyasaWhole 
Abdornmal Pam 3.om 5.2(201 
AccodentallrlfU'l 2.1151 5.4(21) 
BackPall 4.2!101 3.1 (12) 
Chest P11n 08 (2) 2.3191 
Au Syndrome 38(9) 7.3(28) 
Headache 6.4(151 114(441 
lnfecnon 1.3(3) 2.1 fBI 
Pall 0.8(21 2.6(101 
D~gestJYt System 
D1.1rrhea 5.5(13) 9 8 !381 
GastromtestJnal 
Anomaly (polypi 0.8121 44(171 
Nausea 1.3131 2.8(111 
T GOth DISOrder 04(11 2.1 (8) 
Vornrung 0.4(1) 3.4(131 
TABL£4 (coot'~ l 
T reatmeiii-Emergeot AEs Reported by ~ 2'!1. of the Placebo 
ud Laosopnzofe Potieats to the Ti011 ol first Rec:orreoce 
of Disease• i• tbe Maiwte1ance T reabltent Studies 
Trea-atGroup Placebo La_._,. 
CUM CUM 
(N:236) IN =3161 
Mean Exposure (Days) 105.4 267.5 
Musculoslceletal System 
Arthralg11 1.3(3) 44(171 
Myalg11 1.3(3) 2.1(8) 
Nervous System 
Diumess 0.4(1) 2.8(11) 
Resp~ratlliY System 
Branch s 1.3(3) 11(121 
Cough lncreosed 0 2.3(9) 
Pharyngrus 9.3(22) 17.11661 
Rllln s 1.3(3) 5 7(22) 
SmuSltJS 2.5(61 65(25) 
Skm and Appendages 
Rash 3.om 47(181 
Urogemtal System 
Unnary Tract lnfec:0011 2.5(6) 41 (16) 
0 Unti of first rec..rreoce, wthdrawa1 or erod ol mamtenance treatnent 
E..,. .. SIJMiies 
The AEs reported by at least 2'/o of p ems ., any trea~ group are cEsplayed 
by COST ART body system and term arod by treatment group lor controled long· 
term E~KGpean Studies ., Table 5. 
TABL£5 
T reatmeiii-Emergent AEs Reported by ~ 2'!1. of Patients 
T rooted with H,-RAs or laMOpruole ito Long-T ena. 
Phase 11/ 111 H1-RA Controlled European Studies 
Lansopnzole H,-RAs 
Treotmelll Groap (N =263) IN= 161) 
Body Systenv'COST ART T enn "In) "'fnl 
Total Pa ems 
Any bent 49.8(1311 46 61751 
Body as a Whole 
Abdornonal Pam 3.0(8) 17(6) 
Back Pall 2.3161 0.6(1) 
AcCICientallnJUry 15(41 2.5(41 
lnfecnon 11 (3) 11(51 
CardiOVascular System 
Hypenenston 19(5) 2.5(4) 
Digestrve System 
Diarrhea 9.1(24) 4.3(7) 
GastntJs 5.3(14) 1.2(2) 
Consnpanon 2.1m 2.5(41 
Vornttmg 19(5) 11151 
Dyspepsla 1.1 (3) 31 (5) 
Musculos eletal System 
Arthralg10 1.9(5) 2.5(41 
ervous System 
01lllf1tSS 1.9 (5) 2.5(4) 
ResporatllfY System 
Resptratory OISoofer 2.3161 1 1(5) 
Cough Increased 1 1131 2.5 (4) 
The AEs reported by It ast 1" of pauents receMng lood-tn opeo-labellanso-
prazole trea ent'" long-term Et.upean Studies are diarrhea (S.~l esQjlhagtlos 
12.5"'. abdonwlllp .. l21"',gastnbSI21"',fla nee(!~~ adache(U"~ 
coostJpatlOII(l 0'11.1. arod nausea (I 0'11.~ The 11Codence of AEs reported ll the lead· 
., opeo-label penod of e European studies W11S ar tD that seen., controlled 
studies, however, the overall mCidence was ~er fCH' the lead~m open-label 
studies than lor the H1-RA conuolled studies (275" versus 49.8'1.. respectively~ 
Add' onal1dverse e enences occurnng 10 < 1\ of pa ents or subtetts m 
dornesnc anol'or e"'"""""lu..ls.oroccumng sooc:e the drugwasmarte:ed,arl! 
shown below each body syst 
Body as 1 Whol.-aslhen11. candtdiaSIS, chest plln (not otherw~se specified), 
edema, tev.r. syndrome, halitosiS. eCOOII(not otherwose spedied~ malaise, 
carc1100111, general pa 
C~rdrovascul~r Syste : angma, cerebrovascular acc•dent. hypertenseo~ 
hypotensiOn, ntyoeanhl1nfarctton, palprtanons. shock (c~rculatory l11lurel. 
vasodilatJOO; 
D~esrm System: lena. c ISIS, abnonnal stoolsi.,.lena, bezoar, 
consnpotlOII, dry 110uth/tlltst. flaudence, gasuoe errus, go snnal 
hemorrhage, hema e SIS, anore a, Wlcreased appe e. incrused saivaoon. 
rectal hemorrhage. canfiospa dyspepsil. dysphag11. erurunon. OSOilhageal 
stenosiS. 1!$01lhageal Lker. esophagms. stoma ns.lecal distolonnon. tenesmus. 
Lkeranve colins, gastnc notiiAes/fundic glarod polyps. c•cllOIIf; 
Endocnne System: diabetes me goner, hyperglyce~enia; 
Hematll/ogt< •nd L~atJC System ' agraiMocytDSIS, a oplaSIIC ane a, 
hemolySis, hemolync a a. leuiope0111, neuuopenoa, pancytope01a, tlvornbo-
cytopenoa, arod tlvorrbotJc thrombocytopenoc purpura, 
Merabolic and NutrrtJOnJI DISOrrJtrs·gout. weight g01rl'loss. edema: 
Musculoskeletal Srste<n: arthnns!arthralg11, musculoskeletal p11n. myalgia: 
NeiYOUS Srstem: agltl amniSII, apathy, confusion. duzmtss, syncope, ha~ 
luCJ\anoros. hostity aggravated, ibodo decreased. depressloo.~tem~Pe9ia. insmt-
101. sormolenc:e. alnirmaity, IOlllety, nervousness. paresthesia: 
/ltiiWatory System-a bronchitis. cough 11<reased. tlyspneo, hemoplysos, 
llccup, upper respontory ectJon. pneumonoo, epostaJOS; 
Sbn and Appendlges: acne, prunrus. nsh. urtJcona, alopec11, 
Speclll Senses: amblyopia, eye pall. YISIJI!Iield defect ll1nllUS, ophthalnoologoc 
disorders. ear disorder, deafness, ootos medio. taste pen.....n; 
Uruge SystBDra menses..........,., breiS! enlargement! gynec_o-
masna. breast tenderness. glycosuna. potence, itdney colc,.,s. hematuna. 
LmOryurgency 
t The ma}Onty of hema iog1c cases recetved were fOfttgn·sourced and thetr 
relationshop to lansopruole was unclear. 
CotJIIIi....., Tlltnpywith C/~udAno>xici/fir.lnclincaltrialsusmg 
combmanon therapy PREVACID plus elanthromycm and amo c·lil. arod 
PREVACID plus amo ciftin, no adverse reactJOns related to these drug 
c na ns were observed. Adverse reacbOns that have occurred have been 
ned to those at have been preVIously reported Wlth PREVACID, clar-
romycm. or amoXJcilhn. For more mformanon on adverse reac ons wrth 
clanthrornycll or llliOJIIcilin. rl!ferto their respective Product Monograplos, uroder 
the ADVERSE REACTIONS sec-
Triple ruro,y; PlfVACID/cl•ritll""'fCill/,_ncillio: The most frequently 
reported odverse M for pa ms wflo received tnple rapy were diarrhea 
1~1. eadacht (6"1. and taste perverSIOn 15"1. No trea nt-
lll:lergent adversa events were obserwd at Slgnifica higher rates with tnple 
therapy than wrth any dual lherapy r n. 
D11l Tlleropy; PRfVAC/D/omuicillil< The r~ost frequently reported adverse 
events for panents who received PREY ACID ti.d. plus ti.d. dual therapy 
were diarrhea(I'JI.)and headache 17"~ No ~ea~-finlfgent admse MntS 
were observedatSJg a logherra eswrth PREVACID ti.d. plus a ilm 
tid dual therapy than wrth PREVACID alone. 
laboratory nlues: In addinon. theloflow10g changes 10 laboratory parameters 
were reported as adverse events. Abnormal liver luncoon tests, ooc:reased SGOT 
IASn. 1ncreased SGPT IALn. 10crnsed creatinine, r~creased alkaline phos-
phatase, 10creased gamma globulins. mcreased GGTP, Wlcrnsedl decreased/ 
abnonnal WBC. abnormal AG rano, aboonnal RBC, biirubone1111a, eoSioophiha, 
hyperlipe a, 1ncrease decreased electrotytes, increased/ decreased 
cholesterol. llcreosed glucocorncords. U1Creased LDH. 11<reasedl decreased/ 
abnonnal platelets, ond r~creased gastnn levels. Addibonal ISOla ed laboratory 
abnormalities were reported. 
In lhe placebo-cootroled studies. when SGDT (AST] arod SGPT !Alnwere evalu-
ated, 0.4-. fl/2501 piacebo pa ents and m 1217951 lansopmole pa ems had 
enzyme elevations greater than H s UPIM!r of normal range at lhe 
!treatment YISil None of lhese pa nts reported sa:mdice at any dlmg 
lhe study 
For more ormanon on laboratory value changes wtth clanthromyc1n or 
amo cilin, refer to thev respec e Product Mooognphs, uroder the ADVERSE 
REACTIONS secnon 
Postmarbting bperiuce: HypersensrtMty reacbons have been reponed, 
IIIClutMg onaphytaJCS. 
DOSAGE AND ADMINISTRATION 
Daodeaol Ulcor: The recoovneroded adult oral dose is 15 mg ddy before breakfast 
fortwotofotK-ks (See! DICATIONSANDCUNICALUSE.I 
A small percent1ge of patients that 1re H. pylori-negatrve will expenence a 
disease recurrence and wil requlfe rm1menance treaur.ent With an annsecreuwy 
agent PREVACID 15 mg dady before breakfast may be used up to one year for 
lhe ma nancnn n ol recurre duodenal Lkers. 
HelicobiCler "Iori Erodicotioo tt Redoce the /lislr of DHdtoal Ukor 
~
Tn,lo TNra,y; Pf/EVAQ~ The recOIMIIIIded adult 
oraldoseiS30mg PREVACID, SOOmg clarr.fvornyt11,and 1 gamo iln.algwen 
twice dally for 14 days.(Seel DICATID SAND CUNICAl USE.) 011ly doses 
shcMcl be taktn before meals. 
(For additioul iofonaatioo 01 triple therapy for the trealllleat ol 
H. ,rori iofectioo eed actite doodeoal olcer recorreoce, mer to the Hp-PAC 
Prvdact MoMgnplll 
Deal Tllerapy; PREVACID/omoxiciflirL The recommeroded adu~ oral dose IS 
30 g PREVACID arod 1 g amo cinin. eoch giVen three umes d11ly lor 14 days 
(See INDICATIONS AND CUNICAL USE. I D11 doses should be taken before 
meals. 
Opumal therapewc reg1mens conSisting of a shorter treatment duratton for 
lhe eradicanon of Hllicobocter pylon are currently under IOYI50gatJon. For the 
eradiconon of H pylon. 1 cillln and clanthromyc1n should not be admmiS· 
ttted to panents wrth renal enpa~nnentsooc:e the appropriate dosage., this pa nt 
populo non has oot ~~been estabished. 
Gastric Ulcer: The recommeroded adult oral dose is 15 mg daily before breakfast 
for tot. to light weeb. 
o dosage adjusunent IS necessary ll patJents wrth renal · ltr1Cy dosage 
a ustme IS necessary r1 1he PREVACID dosing reganen., older pa nts 
and ll panents wrth lllild to moderate hepa rnpUme Dosong rec a-
IIOOS described ll tho labelilg shcMd be adhered to for older panents arod hepat· 
ICaly rnpued pa Ots. 
PREVACID IS oot lncf•:a ed for ma~ntenancelherapy Wllhe ~ea nt of panems 
wrth gastnc Lker 
Rella Esopbgitis or Poorly~ Reflu &o,Ugitis loclodill!l Patieats 
witlt Barrell's Esoplilglls: The rec roded edub oral dose IS Jl mg daily before 
breH!ast for fotK 1D eoght weeb.(See INDICA nO S MD CU !CAl USE.! 
Mli1teuace TreJtmelt of Huled Reflu Esop 1gitis: For the long-term 
manageroem of pauems wrth healed reflux esophagitis, 15 mg PfiEVACID grttn 
once daily before breakfast has been found to be effective "' controled cinocal 
Ullb of 12 months' duranon. 
The recommended adu~ oral dose of PREVACIO for maintenance treatment 
of pa ems wrth healed reflUllesop/llg IS 15 mg daily before breakfast (See 
I DICATIONSANDCUNICAlUSE.I 
Trutme1t 11d M1i1t!IIICI of PJD:ological Hypersecretory C01ditioas 
loclodiog Zollitover-EIIisoo Syedromo: The dosage of PREVACID ll pa nts wrth 
pathologoc ltypersecrl!tory condinofls varies with lhe indivodual panent. The rec-
oovneroded adu~ oral startl\g dose IS liD mg once a day. Doses shcMcl be adjust-
ed to 1ndmdual pawn needs and s.twuJd continue for as long u c ~l'llcaly 
Indicated. Doseges up to 90 mg b.td. have been red. Daiy dosages of 
grea than 120 mg shcMcl be admnstered ll d'Yided doses. Some panents With 
Zofnger-Eiison syndrome have been ea ed connnuouslywrth PfiEVACID lor 
IT10ft than tot. years. 
Pllieats with Hepotic lmplirmeot The daily dose shcMcl not exceed Jl mg. (See 
WAR INGS.) 
Pllieats with Reullmpairmeot o dosage modificanon of PfiEVACID IS neces-
sary. (See PRECAUTIONS.) 
Eldofly Pllieots: The ddy dose shcMcl not exceed Jl mg. I See PRECAliTIDNS.I 
CoocOIOitaot Aotocicl Use: Simultaneous ad nistra on ol PREVACID wrth 
Mn (alu111111um and mognewm hydroXIde) or · pa (magaldra e) resuhs 
10 lower peak plasma levels, bill does not Significantly reduce b10availabilll'( 
Antacids may be used concomnantly d rl!qtilred. ff sucralfate IS to be giVen con-
comitantly, !'REV ACID shcMcl be admii1Slered at leastllmintJtes poor to sucral-
fate. In cline a! tna1s, antacids were a red coocll!Mantly wrth PREVACID 
de!oyed-release capsules; this did na1 rtere with Its e'fecl 
AVAJLABIUTY OF DOSAGE FORM: PREVACID flansoprazole delayed-release 
capsulesiiS available as 15 mg. opaque, hard gela n. pml: orod green coloured 
capsules ., bottles of 30 and 100 The 30-mg capsules are opaque, hard gela n. 
ponkarod black coloured, avo able'" boules of 30 and 100. 
Referucr. 
1. Ca DD. Richter JE. Robonson M, eul Efficacy a rod sa ery of lansopmole 
• the eatment ol erosrve r esopha AJG 1996;91(9rt7.,_57 
~ Prevacod Product Monograph. Abbott Laboratones. 
Product Monograph available on request 
~Abbottlaboratooe~ lmted PRf/161A01-0ct 19911 •TM I!S1!] 
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more, call 3M Health Care at l-800-3M 
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But unlike them, 
we already have 150 years of practice 
e re Pfi:er a olobal com an · edi ate to di ovenn medicine to help 
people lea lon er healthier and more r uc ive li\·e . e \·e een in the 
di covery me ince in 1 9. 
urin 
tom 
iemi were the fi t to develop a wa 
t w n er druo enicillin. ince th n Pfi:er 
me icine have contribute iQili can l · to the revolution in healthcare of 
our mo ern aoe. 
Our v ork ontinu hol o a new millennium th 
commitment to re earch o our 6 iemi around the world hold real 
hope o unl kino the m · terie Al:heimer di e e arthriti cancer and 
other illne e . P :er i ttin the pace with the worl wide launch of wa e 
o innova i\·e me icin whil al o our ·oun atem~ rotected roduct 
continue to QTOW. 
An erha omeo will help n the wa ·. 
Life is our life's work 
Pfizer Canada Inc., Kir land, Quebec- www.pfizer.ca 
